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GENERAL INTRODUCTION AND 
OUTLINE OF THIS THESIS
C H A P T E R
1
Breast cancer is the most common type of  cancer in women in the western world. In the Netherlands alone, 
one in eight women will develop breast cancer at some point in her lifetime, with a majority occurring after 
the age of  50.1 In postmenopausal women, the majority of  breast tumors grow under the influence of  the 
reproductive hormones, estrogen and progesterone. Characterized by the presence of  hormone receptors, 
these tumors are frequently referred to as ‘endocrine’-sensitive. 
The first major advancement in the treatment of  endocrine-sensitive breast cancer was made in 1896 when 
the surgeon, Sir George Thomas Beatson, reported on a number of  breast tumors that diminished in size 
after removal of  the ovaries of  these women.2 Beatson compared the growth of  breast cancer to changes 
during lactation, describing that “…the changes that take place in the mammary gland in the process of  
lactation are almost identical, up to a certain point, with what takes place in a cancerous mamma.”2 He 
also writes that “...it is custom in certain countries to remove the ovaries of  the cow after calving if  it wished 
to keep up the supply of  milk, and if  this is done the cow will go on giving milk indefinitely.”2 Beatson 
proposed that the removal of  the ovaries would “…arrest cell proliferation and [convert] the cells into 
fatty matter.”2 This observation marked the beginning of  a new development in the treatment of  breast 
cancer and, more than a century later, the principle withstands and breast cancer surgery is frequently 
accompanied by additional (adjuvant) endocrine therapy in patients whose tumors are estrogen receptor 
(ER)- and/or progesterone receptor (PR)-positive. Different types of  endocrine therapy work by lowering 
the levels of  circulating estrogens or by blocking the ER, reducing the risk of  disease recurrence in patients 
with endocrine-sensitive breast cancer.3, 4 
A d j u v a n t  e n d o c r i n e  t h e r a p y
In the early 1960s, tamoxifen, a selective modulator of  the ER, was developed by Dr. Arthur L. Walpole 
and Dr. Dora Richardson, and was originally intended for contraceptive purposes.5 Around the same time, 
the presence of  ER in breast tumors as well as estrogen-dependent breast cancer growth were confirmed6-9, 
leading to the exploration of  its potential use for endocrine-sensitive breast tumors.10 In the years that 
followed, tamoxifen established itself  as standard adjuvant endocrine therapy for women with hormone-
dependent breast cancer following several adjuvant clinical trials, showing significant reductions in both 
breast cancer recurrence and mortality.11-15 
In 1977, an alternative approach to improving breast cancer treatment through inhibition of  the aromatase 
enzyme was proposed by Brodie and colleagues.16 Aromatase inhibitors (AIs) decrease the levels of  circulating 
estrogens through inhibition of  the aromatase enzyme, which facilitates the conversion of  androgens to 
estrogens.17 The incorporation of  aromatase inhibitors (AIs) into adjuvant endocrine therapy regimens in 
the years that followed harbored a great promise. Initially, AIs were studied as part of  a sequential treatment 
regimen, following 2-3 years of  tamoxifen. Trials that compared tamoxifen monotherapy with sequential 
treatment included the Intergroup Exemestane Study (IES), which compared 5 years of  tamoxifen with 
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2-3 years tamoxifen followed by exemestane for 3-2 years (total of  5 years). In this trial, significantly better 
disease-free survival (DFS) and overall survival (OS), as well as fewer recurrent breast cancer events were 
observed in patients in the sequential therapy group.18 In a combined analysis of  the Austrian Breast and 
Colorectal Cancer Study Group (ABCSG)-8 trial and the Arimidex-Nolvadex (ARNO) 95 trial, sequential 
therapy consisted of  switching to anastrozole after 2-2.5 years of  tamoxifen. This analysis revealed small 
improvements in DFS (hazard ratio (HR), 0.6 (95%CI 0.44-0.81), p=0.0009) and treatment toxicities.19 
Finally, the Italian Tamoxifen Anastrozole (ITA) trials, which compared 5 years of  tamoxifen alone with 
tamoxifen followed by anastrozole, showed improvements in relapse-free survival (RFS) (HR 0.64 (95%CI 
0.44-0.94), p=0.023).20
Meanwhile, the Arimidex, Tamoxifen, Alone or in Combination (ATAC) trial had been initiated, which 
randomized postmenopausal, hormone receptor-positive breast cancer patients to 5 years of  tamoxifen or 
anastrozole and revealed improvements in DFS and distant DFS, as well as a reduction in contralateral breast 
cancers (CBC).21 In addition, the Breast International Group (BIG) 1-98 and Tamoxifen and Exemestane 
Adjuvant Multinational (TEAM) trials compared the efficacy and safety of  sequential treatment with AI 
monotherapy.22, 23 The BIG 1-98 trial compared several five-year endocrine treatment regimens (letrozole, 
letrozole followed by tamoxifen, tamoxifen, and tamoxifen followed by letrozole). The analysis compared 
letrozole and letrozole followed by tamoxifen with tamoxifen and tamoxifen followed by letrozole.24 A meta-
analysis of  the different randomized trials comparing tamoxifen with different AI regimens (either alone or 
after 2-3 years of  tamoxifen) by Dowsett et al. showed that 5 years after diagnosis, both AI monotherapy 
and sequential treatment markedly reduced absolute tumor recurrence rates when compared with 5 years 
of  tamoxifen monotherapy (p<0000.1 in both cohorts).25
The TEAM trial was originally designed to compare 5 years of  exemestane with 5 years of  tamoxifen 
in postmenopausal women with hormone receptor-positive breast cancer.22 After the results of  IES were 
reported, however, the TEAM protocol was amended. Five years of  exemestane monotherapy were 
compared with tamoxifen (for 2.5-3 years) followed by exemestane (for 2.5-2 years), also for a total of  
5 years. In this multinational study, almost 10,000 patients were assigned either sequential treatment or 
exemestane alone. The aims of  this study were to compare the efficacy and safety of  exemestane alone with 
sequential treatment. After a median follow-up of  5.1 years, there were no statistically significant differences 
between the two treatment groups: 85% of  the patients in the sequential treatment group and 86% in the 
exemestane alone group were disease free (HR 0.97, 95%CI 0.88-1.08; p=0.60).22
 
E x t e n d e d  a d j u v a n t  e n d o c r i n e  t h e r a p y
In recent years, investigations of  extended (more than 5 years) adjuvant therapy with an AI have been 
initiated and are showing improved outcomes when patients are treated with an AI for longer than 5 years. 
One of  the first studies to investigate extended adjuvant endocrine therapy was the MA.17 study, a placebo-
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controlled trial that randomized postmenopausal women after five years of  tamoxifen, to five years of  
placebo or five years of  letrozole.26 The study was un-blinded after the first interim analysis revealed a 
43% reduction in disease recurrence (p=0.00008) in favour of  letrozole.27 Patients treated with placebo 
were given the choice of  switching to letrozole. A comparison of  patients who chose letrozole compared to 
patients who stayed on placebo after un-blinding revealed a DFS and distant DFS benefit in patients who 
switched to letrozole.28 Currently, several trials are investigating the most optimal treatment schedule in the 
extended adjuvant treatment setting. The Investigation on the Duration of  Extended Adjuvant Letrozole 
(IDEAL) trial is the first prospective, randomized controlled trial to compare 2.5 with 5 years of  extended 
adjuvant letrozole, after 5 years of  any adjuvant endocrine therapy regimen (tamoxifen, AI monotherapy or 
sequential therapy).29 The study comprises 1824 patients and final results of  this trial are eagerly awaited. 
N e o a d j u v a n t  e n d o c r i n e  t r e a t m e n t
It was not until the last part of  the 20th century that the notion of  pre-operative, also known as neoadjuvant, 
systemic therapy came into use. The advent of  post-operative systemic therapy for early breast cancer 
had prompted the need for better control of  both locoregional and micrometastatic tumor growth.30 This 
paradigm shift resulted in the use of  neoadjuvant systemic therapy for treating large or inoperable breast 
cancers. One of  the first trials to study neoadjuvant chemotherapy was the National Surgical Adjuvant Breast 
and Bowel Project (NSABP) B-18 trial, which compared pre-operative with post-operative chemotherapy 
(doxorubicin (Adriamycin) and cyclophosphamide (Cytoxan; AC), every 21 days, 4 courses).30 The pre-
operative treatment arm permitted more breast conservation, especially in women who had been candidates 
for mastectomy earlier, while survival outcomes did not differ between the pre-operative and post-operative 
study groups.
At the same time in 1984, the European Organization for Research and Treatment of  Cancer (EORTC) 
Breast Cancer Cooperative Group devised two prospective, randomized trials (EORTC 10850 and 10851). 
The studies compared modified radical mastectomy (MRM) to wide local excision (WLE) with tamoxifen 
(EORTC 10850) and MRM to tamoxifen only (EORTC 10851) in older (≥70 years) breast cancer patients.31, 32 
OS was similar for both treatment groups in the two studies, and the time to distant disease progression 
was improved in tamoxifen- and WLE-treated patients (EORTC 10850). Both studies, however, showed 
shorter times to local disease progression in tamoxifen-treated patients. Although tamoxifen alone was not 
recommended for older breast cancer patients, based on the results of  the EORTC 10851 study, it was 
evident that the addition of  endocrine therapy might contribute to performing less extensive surgery. In the 
years that have since followed, several studies have investigated the use of  neoadjuvant endocrine therapy 
for enabling downsizing and downstaging of  large or inoperable hormone receptor-positive breast tumors, 
as well as allowing for a better insight into the effects of  endocrine therapy on tumor biology and treatment 
response.33
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The scope of  breast cancer treatment is multifactorial, and combines surgical intervention with systemic 
therapy, which comprises endocrine therapy, chemotherapy, potentially in combination with targeted 
therapy, as well as radiotherapy as the main treatment modalities. National and international treatment 
guidelines currently provide recommendations for surgical and pharmacologic interventions for breast 
cancer treatment.34, 35 Needless to say, these guidelines have targeted the entire population of  breast cancer 
patients, and guidance for individual patients is less prominent. Conventional variables such as age, tumor 
stage, differentiation grade, overexpression of  Human Epidermal growth factor Receptor 2 (HER2), and 
the presence of  ERs and PRs are commonly used to guide treatment decisions, while more patient-specific 
features are less frequently accounted for. The patient also plays a key role in successful treatment and, 
having said this, we are seeing a growing trend towards tailoring breast cancer treatment to the individual 
at hand. In this thesis, we study tumor- and patient-specific characteristics and their capacity to aid the 
decision-making process with respect to endocrine treatment. 
The studies that make up this thesis are based on patient cohorts from three separate clinical trials. All 
trials included postmenopausal, hormone receptor-positive early breast cancer patients. Data from patients 
enrolled in the TEAM trial was utilized for all studies of  adjuvant endocrine therapy. The TEAM trial 
compares 2-3 years of  tamoxifen followed by 3-2 years of  exemestane (sequential therapy) with 5 years of  
exemestane only.22 The IDEAL (Investigation of  the optimal Duration of  Extended Adjuvant Letrozole) trial 
compares 2.5 years with 5 years of  extended adjuvant letrozole, after completion of  5 years of  any adjuvant 
endocrine therapy regimen (either tamoxifen or AI monotherapy or sequential therapy).36 Lastly, the TEAM 
IIA study is a single-arm, prospective clinical trial investigating 6 months of  neoadjuvant endocrine therapy.
PART I – Patient and tumor characteristics
Part I of  this thesis includes studies of  a variety of  patient and tumor characteristics that influence the 
success of  different adjuvant endocrine therapy regimens in postmenopausal early breast cancer patients, 
focusing on ways to tailor endocrine treatment to the individual patient. In chapter 2 and chapter 3, we 
study the importance of  tumor-biologic variations in the postmenopausal endocrine-sensitive breast cancer 
population with respect to choosing the optimal endocrine treatment regimen for certain patient subgroups.
Lifestyle interventions, including physical activity and diet have shown to improve disease outcomes and 
may be especially helpful for certain subgroups of  patients. It has been suggested that body-mass index 
(BMI) has a significant effect on breast cancer outcomes and endocrine treatment efficacy. In chapter 4, we 
study the effect of  BMI on breast cancer outcomes and whether BMI can influence the success of  different 
endocrine treatment regimens. Several studies have addressed the importance of  maintaining a healthy 
body weight, as high BMI has been found to be associated with poorer survival in breast cancer patients. 
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It is well-known that physical activity, in general, can help improve body weight and physical functioning 
as well as help decrease the risk of  developing breast cancer. The effect of  physical activity on breast 
cancer survival has not been as well-studied, especially in the elderly population of  breast cancer patients. 
In addition to poorer breast cancer outcomes, the elderly breast cancer population is at risk of  greater 
functional decline following breast cancer diagnosis and treatment. Therefore, we investigate the effect of  
physical activity on breast cancer outcomes in the elderly population in chapter 5 and chapter 6. 
Current prediction models play an important role in determining prognosis and treatment outcomes 
for various cancers, but are suboptimal in providing long-term prognostic information for an individual 
patient. These so-called ‘static’ models also fail to take into account that cancer patients may experience 
treatment- or disease-related events after diagnosis, which may change their individual prognoses. ‘Dynamic 
prediction’, a very novel concept in medicine, has the capability to account for such events, permitting a 
continuous update of  a patient’s individual prognosis as the time since breast cancer diagnosis prolongs. In 
chapter 7, we present a dynamic prediction model that can help predict an individual patient’s five-year 
OS probability at any point in time in the first three years after breast cancer diagnosis. 
PART II – Quality of  life, treatment compliance and side effects
In Part II, we discuss the impact of  endocrine therapy and its side effects on the daily lives of  breast cancer 
survivors. Although adjuvant endocrine therapy has brought about significant improvements in prognosis, 
treatment with AIs and/or tamoxifen are often accompanied by debilitating side effects such as hot flashes, 
night sweats, bone, joint and muscle pains, in addition to several other symptoms. These side effects can 
have a significant impact on the quality of  life in women, as is described in chapter 8. Severe side effects 
also pose a major threat to premature discontinuation of  endocrine treatment, and with the emergence 
of  recent studies showing that longer treatment durations significantly benefit prognosis, ways to improve 
compliance to therapy need to be addressed. In chapter 9, we report on factors associated with early 
treatment discontinuation in patients treated with extended adjuvant endocrine therapy. In chapter 10 
and chapter 11, we test the hypothesis that specific side effects including vasomotor symptoms (hot flashes, 
night sweats) and musculoskeletal symptoms (bone and joint pain, muscle pain) are related to treatment 
effectiveness in breast cancer patients. Not all patients develop specific side effects of  endocrine therapy, 
even if  we omit the possibility of  this being because patients do not take their prescribed medication. In 
chapter 12, we explore variations in the aromatase gene (CYP19A1) and how these variations may be 
related to the development of  specific side effects. 
PART III – Pre-operative and operative treatment possibilities
Owing to the possibility of  performing less extensive surgery as well as studying a tumor’s response to 
systemic treatment, neoadjuvant therapy has gained much popularity in recent years. Part III presents 
opportunities for incorporating both neoadjuvant chemotherapy and neoadjuvant endocrine therapy into 
the treatment regimens of  postmenopausal early breast cancer patients. In chapter 13, we introduce 
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the concept of  neoadjuvant endocrine therapy and its more widespread applicability for postmenopausal 
patients with endocrine-sensitive breast tumors. Following the literature review, chapter 14 presents a 
prospective clinical trial that investigates six months of  neoadjuvant endocrine therapy in endocrine-
sensitive breast cancer patients. A concluding topic that has enjoyed much attention in the last years is the 
surgical treatment of  the axillary lymph nodes in patients undergoing pre-operative systemic treatment for 
breast cancer. We review this issue in relation to neoadjuvant chemotherapy in chapter 15 and provide 
recommendations based on the available evidence. Finally, chapter 16 discusses how the studies that make 
up this thesis contribute to further personalization of  endocrine therapy for hormone receptor-positive 
breast cancer patients and proposes possibilities to further facilitate patient-tailored treatment.
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Background
There is an ongoing effort to predict disease outcomes in breast cancer patients in order to personalize 
treatment. As adjuvant endocrine therapy plays a major role in the treatment of  postmenopausal, 
endocrine-sensitive breast cancer patients, it is important to understand variations in this population and 
the preference of  specific endocrine therapy regimens in various subgroups. We investigated preferential 
treatment benefits of  sequential or upfront exemestane therapy in specific subgroups of  Dutch and Belgian 
patients enrolled in the Tamoxifen Exemestane Adjuvant Multinational (TEAM) trial.
Methods
The TEAM trial compares a sequential treatment regimen (tamoxifen 2.5-3 years followed by exemestane 
for 2.5-2 years) with exemestane alone for 5 years. Intention-to-treat analyses included 3168 Dutch and 
Belgian TEAM patients. Cox regression analyses, stratified by protocol-defined covariates, were performed 
to assess disease-free survival (DFS) and overall survival (OS). Additional analyses for DFS investigated 
quantitative hormone receptor expression according to the Allred score, and HER2 status in relation to 
treatment regimen.
Results
After a median follow-up of  6.91 years (range 0.06-11.41), overall hazard ratios (HR) for DFS and OS 
were 0.91 (95% confidence interval (CI) 0.85-1.04) and 0.93 (95%CI 0.80-1.08) respectively for upfront 
exemestane compared with sequential treatment. ER-rich patients had a significant DFS benefit when 
treated with upfront exemestane (HR 0.82 (95%CI 0.7-0.95), while ER-poor patients had an improved DFS 
with a sequential treatment regimen  (HR 1.84 (95%CI 1.26-2.69), p-for-interaction=0.001). HER2 status 
did not show any treatment-by-marker interaction.
Discussion
Although exemestane alone compared with sequential treatment did not result in long-term differences in 
overall DFS or OS, certain subgroups of  patients demonstrated a preferential treatment benefit for one over 
the other regimen. 
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A majority of  postmenopausal breast cancer patients have hormone receptor-positive breast tumors, their 
growth being driven by estrogens.1, 2 Therapies have been developed to combat the effect of  estrogens on 
tumor growth, either by selectively modulating the estrogen receptor (ER) as is the case with tamoxifen, or 
by blocking the conversion of  androgens to estrogens through aromatase inhibitors (AIs). Tamoxifen and AIs 
both play a major role in the treatment of  postmenopausal, hormone receptor-positive early breast cancer 
patients. In postmenopausal women, tamoxifen is usually followed by an AI, as the switch to an AI after 2-3 
years of  tamoxifen treatment showed benefits in disease-free survival (DFS) when compared with tamoxifen 
alone.3, 4 AIs may be prescribed as part of  a sequential treatment regimen (tamoxifen for 2-3 years followed 
by an AI for 3-2 years), upfront therapy for a period of  five years, or extended treatment (following five years 
of  tamoxifen therapy).5-10 As adjuvant endocrine therapy assumes a long-term treatment commitment, it is 
important to understand variations in the population with hormone receptor-positive tumors and the role 
of  endocrine therapy in relation to outcomes in different subgroups of  patients. 
Several prognostic factors are known to influence breast cancer survival, but data are limited regarding the 
predictive effects of  these factors on the outcomes of  different endocrine therapy regimens for specific subgroups 
of  patients. For example, our analysis of  semi-quantitative ER expression using the Allred score in relation to 
preferential treatment benefit in ductal and lobular breast cancer patients, specifically, showed a significant benefit 
of  upfront exemestane over sequential treatment in ER-rich (ER Allred ≥7) patients.11 
In establishing more tailored therapy for individual women, it is important to identify different predictive 
factors that can influence treatment success in order to enable physicians to select the most optimal 
treatment regimen together with their patients, whilst reducing the possibility of  unnecessary side effects 
and minimizing the risk of  disease recurrence. In the context of  more extensive follow-up, we explored 
several tumor-specific factors in relation to preferential treatment benefit in Dutch and Belgian patients 
from the Tamoxifen Exemestane Adjuvant Multinational (TEAM) study.10  
P A T I E N T S  A N D  M E T H O D S
TEAM Trial
The TEAM trial is a randomized, adjuvant, phase III, multinational, open label study conducted in 
postmenopausal breast cancer patients with ER- and/or progesterone receptor (PR)-positive tumors. 
Patients were randomized to receive a sequential treatment regimen, consisting of  tamoxifen (20mg, once 
daily, orally) for 2.5-3 years, followed by exemestane (25mg, once daily, orally) for 2.5-2 years thereafter or 
five years of  exemestane (25mg, once daily, orally). All patients provided written informed consent. The trial 
was registered in the Netherlands and Belgium with the Netherlands Trial Register, NTR 267. 
Inclusion in the present study was limited to Dutch (n=2754) and Belgian (n=414) patients only (n=3168). 
The eligibility criteria for Belgium and the Netherlands comprised postmenopausal women with 
I N T R O D U C T I O N
histologically confirmed hormone receptor-positive early breast cancer, who had undergone primary 
surgery with curative intent and had an indication for adjuvant endocrine therapy according to Dutch and 
Belgian treatment guidelines.12 Between July 2001 and February 2006, patients were enrolled in 79 hospitals 
throughout the Netherlands and Belgium. Database lock was on April 4th, 2013. 
Data were collected locally on Case Report Forms and sent to the central datacenter in Leiden, the 
Netherlands. As part of  the TEAM pathology study, central assessment of  ER and PR status (according 
to the Allred score), and of  HER2 status was performed in Edinburgh, United Kingdom.13 The Allred 
score represents a combination of  the percentage of  cells that stain positive for hormone receptors and 
the intensity thereof.14 Subgroup analyses investigated whether there was a beneficial effect on DFS for 
the different treatment arms in relation to three different biomarkers, including, ER Allred and PR Allred 
scores, and HER2 expression/gene amplification (positive/negative), with additional analyses for treatment-
by-marker interactions. 
The primary endpoint of  the current investigation was disease-free survival (DFS), defined as the time from 
randomization to the earliest documentation of  disease relapse (locoregional and/or distant recurrence 
or contralateral breast cancer) or death from any cause.10 Secondary endpoints comprised overall survival 
(OS) and DFS outcomes for specific subgroups of  patients, including age at randomization, ER Allred score 
(≤6/≥7), PR Allred score (≤4/≥5), and HER2 expression (positive/negative).
 
Statistical analyses
Statistical analyses were performed using SPSS 20.0 (SPSS, Chicago, IL). All analyses were performed as 
intention-to-treat analyses. To compare proportional differences between patients by randomized treatment, 
Pearson chi-square tests were used. Kaplan-Meier curves were plotted and Cox Proportional Hazard 
models investigated survival differences with respect to treatment arm (upfront exemestane compared with 
tamoxifen followed by exemestane). All analyses were stratified by protocol-defined stratification variables, 
including adjuvant chemotherapy (yes/no) and time between surgery and the start of  randomized treatment 
(0-3 / 3-6 / >6 months). Interaction terms between treatment arm and grouping variable were included in 
the model to test for the presence of  effect modification.
R E S U L T S
Patients
Out of  3168 patients, 1583 received sequential treatment and 1585 were allotted five years of  upfront 
exemestane. Baseline tumor, patient, and treatment characteristics were equally distributed between the 
two treatment arms (Table 1). Median follow-up of  patients alive was 6.91 years (range 0.06-11.41 years). 
Median age at randomization was 64.6 years (mean 63.5, range 38-96). Centrally revised information on 
ER, PR and HER2 status was available for approximately 85% of  the patients.
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Table 2 provides an overview of  the major types of  events and causes of  death up to the most recent 
follow-up date. Disease relapse in both treatment arms mainly consisted of  distant metastases. The majority 
of  deaths in both the sequential treatment and the upfront exemestane groups were due to breast cancer 
(61.7% and 55.9% respectively), followed by second malignancy (10.8% and 14.5% respectively), and 
cardiovascular events (9.9% and 12.3% respectively; chi-squared p=0.036). 
Table 1. Baseline characteristics of  Dutch and Belgian patients included in the TEAM trial
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Table 2. Events in patients treated with sequential therapy or exemestane only
Disease-free survival and overall survival
At the transition point from tamoxifen to exemestane (or 2.75 years for exemestane-treated patients), 
treatment with exemestane showed a significant DFS benefit when compared with tamoxifen (upfront 
exemestane: HR 0.780 (95%CI 0.631-0.965); p=0.022) (Figure 1). There was no difference in OS between 
sequential treatment and upfront exemestane at the time of  treatment switch (HR 0.875 (95%CI 0.641-
1.194); p=0.398). 
Comparing sequential treatment with upfront exemestane until the most recent follow-up date, the previously 
observed difference between sequential treatment and upfront exemestane was no longer present. At 10 
years of  follow-up, DFS for the sequential treatment arm was 58.6% and was 63.6% for upfront exemestane 
(HR for upfront exemestane 0.911 (95%CI 0.795-1.044); p=0.179 (reference: tamoxifen followed by 
exemestane)) (Table 3). OS was 67.1% in the sequential arm and 68.6% in the upfront exemestane arm 
respectively (HR 0.927 (95%CI 0.795-1.081); p=0.333). 
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Figure 1. Disease-free survival in patients treated with sequential treatment or exemestane only
 
Table 3. Disease-free survival for exemestane only compared with sequential treatment in different subgroups of patients
Biomarker analysis
The majority of  patients (85%) had available data for ER and PR. Most patients had ER-rich (87%) and 
PR-rich (76%) tumors. In this cohort of  patients, we found a significant treatment-by-marker interaction 
for ER Allred score and treatment regimen (p=0.001), with ER-rich patients having a significant DFS 
advantage when treated with upfront exemestane, and ER-poor patients showed better DFS with a 
sequential treatment regimen (reference: tamoxifen followed by exemestane: ER-poor: HR 1.840 (95%CI 
1.257-2.694); p=0.002 and ER-rich: HR 0.816 (95%CI 0.698-0.954); p=0.011) (Figure 2). 
Figure 2. Forest plot depicting disease-free survival in relation to ER, PR and HER2 status in patients treated with 
five years of  sequential treatment or upfront exemestane
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The impact of  PR Allred scores (rich/poor) on preferential treatment for one of  the two regimens was 
investigated in a similar fashion to ER Allred score. Unlike for ER expression, however, no preferential 
treatment benefit was demonstrated for PR Allred score in upfront exemestane-treated patients when 
compared with sequential treatment (PR-poor: HR 1.051 (95%CI 0.815-1.356); p=0.699 and PR-rich: HR 
0.886 (95%CI 0.742-1.056); p=0.177, p-for-interaction=0.276).
Centrally reviewed HER2 status was also available for 2663 patients (84.1%). Approximately 12% of  
patients demonstrated HER2 overexpression (Table 1). Only two of  the patients in this cohort were treated 
with trastuzumab (Herceptin®), owing to the year in which the TEAM study was conducted. HER2-positive 
patients showed poorer DFS outcomes than HER2-negative patients (DFS HR 1.375 (95%CI 1.121-1.687); 
p=0.002). However, neither preferential treatment benefit nor treatment-by-marker interaction were 
observed for HER2 status up to most recent follow-up for DFS (HER2-negative: HR 0.872 (95%CI 0.745-
1.020); p=0.087, HER2-positive: HR 1.084 (95%CI 0.743-1.581); p=0.676, p-for-interaction=0.332).
D I S C U S S I O N
In the present analyses, we report the intention-to-treat findings of  the Dutch and Belgian TEAM patients 
with regard to DFS and OS outcomes of  two commonly used endocrine therapy regimens in postmenopausal 
women with early breast cancer. At the time of  switching from tamoxifen to exemestane, or 2.75 years 
for upfront exemestane-treated patients, treatment with exemestane showed better DFS outcomes when 
compared with tamoxifen. Needless to say, the survival curves converged again after this period. Both DFS 
and OS were similar with respect to endocrine therapy regimen after a median follow-up of  almost 7 years. 
With respect to specific subgroups of  patients, ER Allred score was associated with a preferential treatment 
benefit for one or the other treatment regimen. In the entire Dutch and Belgian TEAM trial cohort, ER-
rich patients, as defined by the Allred score, had a significant DFS advantage when treated with five years 
of  exemestane, when compared to a sequential treatment regimen. ER-poor patients, on the other hand, 
had an improved DFS with a sequential treatment regimen compared with upfront exemestane. Only ER 
Allred score demonstrated a significant treatment-by-marker interaction. PR Allred score and HER2 status 
were not predictive of  a differential treatment benefit.
It is interesting to note that in the period until the switch from tamoxifen to exemestane, there were 
significant DFS and OS benefits in favour of  the exemestane upfront treatment arm, although the curves 
converged thereafter and did not show a statistically significant difference in outcomes. This might be the 
result of  switching from tamoxifen to exemestane in the sequential treatment arm. One may infer that 
the observed difference in risk reduction takes place during the initial years of  treatment and recovers 
in the sequential group after the switch to exemestane is made. Of  note, however, some patients treated 
with tamoxifen experienced side effects and discontinued treatment before the pre-designated switch-
date. A majority of  these patients changed to exemestane or another AI. Therefore, the true effect of  a 
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sequential treatment regimen on disease outcomes may have been slightly overestimated. Although this can 
be considered a valuable representation of  true clinical practices, this finding also limits the comparability 
of  the two treatment arms in this study. 
In our study, data on ER, PR and HER2 expression were centrally assessed and were available for the 
majority of  patients, which confers a major strength of  this investigation. We previously reported a 
significant benefit of  exemestane upfront in ER-rich patients and of  sequential therapy in ER-poor ductal 
and lobular breast cancer patients.11 The current investigation includes all breast cancer subtypes of  this 
cohort and confirms superior outcomes for upfront exemestane in ER-rich patients and of  sequential 
treatment in ER-poor patients, with a significant treatment-by-marker interaction. Results show a strong 
preferential treatment benefit for upfront exemestane in ER-rich patients, but caution is warranted when 
interpreting results in ER-poor patients, as this subgroup comprises only 12% of  the study population. The 
earlier prospectively planned analyses by Bartlett et al. found a similar benefit for five years of  exemestane 
in ER-positive patients, but with a non-significant treatment-by-marker effect. The longer follow-up period 
in the current analyses, as well as our restriction to Dutch and Belgian TEAM participants who may differ 
slightly from the entire TEAM cohort may justify these findings.13, 15 Previously, a combined analysis of  
the ABCSG 8 and ARNO 95 trials described that efficacy of  anastrozole improved as quantitative ER 
expression increased, while effectiveness of  tamoxifen did not improve with increasing ER expression.16 
Similarly, in the TransATAC (Arimidex, Tamoxifen, Alone or in Combination) study, increasing ER 
expression was associated with improved outcomes in anastrozole-treated patients, but not in patients treated 
with tamoxifen.17 Nevertheless, results from the BIG 1-98 trial (using 80% expression as cut-off  value) 
demonstrated improved outcomes with letrozole in patients with lower levels of  ER expression than with 
higher ER expression.18  The high cut-off  point discriminating low from high ER expression in the latter 
study must be taken into account when comparing the results of  these studies. Quantitative ER expression 
may be used to determine which regimen is most suitable for postmenopausal patients who are candidates 
for adjuvant endocrine therapy, if  our data is confirmed and validated in future prospective studies. 
HER2 overexpression is found in less than 20% of  all breast cancers, and is associated with a poorer 
OS and relapse-free survival.19, 20 In the current study, HER2 overexpression was observed in 12% of  the 
patients (of  which only two patients received trastuzumab) and was associated with a significantly worse 
DFS and OS. Studies have shown complex interactions between HER2 and ER pathways, with HER2-
overexpressing tumors possibly more resistant to tamoxifen, a selective ER modulator.21 Simultaneously, 
however, studies have presented conflicting results, also in the present investigation.22-26 There is no evidence 
to suggest a preferential benefit of  exemestane upfront in HER2-positive patients in this cohort. Bartlett et 
al. investigated differential treatment benefit by HER2 status and found a significant benefit of  exemestane 
upfront in HER2-negative patients at 2.75 years, but the effect disappeared after five years.27 The lack 
of  a significant association after five years of  treatment may reflect the consequences of  switching from 
tamoxifen to exemestane after 2-3 years, hereby eliminating the effect of  tamoxifen resistance.
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The TEAM trial was conducted in nine different countries, with the Dutch and Belgian cohort of  TEAM 
trial patients contributing to as much as 32% of  all trial patients. The Dutch and Belgian study population 
represents a rather homogeneous group of  patients, as similar eligibility criteria were employed. For this 
reason it was possible to investigate prognostic and predictive factors associated with treatment success 
in this cohort. In light of  more tailor-made treatment of  patients with breast cancer, the importance of  
determining the optimal adjuvant endocrine therapy regimen is ever increasing. 
C O N C L U S I O N
Overall, there were no differences in efficacy of  the two endocrine therapy regimens in the Dutch and 
Belgian cohort of  patients, which is in line with the results of  all patients included in the international 
TEAM trial. A slight benefit was observed in this cohort at 2.75 years after the start of  treatment in favour 
of  exemestane upfront, but this effect disappeared after 5 years. Patients who had a lower ER Allred score 
(≤6) had improved outcomes when treated with tamoxifen followed by exemestane. These hypothesis-
generating findings can have important consequences for daily clinical practice regarding the choice for a 
more personalized treatment regimen.
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A B S T R A C T
Background
Multiple studies suggest better efficacy of  chemotherapy in invasive ductal breast carcinomas (IDC) than 
invasive lobular breast carcinomas (ILC). However, data on efficacy of  adjuvant endocrine therapy regimens 
and histological subtypes is sparse. This study assessed endocrine therapy efficacy in IDC and ILC. The 
influence of  semi-quantitative estrogen receptor (ER) expression by Allred score was also investigated.
Methods
Dutch and Belgian patients enrolled in the Tamoxifen Exemestane Adjuvant Multinational (TEAM) trial 
were randomized to exemestane (25mg daily), alone or in sequence with tamoxifen (20mg daily) for 5 years. 
Inclusion was restricted to IDC and ILC patients. Histological subtype was assessed locally; ER expression 
was centrally reviewed according to Allred score (ER-poor (≤6;n=235); ER-rich (≥7;n=1789)). Primary 
endpoint was relapse-free survival (RFS), which was the time from randomization to disease relapse.
Results
Overall, 2140 (82%) IDC and 463 (18%) ILC patients were included. RFS was similar for both endocrine 
treatment regimens in IDC (HR for exemestane was 0.83 (95%CI 0.67-1.03)), and ILC (HR 0.69 (95%CI 
0.45-1.06)). Irrespective of  histological subtype, patients with ER-rich Allred scores allocated to exemestane 
alone had an improved RFS (multivariable HR 0.71 (95%CI 0.56-0.89)). In contrast, patients with ER-
poor Allred scores allocated to exemestane had a worse RFS (multivariable HR 2.33 (95%CI 1.32-4.11)). 
Significant effect modification by ER-Allred score was confirmed (multivariable p=0.003).
Discussion
Efficacy of  endocrine therapy regimens was similar for IDC and ILC. However, ER-rich patients showed 
superior efficacy to upfront exemestane, while ER-poor patients had better outcomes with sequential 
therapy, irrespective of  histological subtype, emphasizing the relevance of  quantification of  ER expression.
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I N T R O D U C T I O N
Treatment decisions in breast cancer therapy are increasingly dependent on a growing number of  molecular 
tumor characteristics, consequently paving the way towards individual targeted treatment regimens. Invasive 
ductal carcinoma (IDC), is by far the most common type of  breast cancer.1 The second largest group, found 
in 10-15% of  all female breast cancers is invasive lobular carcinoma (ILC); ILC patients tend to be older, 
and tumors are frequently larger in size, estrogen and progesterone receptor (ER and PR) positive, and 
human epidermal growth factor receptor2 (HER2), p53, and epidermal growth factor receptor (EGFR) 
negative when compared to IDC.2 ILC is also frequently associated with higher ER expression than IDC.3, 4 
With regard to endocrine therapy, several reports have endorsed the association between higher levels of  
ER expression and the prediction of  efficacy of  endocrine therapy.5-7 However, the association between 
histological subtype and adjuvant endocrine therapy efficacy is seldom addressed, as reports have frequently 
combined IDC and ILC in these efficacy analyses. In 1987, Smith and colleagues demonstrated similar 
survival after endocrine treatment with tamoxifen or ovarian ablation in IDC and ILC.8 Another study 
investigated pathologic parameters and adjuvant tamoxifen response in IDC and ILC. But interaction 
analyses did not show significant differences in response to tamoxifen in IDC compared with ILC, and 
inclusion was restricted to premenopausal patients of  whom fewer than 2% were treated with adjuvant 
chemotherapy.4 A study by Rakha and colleagues, on the other hand, demonstrated a better response to 
various forms of  endocrine therapy (ET) (tamoxifen, aromatase inhibitors (AIs), ovarian ablation or high-
dose progestins) in ILC than IDC.9 Thus, data comparing treatment response between the two major 
subtypes are scarce and inconsistent, and lack data on quantitative hormone receptor expression.
Upfront treatment with an AI or sequential therapy with tamoxifen followed by an AI for a total of  five years 
is currently the most widely applied endocrine treatment regimen for postmenopausal hormone receptor-
positive early breast cancer patients.10 However, recommendations for prescribing adjuvant endocrine 
therapy make no distinction between IDC and ILC or quantitative hormone receptor expression.11 In a 
recent report of  the Tamoxifen Exemestane Adjuvant Multinational (TEAM) trial by Bartlett and colleagues, 
a nonsignificant benefit for exemestane compared with tamoxifen was established in patients with high 
ER expression based on Allred scores, although follow-up was limited to 2.75 years.12 The TransATAC 
(Arimidex, Tamoxifen Alone or in Combination) trial also demonstrated a significant improvement in time 
to relapse with respect to increasing ER expression in patients treated with anastrozole, while this could 
not be established for tamoxifen-treated patients.13 At two years, recurrence rates were lower for ER-poor 
patients for tamoxifen versus anastrozole, but by about 5 years, rates were similar. However, no analyses by 
histological subtype were performed. 
Current evidence is too inconsistent to establish a preferential treatment for histological subtypes in clinical 
practice. The reported variability in evidence regarding outcome after ET in IDC and ILC may be due to 
relatively small numbers of  included ILC cases, as well as the retrospective nature of  many studies previously 
reported. As ILC is more often ER-positive and frequently associated with stronger ER expression than IDC, 
C H A P T E R  336
we investigated whether the histological subtype would translate to differential efficacies of  two endocrine 
treatment regimens in Dutch/Belgian patients included in the TEAM trial on the basis of  quantitative ER 
expression using the Allred score.12, 14
M A T E R I A L S  A N D  M E T H O D S
International TEAM trial design
The TEAM trial is a randomized, adjuvant, phase III, multinational, open label study conducted in 
postmenopausal women with estrogen and/or progesterone receptor positive tumors. Patients were 
randomized to receive either exemestane 25 mg once-daily for five years or tamoxifen 20 mg once-daily for 
2.5–3 years, followed by exemestane 25 mg once-daily for 2.5–2 years, for a total of  five years. Participants 
were enrolled in Belgium, the Netherlands, United Kingdom, Ireland, United States of  America, Japan, 
Greece, Germany and France. Eligibility criteria have been published in earlier reports.10, 15 In short, 
postmenopausal patients with histologically confirmed breast adenocarcinoma, who completed local 
therapy with curative intent, i.e. without evidence of  metastatic disease, were eligible. Appropriate approvals 
from the ethical committees were obtained. All patients provided written informed consent, and additional 
consent was obtained from patients in the tamoxifen group for the switch to exemestane. 
Design of  the current study
Inclusion in the present study was restricted to Dutch and Belgian patients, due to the central review 
of  tumor characteristics in this population (n=3167). Patients with a lobular or ductal tumor subtype 
(n=2603) were eligible for inclusion. The remaining patients had invasive mixed (n=134, 4.2%), unspecified 
(n=24, 0.8%) and unknown (n=406, 12.8%) subtypes. The database was locked on February 23rd, 2011. 
Data collection was performed locally on specific study case report forms, and transferred to the central 
datacenter in Leiden, the Netherlands. Histological subtype was determined by the local pathologist 
conform international criteria as described in the literature.16 The use of  E-cadherin was not used routinely. 
Auditing of  pathology reports was performed centrally in Leiden, the Netherlands. ER and PR expression 
was reassessed and quantified centrally in Edinburgh, United Kingdom. Detailed information is provided in 
a recent report by Bartlett and colleagues.12 Estrogen and progesterone receptor expression were evaluated 
as binary categories according to the Allred score, with PR and ER cutoff  at the median in line with those 
reported by Bartlett et al. (PR-poor ≤4 versus PR-rich ≥5; ER-poor ≤6 versus ER-rich ≥7).12 Patients with 
unknown ER Allred scores (n=108) were not included in the survival analyses by Allred score, irrespective 
of  their PR score. To assess the robustness of  the findings, additional analyses were performed using the ER 
histoscore.12 ER histoscore was dichotomized at the median. ER receptor expression and histoscore could 
be determined for 2461 patients (94.5%). 
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Endpoints
The primary endpoint of  the current study was relapse-free survival (RFS), which was defined as the time 
from randomization to the earliest documentation of  disease relapse. Disease relapse was defined as tumor 
recurrence (locoregional or distant), ipsilateral or contralateral breast cancer. Ductal carcinoma in situ was 
not considered a relapse.10
Statistical analysis
Statistical analyses were performed using SPSS 17.0 (SPSS, Chicago, IL) and R statistical package. To 
compare differences in proportions between patients with lobular and ductal breast tumors, Pearson 
chi-square tests and the Independent sample t-tests were used. Kaplan-Meier curves were plotted and Cox 
proportional hazard models were used to assess survival differences with respect to treatment arm. Survival 
analyses were stratified by histological subtype and ER Allred score. Interaction terms between treatment arm 
and histological subtype, and between treatment arm and ER Allred score respectively, were included in the 
Cox proportional hazard model to test for the presence of  effect modification. Multivariable survival analyses 
by histological type were adjusted for age, histological grade (Bloom Richardson grade 1;2;3), T-stage (1;2;3,4), 
nodal stage (negative; positive), ER Allred score (ER-rich; ER-poor), PR Allred score (PR-rich; PR-poor), 
HER2 status (positive; negative), most extensive surgery (mastectomy; wide local excision), radiotherapy (yes; 
no), and chemotherapy (yes; no). Multivariable analyses by ER Allred score were adjusted for age, histological 
grade (Bloom Richardson grade 1;2;3), T-stage (1;2;3,4), nodal stage (negative; positive), PR Allred score (PR-
rich; PR-poor), HER2 status (positive; negative), most extensive surgery (mastectomy; wide local excision), 
radiotherapy (yes; no), and chemotherapy (yes; no). To evaluate the interaction between randomized treatment 
and ER expression in more detail, we performed a sliding window STEPP analysis. 17, 18 All statistical tests were 
two-sided.  A p-value of  <0.05 was considered statistically significant.
 
R E S U L T S
Overall, 2603 patients from the Netherlands and Belgium who were included in the multinational TEAM 
trial, were included in this analysis, of  which 2140 (82%) presented with IDC and 463 (18%) with ILC. 
Baseline characteristics of  the included patients are shown by histological subtype in Table 1. Patients with 
a lobular subtype were significantly older (p=0.004), had larger tumors (p<0.001) and more frequently were 
node positive (p=0.034) and had an unknown tumor differentiation grade (p<0.001). Moreover, patients 
with ILC more frequently underwent a mastectomy (p<0.001) and received less chemotherapy (p=0.024). 
No differences were observed for other therapies applied. 
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Table 1: Patient characteristics by histological subtype.
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At database lock, there were 338 (16%) relapses in patients with IDC and 83 (18%) in patients with ILC. 
Five-year RFS was 86% for IDC and 83% for ILC (reference: IDC, univariate hazard ratio (HR) for ILC 
1.15 (95% confidence interval (CI) 0.90-1.46), p=0.257; ILC multivariable HR 1.18 (95%CI 0.89-1.57), 
p=0.257). Table 2 shows efficacy analyses stratified by histological subtypes. In patients with IDC, RFS 
was not significantly different for either treatment regimen (sequential therapy functioned as a reference, 
univariate HR for exemestane: 0.83 (95%CI 0.67-1.03), p=0.089; multivariable HR 0.90 (95%CI 0.72-
1.13), p=0.373). Comparable results were observed in patients with ILC (univariate HR 0.69 (95%CI 0.45-
1.06), p=0.089; multivariable HR 0.61 (95%CI 0.37-1.01), p=0.053). In order to assess whether efficacy 
analyses were modified by histological subtype, we included an interaction term between randomization 
and histological subtype. No significant interaction was observed (multivariable p=0.148). 
Table 2. Relapse-free survival by treatment regimen, stratified by histological subtype.
The number of  patients with an ER-rich tumor was 1789 (89.5%) in IDC patients, and 380 (87.6%) in ILC 
patients (p=0.234). Median ER Allred scores were similar in IDC and ILC patients (7 versus 7), mean ER 
Allred score was slightly lower in IDC patients (6.89 versus 6.98, p=0.042). Due to the fact that a previous 
study showed better RFS in patients with ER-rich Allred scores, and because patients with ILC more 
frequently present with ER-positive disease, survival by ER Allred score was assessed in patients with ductal 
and lobular subtypes separately. 
For both histological subtypes, ER-rich Allred scores showed superior outcomes for upfront exemestane 
in both univariate and multivariable analyses (Supplementary Table 1). In contrast, in both IDC and ILC 
patients with ER-poor Allred scores, those who were allocated exemestane had a worse relapse-free survival. 
No significant effect modification by histological subtype was observed for ER-rich Allred scores (p=0.201) 
and ER-poor Allred scores (p=0.799). 
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Because of  the absence of  effect modification, survival analyses were repeated for all patients. Cumulative 
incidence of  breast cancer relapse by treatment regimen for both patients with ER-rich and ER-poor 
tumors is shown in Figure 1. As shown in Table 3, patients with ER-rich Allred scores and allocated 5 years 
of  exemestane showed a more than 30% improved RFS when compared to patients allocated sequential 
treatment, which was confirmed in multivariable analyses (HR for exemestane: 0.72 (95%CI 0.57-0.90), 
p=0.004). In contrast, ER-poor Allred score in combination with allocation to exemestane monotherapy 
was associated with a worse RFS, which was even more pronounced after multivariable analyses (HR 
for exemestane: 1.85 (95%CI 1.11-3.09), p=0.019). ER Allred score was a significant effect modifier of  
endocrine therapy efficacy in all patients (multivariable p for interaction=0.003). Similar analyses were 
performed for PR Allred score, but no significant effect modification was observed (p for interaction=0.137).
Table 3. Relapse-free survival by treatment regimen, stratified by ER Allred score.
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To assess the robustness of  the findings, additional analyses were performed using the ER histoscore 
instead of  the ER Allred score. ER histoscore was dichotomized at the median, which resulted in 1231 
patients with ER-rich tumors and 1230 patients with ER-poor tumors. Results are shown in Supplementary 
Table 2. In both univariate and multivariable analyses, patients with a high histoscore derived a significant 
benefit from exemestane monotherapy (multivariable HR for exemestane was 0.56 (95%CI 0.39-0.80), 
p=0.001). No difference was observed for patients with a low histoscore (multivariable HR for exemestane 
was 1.04 (95%CI 0.80-1.34), p=0.779). Nevertheless, significant effect modification by histoscore (p=0.005) 
was observed. Additionally, a sliding window STEPP analysis was performed (Figure 2), which showed a 
dose-response relation. Moreover, only those patients with the lowest ER histoscores derived benefit from 
a sequential therapy regimen, while with increasing histoscore, the benefit of  exemestane monotherapy 
increased. Lastly, as ILC patients received less chemotherapy, sensitivity analyses were also performed 
restricted to patients without prior chemotherapy. These analyses revealed similar results (data not shown).
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D I S C U S S I O N
This study showed no preferential benefit for endocrine therapy based on histological subtype in patients 
with either IDC or ILC. However, a major finding of  the present study was that the efficacy of  endocrine 
therapy regimens was modified by the ER Allred score: an improved RFS was demonstrated in ER-rich 
patients when treated with five years of  exemestane, whereas ER-poor patients benefited more from the 
sequential treatment strategy. 
Several analyses were performed to assess sensitivity of  the used variables and robustness of  our findings. 
First, survival analyses were repeated with ER histoscore instead of  ER Allred score, which revealed 
comparable results. Next, a sliding window STEPP analysis was performed, which showed a dose-response 
relation between increasing ER histoscore and benefit of  exemestane monotherapy. It was shown that only 
those patients with the very lowest ER histoscores derived benefit from sequential therapy. This is in line 
with the results of  our Cox regression analyses, in which the effect in ER-rich patients is more outspoken 
than in ER-poor patients. Lastly, analyses were restricted to patients without prior chemotherapy, which did 
not alter the results.
Despite the numerous differences between IDC and ILC, histological subtype did not modify the efficacy 
of  treatment regimen. As literature suggests different distributions of  ER Allred scores for IDC and ILC 
patients3, 4, survival analyses by Allred score for both IDC and ILC separately were performed. Again, similar 
effects in both IDC and ILC patients were observed, in which higher ER Allred scores were predictive of  
a better response to exemestane monotherapy, whereas a sequential treatment regimen was preferred in 
patients with lower ER Allred scores. These findings support the supposition of  at least a similar efficacy 
of  endocrine treatment in IDC and ILC. Of  note, a prior publication by Pestalozzi et al. revealed changes 
in survival advantage for IDC and ILC over a 25-year period; up to six years, there is a survival benefit for 
ILC, after which the advantage changes to IDC.19 It is therefore important to interpret our results in the 
context of  longer-term findings.
Regardless of  histological subtype, a significant effect modification by ER Allred score was ascertained. 
Patients with ER-rich tumors responded better to five years of  exemestane, and patients with ER-poor 
tumors were better off  with the sequential treatment regimen. It is tempting to speculate on the mechanisms 
which may explain the results observed. Although not the case in all patients, ER expression can decrease 
during tamoxifen treatment, also one of  the mechanisms that contribute to reduced tolerability to endocrine 
treatment over time.20, 21 We may thus contemplate that more rapid exhaustion of  ER expression leads to 
an improved response to a new mechanism that counters the effect of  estrogens on tumor growth, namely 
through the inhibition of  aromatase. Therefore, in ER-poor tumors one can argue that these more readily 
develop endocrine resistance than ER-rich tumors, and thus the mechanism of  switching therapy is more 
relevant than the therapy itself.
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A recent report by Bartlett and colleagues in the international TEAM data suggested a beneficial effect of  
exemestane for ER-rich patients.12 However, in contrast to the present investigation, no significant treatment 
effect modification by ER Allred score was observed. This may be explained by the restriction to the two major 
histological subtypes in the current study. Second, the present findings are based on the Dutch and Belgian 
TEAM participants only, who may display slightly different characteristics than the combined international 
data.15 However, as nearly one third of  the patients included in the international study are of  Dutch/Belgian 
origin, this is not likely to have a major influence on our findings. Third, the analyses by Bartlett and colleagues 
were limited to 2.75 years of  follow-up, whereas the median follow-up of  the current study was 5.2 years.
Data are conflicting on the topic of  prognostic value of  quantitative hormone receptor expression. 
Previously, Mauriac and colleagues described prognostic risk factors that are associated with disease relapse, 
based on findings in the Breast International Group (BIG) 1-98 trial.22 In these analyses, a beneficial effect 
of  letrozole versus tamoxifen was found in patients with poorer prognoses (in terms of  tumor burden and 
aggressiveness), regardless of  the inclusion of  quantitative ER expression in the analysis.22 In the same 
cohort of  patients, Viale et al. found that patients with lower levels of  ER (<80%) had more benefit of  
letrozole monotherapy than patients with higher levels of  ER (≥80%), while this was not established in 
another report by Regan et al.23 In contrast, combined analyses of  the ABCSG 8 and ARNO 95 trials 
concluded that treatment efficacy with anastrozole improved with increasing ER expression, while this was 
not the case in tamoxifen-treated patients.24 
While our results remain to be confirmed in other studies, there is reason to believe that the differential 
response based on ER expression is of  clinical relevance. The importance of  quantitative associations between 
hormone receptor content and response to endocrine therapy has been documented in the past, and several 
semi-quantitative scoring systems have been proposed in order to reduce the number of  borderline cases of  
ER-positive tumors. However, it is still infrequently used to determine treatment regimen clinically. 
A major strength of  the present investigation is the relatively large cohort of  patients with ILC as well as the 
randomized design of  this study, which assures quality controlled data and an extended record of  patient 
and treatment characteristics. More importantly, the centrally reviewed ER expression excluded variation 
between pathology centers. Since histological subtype was assessed locally, we cannot exclude a potential bias 
in the inclusion of  our patients. Inclusion in the TEAM study was restricted to ER-and/or PR-positive breast 
tumors, therefore it was not possible to elaborate on the proportion of  ILC patients with ER-positive tumors 
compared to IDC patients. It is known that ILC patients more frequently present with ER-positive tumors, 
which predicts a superior response to endocrine therapy.25-28 Although a significant effect modification by ER 
expression was observed, the sliding window STEPP analysis indicated that only those patients with very low 
ER expression may be better off  with a sequential treatment, whereas patients with very high ER expression 
derive benefit from exemestane monotherapy. The retrospective, unplanned nature of  this analysis renders our 
investigation hypothesis generating, and these results will need to be validated through further investigation 
prospectively in order to define a possible ER expression cutoff  for treatment preference.
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 There was no difference in efficacy of  endocrine treatment between IDC and ILC, and therefore endocrine 
therapy remains warranted in ILC patients. Instead, the extent of  ER positivity may be superior in predicting 
treatment efficacy than histological subtype. In other words, our hypothesis was not confirmed on the basis 
of  histological subtypes. Alternatively, an effect modification for treatment modality by ER expression in 
both subtypes was established. The semi-quantitative analysis of  ER expression in postmenopausal early 
breast cancer patients may therefore be an important item in clinical decision-making to determining the 
optimal therapeutic regimen.  
 
Supplementary Table 1. Relapse-free survival by treatment regimen, stratified by ER Allred score and histological subtype.
Supplementary Table 2. Relapse-free survival by treatment regimen, stratified by ER histoscore. 
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Background
The relationship between body-mass index (BMI, kg/m2) and breast cancer outcomes in endocrine-sensitive 
early breast cancer patients is gaining recognition with regard to potential clinical relevance. Evidence 
suggests that obesity is associated with poorer outcomes following breast cancer diagnosis. We investigated 
the relationship between BMI and survival outcomes as well as BMI in relation to treatment efficacy in the 
Tamoxifen Exemestane Adjuvant Multinational (TEAM) trial.
Methods
The TEAM trial is an international, randomized, phase III, study conducted in postmenopausal, endocrine-
sensitive early breast cancer patients allocated sequential treatment with tamoxifen followed by exemestane 
or exemestane upfront, for a total of  5 years. Underweight (BMI<18.5kg/m2) and severely obese 
(BMI>45kg/m2) patients were excluded from the analyses. Univariable and multivariable Cox regression 
analyses assessed disease-free survival (DFS) and breast cancer-specific survival (BCSS) in relation to BMI 
and Kaplan-Meier curves were plotted. Interaction terms for BMI and treatment regimen tested for effect 
modification. Multiple imputations were performed in an additional analysis to account for missing data 
and 25 iterations were generated.
Results
After exclusion of  patients without any available BMI data, as well as patients who were underweight or 
severely obese, 4711 patients were included. Overweight and obese patients showed similar hazard ratios 
(HR) for DFS and BCSS compared with normal-weight patients (DFS: overweight HR=0.91 (95%CI 
0.79-1.05); obese HR=0.98 (95%CI 0.83-1.15). BCSS: overweight HR=1.07 (95%CI 0.82-1.40); obese 
HR=0.95 (95%CI 0.73-1.25)). BMI did not define benefit for one or the other treatment regimen with 
regard to DFS or BCSS. Imputed data analyses did not alter the results.
Discussion
BMI was not associated with differences in DFS or BCSS, nor was preferential treatment benefit affected 
by BMI. 
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I N T R O D U C T I O N
Obesity is affecting a growing number of  women worldwide.1 In Europe and other high-income countries, 
both age and obesity are on the rise, and are expected to continue to increase in the upcoming years.2 
Increasing weight is associated with the development of  chronic diseases and multiple comorbid conditions 
including breast cancer, especially in the aging population. A growing global epidemic, obesity not only 
contributes to the risk of  developing breast cancer 3, 4, but also to the clinical course of  established disease.5-7 
In early breast cancer patients, the relationship between body-mass index (BMI, kg/m2) and breast cancer 
outcomes is of  significant clinical importance. Obesity has been associated with poorer breast cancer 
outcomes overall and following primary treatment5, including a higher risk of  breast cancer recurrence.6, 8 
In their review, Chlebowski and colleagues demonstrated an almost two-fold increase in the risk of  
recurrence at 5 years in relation to BMI.6 
Systemic treatment in endocrine-sensitive breast cancer patients is frequently accompanied by unintentional 
weight gain9, 10, reported to range between 2.5 and 6.2 kg in the first year of  diagnosis.11 Older women 
especially are burdened by weight gain, both physiologically as time passes since menopause, and after 
breast cancer diagnosis and treatment. In addition to poorer outcomes after/during breast cancer treatment 
associated with increasing BMI, comorbidities and functional limitations associated with obesity are 
also considered risk factors for poorer breast cancer outcomes.12 We investigated the impact of  BMI on 
disease-free survival (DFS) and breast cancer-specific survival (BCSS) as well as the benefit of  sequential 
versus upfront aromatase inhibitor (AI) treatment in relation to BMI in postmenopausal, endocrine-sensitive 
early breast cancer patients treated with adjuvant endocrine therapy.
M A T E R I A L S  A N D  M E T H O D S
The Tamoxifen Exemestane Adjuvant Multinational (TEAM) trial is a randomized, adjuvant, phase III, 
multinational, open label study conducted in postmenopausal early breast cancer patients with estrogen 
receptor (ER)- and/or progesterone receptor (PR)-positive tumors.13 Relevant eligibility criteria comprised 
prior primary surgery with curative intent and an indication for adjuvant endocrine therapy. Patients were 
randomized to five years of  exemestane (25mg, once daily) or a sequential treatment regimen, consisting 
of  tamoxifen (20mg, once daily) for 2.5-3 years, followed by exemestane (25mg, once daily) for 2.5-2 years 
thereafter (for a total of  5 years). All patients provided written informed consent, and additional consent 
was obtained from patients in the sequential treatment group for the switch to exemestane. The trial was 
registered with ClinicalTrials.gov in France (NCT00279448), UK and Ireland (NCT00032136), USA 
(NCT00036270), with Ethics Commission Trial in Germany (27/2001), with University Hospital Medical 
Information Network-Clinical Trials Registry in Japan (C000000057), and in the Netherlands and Belgium 
with the Netherlands Trial Register (NTR 267). 
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Data were collected locally and transferred to the central datacenter in Leiden, the Netherlands. BMI 
was calculated using height and weight measurements, which were collected at baseline or randomization 
in Belgium, Germany, Greece, the Netherlands and UK/Ireland and were unavailable for France and 
USA. Patients were assessed every three months during the first year of  treatment, and at least once yearly 
thereafter.
Statistical analyses
Statistical analyses were performed using SPSS 20.0 (SPSS, Chicago, IL). All analyses were performed 
by intention-to-treat. Patients from countries that did not provide any BMI data (USA and France), other 
patients without any BMI data, as well as underweight (BMI<18.5 kg/m2, n=42) and severely overweight 
(BMI>45 kg/m2, n=12) patients were excluded from the analyses (Figure 1). To compare proportional 
differences between patients by BMI, Pearson chi-square tests were used. DFS and BCSS in relation to BMI 
were modeled in univariable and multivariable Cox proportional hazard models (hazard ratio (HR) with 
95% confidence intervals (95%CI)) and Kaplan-Meier curves were plotted. Multivariable Cox regression 
analyses were adjusted for age and country. Interaction terms for BMI and treatment regimen were 
incorporated to test for effect modification.
 
Figure 1. CONSORT diagram of  patients included in the non-imputed dataset
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Multiple imputation
Due to the large number of  patients without BMI data, missing BMI data were imputed (multiple 
imputations) using a model that included country, treatment, BMI, height, weight, age, T- and N-stage, 
grade, histological type, ER, PR and HER2 (human epidermal growth factor receptor 2), and outcome 
measures for survival. France and USA were excluded from imputations, as these countries did not provide 
height and weight measurements for any of  their patients. We generated 25 iterations and combined the 
estimates and standard errors using Rubin’s Rules (micombine in STATA). Multiple imputation by chained 
equations was used, which assumes a multivariable distribution without specifying its form. In STATA, 
multiple imputation was performed using the Imputation by Chained Equations (ICE) model. Univariable 
and multivariable survival analyses were used to study associations between BMI and survival, and between 
randomized treatment and survival, stratified by BMI. Interaction terms between BMI and randomized 
treatment were included in the model. All variables with a p-value ≤0.05 after univariable analyses were 
entered in the multivariable model. DFS and BCSS were calculated using multivariable Cox proportional 
hazard models with any recurrence, death or breast cancer death as event. Kaplan-Meier survival estimates 
were used to plot the survival for randomized treatment, stratified by BMI. 
R E S U L T S
BMI data (height and weight) was available for 4711 patients. BMI was normally distributed (median 26.2, 
standard deviation 4.68) and median follow-up of  patients alive was 6.5 years (range 0-10.73 years). Table 
1 shows patient, tumor and treatment characteristics for both the non-imputed and imputed datasets, and 
Table 2 depicts the distribution of  characteristics according to BMI category for the non-imputed datasets. 
2327 (49.4%) patients received tamoxifen followed by exemestane and 2384 (50.6%) patients exemestane 
upfront. BMI was higher in older than in younger patients, and the distribution of  patients across the BMI 
categories differed between countries.
Patients with available BMI data had larger tumors with higher nodal stages and were younger than patients 
with missing BMI data (Supplementary Table 1). In addition, patients in whom BMI was known were more 
frequently treated with radiotherapy and chemotherapy. Nevertheless, DFS did not differ between patients 
with and without reported BMI data.
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Table 1. Baseline characteristics for the non-imputed and imputed datasets
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Table 2. Baseline characteristics in relation to BMI category for patients included in the non-imputed dataset
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Breast cancer outcomes
After a median follow-up of  6.5 years, DFS was 63.1%, 63.2% and 65.5% for normal-weight, overweight 
and obese patients respectively. Multivariable Cox regression analyses, adjusted for age and country, did not 
reveal any statistically significant differences between in DFS according to BMI. Compared with normal-
weight patients, overweight and obese patients showed similar hazard ratios (HRs) for DFS (overweight HR 
0.91 (95%CI 0.79-1.05) and obese HR 0.98 (95%CI 0.83-1.15)) (Table 3).
BCSS analyses also did not show any differences in cumulative incidence of  breast cancer-related death in 
normal-weight, overweight and obese patients following both univariable and multivariable Cox regression 
analyses. BCSS was 24.4%, 24.5% and 24.6% for normal-weight, overweight and obese patients respectively 
(overweight HR 1.07 (95%CI 0.82-1.4); obese HR 0.95 (95%CI 0.73-1.25)) (Table 3).
 
Table 3. Disease-free and breast cancer-specific survival in relation to BMI in patients treated with adjuvant 




Stratified analyses were performed to assess the effect of  treatment benefit across the different BMI 
categories. Figure 2 depicts DFS outcomes for sequential treatment versus exemestane upfront in normal-
weight, overweight and obese patients separately. In normal-weight patients, a tendency towards a benefit 
for exemestane upfront over sequential treatment was found (multivariable HR 0.80 (95%CI 0.65-0.97); 
p=0.025). However, treatment-by-marker analyses did not show significant effect modification for differential 
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treatment efficacy in relation to BMI (p-for interaction>0.05). In overweight and obese patients, analyses 
showed similar DFS outcomes for tamoxifen followed by exemestane and for exemestane only (Table 4). 
Figure 2. Kaplan-Meier survival figures for disease-free survival according to BMI category in the non-imputed dataset 
With respect to BCSS, normal-weight patients also demonstrated better outcomes with exemestane only 
compared to tamoxifen followed by exemestane (multivariable HR 0.76 (95%CI 0.60-0.95); p=0.018), 
although interaction tests did not reveal statistical significance (p-for interaction>0.05). There was no 
difference in treatment efficacy in overweight or obese patients (overweight: multivariable HR 0.90 (95%CI 
0.71-1.15); obese: multivariable HR 0.90 (95%CI 0.66-1.21)) (Table 4). 
Imputed data 
Multiple imputations were performed to account for the large number of  missing height and weight measurements 
encountered in our dataset. Following imputation, there were no changes in DFS and BCSS outcomes for normal-
weight, overweight or obese patients compared with the non-imputed dataset (Table 3). Furthermore, imputed 
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analyses did not reveal a significant benefit for exemestane upfront in normal-weight patients for either DFS 
or BCSS (DFS: multivariable HR 0.90 (95%CI 0.74-1.10); p=0.32; BCSS: multivariable HR 0.85 (95%CI 
0.67-1.07); p=0.16) (Table 4, Figure 3). Interaction tests between BMI and randomized treatment did not 
show significant effect modification (p>0.05 for both DFS and BCSS).
Figure 3. Kaplan-Meier survival figures for disease-free survival according to BMI category following multiple 
imputation
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Table 4. Univariable and multivariable Cox regression analyses of  disease-free survival and breast cancer-specific 
survival according to BMI category in the non-imputed dataset
 
D I S C U S S I O N
In our cohort of  postmenopausal, endocrine-sensitive breast cancer patients, BMI was not found to be an 
adverse prognostic factor for DFS or BCSS. Normal-weight patients, demonstrated a tendency towards 
superior results with exemestane upfront, but the treatment-by-marker interaction test did not reach 
statistical significance. In addition, no significant benefit for either tamoxifen followed by exemestane or 
upfront treatment with exemestane in relation to BMI was found following multiple imputation analyses. 
In postmenopausal breast cancer patients, obesity is associated with an increased risk of  the development 
of  breast cancer.3, 14 In addition, after breast cancer diagnosis, obesity has been described to have an adverse 
effect on survival5-7, and an earlier meta-analysis demonstrated a significantly poorer survival in obese breast 
cancer patients when compared with non-obese patients.15 The increase in breast cancer risk associated with 
higher BMI may be related to higher levels of  circulating estrogens in postmenopausal women16, as obesity 
is associated with increased estrogen synthesis, insulin resistance and altered inflammatory mediators, which 
play a role in promoting estrogen synthesis and breast cancer growth.17-20 In contrast to earlier reports, 
however, our cohort showed that survival outcomes were similar in normal-weight, overweight and obese 
patients, implying that BMI does not compromise survival in this specific cohort of  postmenopausal, 
endocrine-sensitive early breast cancer patients. 
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Evidence of  a relationship between preferential treatment benefit and BMI is still relatively sparse. It has been 
implied that AIs are less effective in overweight or obese women, but only a limited number of  studies have 
compared tamoxifen with AIs in relation to BMI.21-25 Previously, Dignam and colleagues studied outcomes of  
5 years of  adjuvant tamoxifen versus placebo treatment in relation to BMI in the NSABP B14 trial. Treatment 
efficacy did not differ between obese (BMI ≥30 kg/m2) and underweight/normal-weight patients (BMI <25 
kg/m2).26 In postmenopausal women in the ATAC (Arimidex, Tamoxifen Alone or in Combination) and 
the BIG (Breast International Group) 1-98 trials, there was no significant benefit of  tamoxifen over AIs in 
overweight or obese patients following 5 years of  endocrine treatment.21, 24 In the ATAC trial, a non-significant 
benefit of  anastrozole over tamoxifen was reported in patients with a BMI <23 kg/m2. Higher BMI was 
also not associated with a differential treatment benefit.24 In another study by Wolters et al. a non-significant 
survival benefit in favor of  AIs compared with tamoxifen in normal- and intermediate-weight endocrine-
sensitive postmenopausal patients was demonstrated, and the opposite (also non-significant) was noted for 
obese patients.25 In the present analyses, obese patients also did not benefit from sequential treatment over 
exemestane upfront. Of  note, in contrast to the abovementioned studies, overall analysis of  the TEAM trial 
did not reveal DFS or OS differences between sequential and upfront treatment.13 
Although the currently available randomized studies have not provided striking evidence for a preferential 
treatment benefit in relation to BMI, it is tempting to speculate that there could be a biological rationale for 
differential efficacy between tamoxifen and exemestane treatment regimens in postmenopausal, endocrine-
sensitive breast cancer patients. AIs reduce the peripheral conversion of  androgens, also largely found in 
adipose tissue in postmenopausal women.27 Moreover, aromatization of  androstenedione to estrogens is 
related to body weight.24, 28-30 Previously, Pfeiler and colleagues measured estradiol levels after 3 months of  
AI treatment and demonstrated that obese postmenopausal patients had (non-significantly) higher estradiol 
levels than non-obese patients.31 Two groups have also studied variations in pharmacokinetics of  letrozole and 
found that differential plasma letrozole concentrations were associated with variations in CYP2A6 and BMI.32, 
33 The lack of  a differential treatment effect may hence be the result of  suboptimal reductions in circulating 
estrogen levels in larger patients, in which case future research may need to focus on quantitative assessments 
of  estrogen levels during endocrine treatment.
Approximately half  of  the entire TEAM cohort had BMI data available, and hence poses a limitation to 
the interpretation and wider applicability of  our results. Despite prognostically less favorable breast cancer 
characteristics, DFS outcomes were not worse in patients with documented height and weight measurements 
when compared with those patients whose BMI data was not reported. Additional analyses by means of  
multiple imputation were performed to deal with the large amount of  missing data. Multiple imputation can 
help reduce reporting bias to some degree, although it does not completely compensate for data not completely 
missing at random. A plausible explanation for the non-random nature of  the missing data in relation to BMI 
may be more accurate documentation of  height and weight in patients who require adjuvant chemotherapy, 
although this reasoning was not entirely supported by our cohort. 
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In conclusion, BMI was neither associated with survival outcomes nor variable treatment efficacy with respect 
to the two treatment regimens studied. Although more evidence for a stronger biological relationship is 
warranted before clinical decision-making is adapted to BMI, a progressively prevalent conception is that the 
dosage of  AIs may need to be proportionally adjusted with increases in BMI in order to accomplish adequate 
aromatase inhibition.
Supplementary Table 1. Baseline characteristics of  patients with and without BMI data
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A B S T R A C T
The effect of  physical activity (PA) on cancer survival is still the topic of  debate in oncology research focusing 
on survivorship, and has been investigated retrospectively in several large clinical trials. PA has been shown 
to improve quality of  life, fitness and strength, and to reduce depression and fatigue. At present, there is a 
growing body of  evidence on the effects of  PA interventions for cancer survivors on health outcomes. PA 
and functional limitations are interrelated in the elderly. However, the relationship between breast cancer 
survival and PA in older breast cancer patients has not yet been fully investigated. Our systematic review 
of  the existing literature on this topic yielded seventeen studies. Most reports demonstrated an improved 
overall survival (OS) and breast cancer-specific survival (BCSS). Furthermore, in studies that compared 
younger women with older or postmenopausal women, it was suggested that the beneficial effect of  PA may 
be even greater in older women. Understanding the interaction between physical functioning and cancer 
survival in older breast cancer patients is key, and may contribute to successful treatment and survival. In 
this population of  cancer survivors it is therefore imperative to embark on research focused on improving 
physical functioning in the context of  comorbidities and functional limitations. 
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I N T R O D U C T I O N
There is a growing body of  evidence on the effects of  physical activity (PA) interventions for cancer survivors 
on health outcomes. PA in breast cancer has shown to improve quality of  life, fitness and strength and to 
reduce depression and fatigue.1 Also, PA has shown to have an inverse association with postmenopausal 
breast cancer risk.2 Previous randomized controlled trials have demonstrated better quality of  life and other 
health outcomes in patients who undertake regular PA.3 The effect of  PA on cancer survival after breast 
cancer diagnosis, however, is still the topic of  debate in oncology research.4 
Breast cancer is increasingly becoming a disease of  the elderly and, simultaneously, the number of  breast 
cancer survivors is steadily rising.5 For example, in the United Kingdom, 45% of  breast cancer patients are 
older than 65 years at diagnosis.6 In elderly patients, cancer occurs in a background of  normal aging and 
comorbidity, thereby making this specific population heterogeneous in nature. Although older patients are 
known to have a higher disease-specific mortality, more than 65% of  breast cancer patients older than 75 
years die of  other causes than breast cancer.7 In contrast to younger patients, survival in the elderly breast 
cancer population has not improved in the last decade.8 While breast cancer has a profound effect on 
psychological functioning and quality of  life in younger females, elderly patients are affected by the disease 
physically more than psychologically.9 At an older age, the decline in physical functioning may be induced or 
amplified as a result of  local and/or systemic treatments. Regardless of  age, decline in physical functioning 
is associated with higher mortality.10 Therefore, new strategies to decrease the effect of  breast cancer on 
physical decline and to improve overall and disease-specific survival are needed. The purpose of  this study 
was to review the current literature in relation to the effect of  PA on survival in breast cancer patients, with 
a focus on the elderly breast cancer patient in particular.
M A T E R I A L S  A N D  M E T H O D S
Search strategy
Studies were identified through systematic review of  the available literature in the PubMed database, 
EMBASe, Cochrane and Web of  Science up to November 9th, 2012. PubMed, EMBASE, Cochrane 
and Web of  Science were all searched using the following set of  search terms which described breast 
cancer, physical activity, survival and elderly patients according to the following algorithm: (“Breast 
Neoplasms”[majr] OR “breast cancer”[ti] OR “Breast Neoplasm”[ti] OR “Breast Tumors”[ti] OR “Breast 
Tumor”[ti] OR “Breast Tumours”[ti] OR “Breast Tumour”[ti] OR “Breast Carcinoma”[ti] OR “Breast 
Carcinomas”[ti] OR “Cancer of  the Breast”[ti] OR “Cancer of  Breast”[ti]) AND (“physical activity” 
OR “Motor activity”[mesh] OR “Sports”[mesh] OR “Exercise”[mesh] OR Exercise[ti] OR Exercises[ti] 
OR “Resistance Training”[ti] OR Running[ti] OR Jogging[ti] OR Swimming[ti] OR Walking[ti] 
OR “Sports”[mesh] OR “Physical Exertion”[Mesh] OR exertion[ti]) AND (survival OR surviv* OR 
“Survival”[Mesh] OR “Mortality”[Mesh] OR “mortality”[Subheading] OR “Survival Rate”[Mesh] 
OR “Survival Analysis”[Mesh]) AND (“Aged”[mesh] OR Elderly OR aged OR Adult OR Adults OR 
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“Adult”[mesh] OR woman[tiab] OR women[tiab]) AND (eng[la]) AND (“Cohort Studies”[mesh] OR 
prognosis). 
Selection criteria
Two independent reviewers (D.F., N.G.) selected studies for inclusion in the review. Only reports written in 
English were eligible. Articles included original studies in which the effect of  PA on survival outcomes was 
investigated in breast cancer patients only. Studies were included if  the primary or secondary outcome was 
related to the influence of  PA on OS, BCSS or breast cancer recurrence after breast cancer diagnosis. PA 
was defined as any physical activity relating to aerobic, endurance, or strength training for the purposes 
of  recreation, household, commuting, or work. Where evident, activities including yoga, Pilates, Tai 
Chi, or stretching were not included in the analyses. There were no restrictions with regard to patient 
characteristics, breast cancer subtype, treatment, age, condition, comorbidities, and other features. Only 
studies investigating leisure or total activity (occupational and/or non-occupational) were selected. Studies 
measuring PA using biological parameters (i.e. cardiorespiratory fitness, energy expenditure (in KJ or Kcal), 
oxygen use (in vO2 /vCO2), etc.) were not included in our selected abstracts. In case of  an update of  
previously published data, the most recent publication was included. Reports on pilot data or descriptions 
of  a study design were excluded from this review. Studies were also excluded if  the PA intervention was 
combined with another intervention.  To ensure that no other studies were missed for inclusion in the 
current review, additional articles were identified by a manual search of  the reference list of  the selected 
manuscripts. 
Data extraction
Data extraction was performed by 3 reviewers (D.F., N.G. and M.D.). Relevant data was determined 
prior to reading the selected articles. For all included studies, we documented the type of  study, inclusion 
period, year of  publication, primary and (where possible) secondary endpoints. Results from each study 
was documented and independently reviewed and verified by two independent reviewers (D.F. and N.G.). 
Aspects of  PA were the type of  activity, PA measurement unit (including frequency, duration and intensity, 
which were frequently converted into Metabolic Equivalent Task (MET) hours), time and timeframe of  
measurement(s), method of  data collection, number of  patients, mean and median age and age range, in- 
and exclusion criteria, as well as tumor- and patient-related characteristics. Results for specific population 
subgroups, including age (and/or menopausal status) and Body-Mass Index (BMI) were documented where 
available. Due to the fact that ages varied greatly between studies, we defined ‘elderly’ as 65 years or older. 
Primary and/or secondary endpoints included all-cause mortality, breast cancer-specific mortality, and 
breast cancer recurrence. 
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Patients
A total of  497 unique articles were identified in the PubMed, EMBASe, Cochrane and Web of  Science 
searches, of  which seventeen studies were deemed eligible after applying in- and exclusion criteria to the 
titles and abstracts (Table 1 and Figure 1). A total of  35,026 breast cancer patients were included in our 
review. Only one study investigated solely postmenopausal patients.11 In most studies, PA was measured in 
the first year after primary diagnosis. Two studies only included patients who were diagnosed with early-
stage breast cancer. Fourteen studies also included patients with a more advanced breast cancer stage.
Figure 1. Flow chart
Studies
The majority of  the studies assessed were prospective observational cohort studies.11-23 Two studies were 
part of  the same side study of  a randomized controlled trial investigating dietary change.24, 25 A final study 
was a retrospective analysis of  PA in patients participating in a multicenter case-control study.26 
Questionnaires
In all studies, data collection was through self-administered and/or interviewer-administered questionnaires, 
performed either in person or by telephone. Questionnaires were completed either once 12-15, 18, 19, 21-23, 25, 26 
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Table 1. Physical activity outcomes in all studies
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or on two or more occasions.11, 16, 17, 20, 24, 27 Questionnaires included inquiries on occupational, recreational 
and/or household activities, either combined or separately. Furthermore, data were collected on either 
current, pre-diagnostic or post-diagnostic PA, or a combination of  these. For most studies11, 14, 16, 17, 20, 23, 23-
25, 27 Metabolic Equivalent Task (MET)-hours were used (or calculated) to assess PA in relation to survival 
outcomes. MET-hours are a validated measurement of  PA, and are frequently used to define intensity 
and duration of  PA. One MET-hour is defined as the equivalent of  sitting quietly, or 3.5ml oxygen*kg-1 
body weight*minute-1 (1 kcal*kg-1 body weight*hour-1).28 The remaining studies used either the absolute 
number of  hours of  PA12, 15, 21, 22, 26  or the total kcal expended per week.19 A majority of  studies used 
validated questionnaires, including the Modifiable Activity Questionnaire 17 and the Collaborative Women’s 
Longevity Study (CWLS) questionnaire.27 In most studies, tumor and treatment characteristics, socio-
demographic characteristics, lifestyle habits (education, occupation, smoking, alcohol use), menstrual and 
reproductive history, exogenous hormone use, and comorbidities were also documented. 
Primary endpoints
Fourteen studies assessed all-cause mortality11-15, 17, 18, 20, 21, 23-27, 12 studies assessed breast cancer-specific 
mortality11-14, 16, 17, 19-22, 26, 27, and three studies investigated breast cancer recurrence as primary endpoint(s).14, 
20, 24 All hazard ratios (HR) reported in this review concern the highest amount of  PA versus the lowest 
amount of  PA, the lowest level of  PA being the reference value. All reported HRs are multivariable adjusted. 
Effects of  physical activity on breast cancer-specific and all-cause mortality
Eight out of  12 studies that investigated the effect of  PA on BCSS found a significant advantage of  PA on survival, 
ranging from a 36-67% reduction in risk of  death for the highest amount of  PA versus no PA (HR ranging from 
0.53 (95%CI 0.35-0.80) to 0.80 (no 95%CI reported)11-14, 16-18, 27. Three of  the remaining four studies found a non-
significant benefit (HR 0.85 (95%CI 0.68-1.07), HR 0.72 (95%CI 0.29-1.81), HR 0.90 (95%CI 0.51-1.58))19, 20, 26 
while the fourth study found a non-significant worse BCSS (HR 1.30 (95%CI 0.81-2.09)).
Fourteen studies described the effect of  PA on all-cause mortality, of  which ten studies found a significant 
improvement in all-cause mortality with increasing PA.13, 14, 17, 18, 20, 21, 24, 25, 27 This effect ranged from 14% to 
56% (HR ranged from 0.39 (95%CI 0.21-0.72) to 0.73 (95%CI 0.60-0.89). The remaining studies reported 
a non-significant protective effect of  PA on all-cause mortality.
Physical activity outcomes in elderly patients
There were no studies that investigated elderly patients (defined as older than 65 years) separately. However, 
eight studies stratified their analyses by menopausal status or age12, 13, 15-19, 27, and one study included 
postmenopausal patients only (Table 2).11 Five studies grouped their patients by pre- and postmenopausal 
status11, 13, 15-17, 19, while the remaining studies stratified their analyses by age.12, 17, 18, 27 Three studies found a 
significantly lower risk of  either breast cancer-specific mortality16 (HR 0.80 (95%CI 0.60-1.06)) or overall 
mortality17 (HR 0.29 (95%CI 0.14-0.60)) in the older or postmenopausal active group (highest versus lowest 
amount of  PA) (data from Keegan et al.18 not shown). The study in which exclusively postmenopausal 
patients were included demonstrated a significantly lower risk of  all-cause mortality (HR 0.67 (95%CI 0.46-
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0.96)) and breast cancer-specific mortality (HR 0.61 (95%CI 0.35-0.99)) in patients who were moderate- to 
vigorously active after diagnosis.11 The remaining five studies all reported a non-significant benefit of  PA 
on outcomes.12, 13, 15, 19, 27
Differences in outcomes between pre- and post-diagnostic physical activity 
Out of  all studies, eleven investigated the effect of  pre-diagnostic PA on overall mortality, breast cancer-
specific mortality and/or disease-free survival.12-15, 18, 19, 21-23, 25, 26 Three studies assessed the effect of  post-
diagnostic PA16, 20, 27, one study investigated the effect of  post-diagnostic PA at different time points24, and the 
remaining two studies examined both pre- and post-diagnostic PA.11, 17 These two studies looked at the effect 
of  pre-diagnostic PA as well as the effect of  change in PA after diagnosis on at least one of  the outcomes. 
 
Table 2. Physical activity outcomes in older breast cancer patients
    
 
Pre-diagnostic PA lead to a significantly better OS in five out of  11 studies13, 14, 18, 21, 25, of  which three studies 
also ascertained a significantly better BCSS.13, 14, 21 The remaining studies found beneficial effects, although 
they did not reach statistical significance. All studies investigating post-diagnostic PA found a beneficial effect 
on OS.11, 16, 17, 20, 24, 27 BCSS was significantly lower in three out of  five studies that had this endpoint.16, 17, 27
An increase in PA was beneficial in one out of  two studies, with a HR of  0.67 (95%CI 0.46-0.99) (for the 
greatest increase in physical activity).11 Although the second study investigating change in physical activity 
found a non-significant benefit of  increased physical activity (HR 0.55 (95%CI 0.22-1.38)), a much higher 
risk of  all-cause mortality was established in patients with a reduction in PA (HR 3.95 (95%CI 1.45-10.5)) 
(Table 3).17 
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Table 3. Effect of  physical activity on outcomes
Physical activity in different BMI-groups
Nine studies stratified their analyses by different BMI-groups.11-13, 17, 18, 20, 21, 23, 27 Two studies reported on breast 
cancer-specific mortality as well as all-cause mortality for the stratified groups, while one study reported on 
breast cancer-specific mortality only. The remaining six studies reported all-cause mortality only for the 
different groups. The study by Cleveland et al.13 showed a non-significant lower risk of  breast cancer-specific 
mortality in active patients with a BMI under 25 (HR 0.57 (95%CI 0.30-1.09)) and a significantly lower risk 
in active patients with a BMI over 25 (HR 0.63 (95%CI 0.40-0.99)).13 Similarly, the study by Holick et al.27 
found a better BCSS for active patients with a BMI below 25 (although not statistically significant), and a 
borderline significant effect in patients with a BMI above 25 (HR 0.63 (95%CI 0.39-1.02)).27 West-wright et 
al.21 did not find a significant benefit for active patients with a BMI under 25 (HR 1.15 (95%CI 0.32-0.86)), 
but a significantly better BCSS in  patients with a BMI above 25 (HR 0.41 (95%CI 0.23-0.74) for high PA 
versus low PA). In patients with a BMI below 25, all-cause mortality was significantly lower in four out of  
eight studies.12, 13, 20, 27 One study reported a benefit that was even greater in patients who were 55 years or 
older.13 Four studies found a lower all-cause mortality in active patients with a BMI over 25.13, 17, 23, 27
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We present an overview of  the available literature on the effect of  PA on breast cancer outcomes. Most 
studies demonstrate that PA has a positive effect on OS and BCSS. Post-diagnostic PA was most beneficial 
for breast cancer outcomes. Most investigations were observational studies with low median ages, with the 
exception of  one study that investigated only postmenopausal breast cancer patients. Although no study 
specifically addressed patients who were 65 years or older, we observed that older and/or postmenopausal 
patients acquired the greatest advantage of  PA. 
Several explanations have been proposed for the age-related benefit. In addition to concurrent comorbid 
conditions, aging is associated with declines in physical and cognitive functioning. A large cohort study 
of  breast cancer survivors showed that functional limitations were associated with  worse all-cause and 
competing-cause mortality.29 Cancer patients are at increased risk of  reporting limitations in their activities 
of  daily living compared to non-cancer patients.9, 30 Several exercise programs demonstrated varying positive 
effects in older people, including improved muscle strength and gait speed, reduction in falls, improved 
balance, bone mineral density and increased mental health.31-37 The Canadian Study of  Health and Aging 
showed that older persons who participated in high levels of  PA had a lower risk of  death than those who 
did little or no exercise; the absolute benefits were greatest for those with the highest number of  health 
deficits.37 
Investigators have speculated on the biological mechanism behind these findings. The effect of  PA on 
breast cancer specific survival was stronger for overweight patients (BMI>25) than normal-weight patients. 
Although these findings were not paralleled for all-cause mortality, the effect of  PA on the reduction in 
weight and, subsequently, on insulin levels are a likely explanation. It is well-known that postmenopausal 
patients with obesity and high insulin levels and/or diabetes mellitus have a greater risk of  breast cancer.38-40 
Insulin resistance is thought to influence the risk of  breast cancer recurrence and mortality41-43 Pasanisi 
et al. found that higher insulin levels and insulin resistance syndrome are associated with breast cancer 
mortality.41 Importantly, PA can significantly lower insulin levels in women with breast cancer. It has also 
been suggested that PA reduces breast cancer risk by improving metabolic profiles as well as by decreasing 
levels of  endogenous estrogens and body fat.44 
Aging is a strong predictor of  functional decline and comorbidities, and literature suggests that older cancer 
patients are more likely to be affected by cancer in terms of  physical than cognitive functioning.9, 45, 46 
Physical domains are especially important in elderly patients, as they can make the difference between 
independent and assisted living. As breast cancer in elderly patients is predominantly estrogen receptor 
(ER)-positive, systemic endocrine treatment is frequently warranted. Toxicities of  endocrine therapy and 
the larger number of  comorbid conditions with increasing age may result in patients being more vulnerable 
to the clinical consequences of  adverse events. Previous reports have demonstrated that PA can improve 
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comorbid conditions and adverse effects of  adjuvant treatment 47, 48, therefore, PA can provide an additional 
benefit in these patients.
Because of  the heterogeneity of  the data collected and different definitions of  low, moderate and high 
intensity PA, we could not perform a pooled meta-analysis of  the reported HRs. Furthermore, this study is 
limited to some extent by the lack of  evidence that focuses on the effect of  PA on breast cancer outcomes in 
the elderly breast cancer patients specifically. Consequently, the effect of  PA on overall and breast cancer-
specific mortality in elderly patients may reveal an even greater benefit, given the prevalence of  more 
ER-positive tumors as well as frailer patients who are likely to gain most from PA. To add,  it is important 
to realize that other factors may also influence the possibility for patients to partake in PA at all. One can 
presume that, generally speaking, patients without functional limitations are more likely to be healthy and 
capable of  exercising, while patients who are restricted due to health deficits are already less physically 
active, and thus at an increased risk of  adverse outcomes. For this reason, further investigations into the 
cancer-aging interface and the influence of  breast cancer on functional decline in elderly patients are 
indispensable. We have initiated ‘Climb Every Mountain’, a longitudinal, prospective cohort study that 
measures physical, cognitive, and social health during and after breast cancer treatment. The purpose of  
this study is to generate new knowledge on the prevalence and impact of  functional, cognitive, and social 
limitations in elderly breast cancer survivors. A second phase will use those domains most affected by cancer 
diagnosis and treatment, to develop a patient-tailored physical intervention study aimed specifically at the 
elderly breast cancer patient. 
C O N C L U S I O N
This review covers a very heterogeneous group of  patients, consisting of  pre-and postmenopausal breast 
cancer patients with varying tumor-biological and clinical characteristics. In older breast cancer patients 
specifically, the majority of  studies demonstrated a decrease in both all-cause and breast cancer-specific 
mortality with increasing levels of  PA. To add, the decrease in breast cancer-specific mortality was more 
prominent in overweight patients than in normal-weight patients. Overall, it can be concluded that some 
degree of  PA leads to improved survival outcomes in breast cancer patients, which provides the prospect of  
employing a practical intervention that can act as a targeted treatment for breast cancer. 
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A B S T R A C T
Background
Physical activity has been related to improved breast cancer outcomes in several previous studies. Especially 
in the older breast cancer  population, physical activity may be of  importance, as high age is associated with 
comorbidity and poor physical function. However, no previous studies investigated the relation between 
physical activity and breast cancer outcomes in older patients specifically. The purpose of  this study was 
to investigate the relation between physical activity on overall survival (OS), breast cancer-specific survival 
(BCSS) and recurrence in postmenopausal breast cancer patients based on age-group 
Methods 
The TEAM-Lifestyle study is a side-study of  the Tamoxifen Exemestane Adjuvant Multinational (TEAM) 
trial, which prospectively investigated lifestyle habits of  postmenopausal, hormone receptor-positive breast 
cancer patients.  The effects of  pre-diagnosis and post-diagnosis physical activity on OS, and BCSS  and 
recurrence-free period (RFP) were calculated using Cox regression and competing risk regression models. 
Results
Among 521 patients, high levels of  physical activity before and after diagnosis were associated with a better 
OS (multivariable hazard ratio (HR) 0.50 (95%CI 0.26-0.98) and HR 0.57 (95%CI 0.26-1.40) for patients 
who were very active (upper quartile) before and after diagnosis respectively, compared to relatively inactive 
patients). This was most evident in patients aged 65 years and older. Physical activity was not significantly 
related to BCSS or RFP. 
Discussion
OS was better in patients who were active before and after diagnosis, especially in older patients who 
were active before diagnosis. In contrast to previous studies, breast cancer survival and recurrence were 
not significantly associated with physical activity. These hypothesis-generating findings confirm the need 
for more studies investigating the use of  physical activity to supplement breast cancer treatment in older 
patients.
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I N T R O D U C T I O N
There is a growing body of  evidence on the beneficial effects of  physical activity in breast cancer patients. 
A recent meta-analysis showed that physical activity improves body composition, physical function, 
psychological complaints and quality of  life in breast cancer patients.1 To add, physical activity has been 
found to improve fitness and strength and reduce depression and fatigue.2 Furthermore, a multitude of  
studies have demonstrated the positive effects of  physical activity on decreasing the risk of  developing 
breast cancer.3 It has been suggested that these so-called ‘modifiable’ components, which are influenced by 
physical activity, may also favourably affect cancer survival.4, 5 In a systematic review, we previously reported 
that physical activity is associated with overall survival (OS) and breast cancer-specific survival (BCSS), with 
post-diagnosis physical activity being most beneficial for these breast cancer outcomes.6 However, none 
of  the previous studies reported age-specific outcomes for patients over the age of  65, although this older 
breast cancer population in particular, may benefit from physical activity.
Older breast cancer patients deserve extra attention, as high age is related to poor physical function and 
other comorbidity7, 8, and maintenance of  pre-diagnosis physical activity levels could play an important role 
in sustaining functional mobility in this more vulnerable population. Older breast cancer patients differ 
from younger breast cancer patients in many other aspects; older patients generally present with higher 
tumor stages9 and are more frequently affected by comorbid conditions affecting physical functioning than 
their younger counterparts.10
The aim of  this study was to assess the relationship between recreational physical activity and OS, BCSS 
and relapse-free period (RFP)  in postmenopausal, hormone-receptor positive breast cancer patients of  
different ages. 
M A T E R I A L S  A N D  M E T H O D S
The Tamoxifen Exemestane Adjuvant Multicenter (TEAM) trial is an international, open-label randomized 
controlled trial that compared two regimens of  hormonal treatment in postmenopausal, hormone receptor-
positive breast cancer patients. The study design and population of  the trial have previously been described 
in detail.11 The current study is a side-study of  the TEAM trial, also known as the TEAM-Lifestyle side-study 
(TEAM-L). This side-study prospectively investigated lifestyle habits in a subset of  543 patients. The design 
and study population of  the TEAM-L have also been described elsewhere.12 Briefly, the TEAM-L consisted 
of  two questionnaires at one and two years after diagnosis. In the first questionnaire, patients reported 
both pre-diagnosis (T0) and current (T1)  physical activity levels, demographic factors, reproductive factors 
and other lifestyle habits. The second questionnaire (T2) consisted of  the same questions, excluding pre-
diagnosis lifestyle characteristics.
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Data collection
Patient, tumor and treatment characteristics were collected by the TEAM datacenter (Leiden, the 
Netherlands). For this study, patients were included if  they completed either one or both questionnaires. If  
a patient had a recurrence before completing the questionnaire, she was excluded from the analysis. Follow-
up was defined as the time between completing the questionnaire (T0 and T1 at one year after diagnosis 
and T2 at two years after diagnosis), until an event last follow-up visit or loss to follow-up. Follow-up was 
complete until August 15th 2012.
Physical activity measures
Questions assessing physical activity were derived from the validated European Prospective Investigation 
into Cancer physical activity Questionnaire.13 Patients were asked to report the amount of  time they spent 
per week in summer and winter on the following activities: walking, cycling, gardening, housekeeping and 
sports (three different types of  sport could be specified). The mean number of  hours spent at these activities 
per week in summer and winter was calculated. Metabolic Equivalent Intensity Values (MET values) were 
calculated in order to include an estimate of  the intensity of  the reported physical activity.14 
For this study, we evaluated recreational physical activity only, which was defined as walking, cycling, gardening 
and sports. For the analyses, patients were grouped into quartiles, based on the distribution of  the total number 
of  MET-hours of  physical activity per week in the whole study population. Additionally, we performed all 
analyses in quartiles based on the total number of  absolute hours spent on physical activity per week.
Statistical analyses
IBM SPSS statistics version 20.0 was used for all analyses, with an exception of  the Fine and Gray analyses, 
which were performed in STATA version 12.0. All analyses were two-sided and p-values of  0.05 were 
considered statistically significant. If  data were missing, patients were not excluded from the analyses, but 
analysed in a category “unknown” within the same variable, with the exception of  patients with a missing 
status for physical activity measurements; these patients were excluded from the analyses.
The effect of  pre-diagnosis physical activity (T0) and post-diagnosis physical activity (T2) on overall survival 
was calculated in univariable and multivariable Cox regression models. The multivariable models were 
adjusted for clinically relevant confounders (age, number of  comorbidities, T-stage, N-stage, Body Mass 
Index (BMI, kg/m2) and adjuvant chemotherapy). BCSS was defined as time until breast cancer death. 
RFP was defined as the time until disease recurrence or breast cancer death. Both BCSS and RFP were 
calculated using Fine and Gray analyses, which takes the risk of  competing mortality into account. Again, 
these analyses were adjusted for clinically relevant confounders. Age-stratified (<65 vs ≥65 years) analyses 
were also performed for all outcome measures. 
Due to small numbers of  events in some subgroup analyses, we also performed sensitivity analyses that 
compared the three highest quartiles of  physical activity (any physical activity) with the lowest  quartile (very 
low). As the number of  hours spent on physical activity at one year after diagnosis (T1) could be affected by 
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breast cancer treatment during this period, the effect of  post-diagnosis physical activity was assessed based 
on the physical activity at two years after diagnosis (T2).
To assess potential effect modification by BMI, we performed  a sensitivity analysis in which we assessed the 
effect of  post-diagnosis physical activity on all outcomes in combination with BMI by creating a variable 
that combined physical activity and BMI. We distinguished four groups: low physical activity (defined as 
the two lower quartiles) and BMI ≥25 (reference group), low physical activity and BMI <25, high physical 
activity (defined as the two upper quartiles) and BMI ≥25, and high physical activity and BMI <25. To add, 
we performed analyses for BCSS and RFP using Cox Regression models, in order to assess the influence of  
competing risks on our results. Finally, we presented causes of  death per physical activity level.
Table 1. Patient characteristics
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R E S U L T S
Patient characteristics
Overall, 521 patients who completed the first questionnaire were included in the analyses regarding pre-
diagnosis physical activity. For the second analyses investigating post-diagnosis physical activity, 436 patients 
were included (Figure 1). The median age of  the patient population was 63.6 years (Table 1). Most patients 
had one or more comorbidities (72%), and the majority of  patients (55%) had a BMI of  25 or higher. 
Patient-, tumor- and treatment-characteristics were not different between the four quartiles of  pre-diagnosis 
physical activity, with the exception of  age and chemotherapy (Supplementary Table 1). Mean pre-diagnosis 
physical activity level was 10.9 hours per week, while the mean post-diagnosis physical activity level was 
10.0 hours per week. 
Figure 1. Patients included in this study
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Pre-diagnosis physical activity
Overall survival was better in patients who were physically active before diagnosis, both in the analyses based 
on MET-hours as well as in the analyses based on the absolute number of  hours. This effect remained similar 
with additional adjustments for number of  comorbidities, T-stage, N-stage, mean BMI and chemotherapy 
(Hazard Ratio (HR) 0.57, 95% Confidence Interval (CI) 0.31-1.05 for low physical activity, 0.48, 95% CI 
0.25-0.91 for high physical activity and 0.50, 95% CI 0.26-0.98 for very high physical activity, compared to 
the very low physical activity, p=0.10, Table 2). 
 
Table 2. Physical activity in relation to survival outcomes
 
Breast cancer specific survival according to Fine and Gray analysis was not statistically significant in 
association with physical activity levels. Also, the recurrence-free period according to Fine and Gray was 
not statistically significant in relation to the four quartiles. The analyses performed with categories based on 
the absolute hours per week showed similar results (Table 2).
Post-diagnosis physical activity
Post-diagnosis survival was calculated in all patients who completed T2 and did not have a recurrence before 
T2. Overall, 435 patients were included in these analyses. Overall survival was statistically significantly 
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better in patients who were relatively active (HR 0.43, 95% CI 0.19-0.94 for low physical activity, HR 0.60, 
95% CI 0.29-1.22 for high physical activity and HR 0.57, 95% CI 0.26-1.40 for very high physical activity 
compared to very low physical activity, p=0.34, Table 2). Breast cancer specific survival and recurrence-free 
period did not differ between the four quartiles of  physical activity (Table 2). 
Age-specific results
With regard to pre-diagnosis physical activity, age-stratified analyses (<65 vs ≥65 at breast cancer diagnosis) 
demonstrated that overall survival was significantly better in active patients aged 65 years and older 
compared to relatively inactive patients (multivariable HR 0.63, 95% CI 0.30-1.35 for low physical activity, 
HR 0.44, 95% CI 0.19-1.03 for high physical activity and HR 0.34, 95% CI 0.11-1.01 for very high 
physical activity compared to very low physical activity, Table 3). No statistically significant differences 
between the four quartiles were observed for any of  the outcomes in patients aged 65 years and younger, 
although all estimates for overall survival were below one and the number of  evens was very small. Breast 
cancer specific survival and relapse-free period were not significantly associated with physical activity levels.
Sensitivity analyses 
Additional sensitivity analyses in which the upper three quartiles in the age-specific analyses were combined 
showed similar results in both age-groups (Table 3). 
 
Table 3. Pre-diagnosis physical activity in relation to survival outcomes, stratified by age at diagnosis 
.
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We investigated the influence of  high BMI and physical activity in relation to outcomes by stratifying 
by BMI category. Normal-weight (BMI<25) and overweight or obese (BMI≥25) patients were assessed 
separately. The combination of  post-diagnosis physical activity and BMI was not statistically significant in 
relation to overall survival, breast cancer specific survival or relapse-free period (Supplementary Table 2).
Furthermore, Cox Regression analyses for both prediagnostic and postdiagnostic physical activity in relation 
to breast cancer specific survival and relapse-free period showed similar results as the Fine & Gray analyses 
(data not shown). Finally, causes of  death per physical activity level show that the majority of  patients  who 
died, died from breast cancer, second malignancies or cardiovascular death (Supplementary Table 3). 
D I S C U S S I O N
This study shows that physical activity was  associated with an improvement in overall survival, both before 
and after diagnosis. Especially in patients older than 65, a high level of  pre-diagnosis physical activity 
was related to a better overall survival compared to lower levels of  physical activity. Breast cancer specific 
survival and recurrence-free period were not significantly associated with physical activity levels, and no 
trends towards a better breast cancer specific survival or recurrence-free period were observed. 
Although we did not observe a statistically significant association between physical activity and breast 
cancer death or recurrence, many previous studies have demonstrated favourable effects of  physical activity 
on breast cancer-specific survival in breast cancer survivors.4, 6, 15 Several mechanisms could explain these 
contradicting results. First, the Dutch population is, in general, more active compared to other Western 
societies16, especially when compared to the United States, where most of  the previous studies were 
performed.4, 15 Furthermore, the TEAM-trial included postmenopausal women who generally had a high 
socio-economic status and a low comorbidity burden compared to the general population.17 For this reason, 
it is possible that even the “very low physical activity” category was, in fact, quite active in which case the 
differences in outcomes were absent. Second, the TEAM-trial included relatively many older patients.18 
Since the risk of  dying from other causes than breast cancer (competing causes of  death) strongly increases 
with age18, possibly, the absolute benefits of  physical activity could be less pronounced in this population. 
However, competing risk analyses did not differ from regular analyses in our data. Especially cardiovascular 
mortality could be improved in active patients19, but the number of  events was too small to investigate this 
in further detail (Supplementary Table 3).  
The biological mechanism behind improved breast cancer outcomes in physically active patients, as was 
observed in previous studies, remains to be elucidated. It has been suggested that obesity and insulin 
resistance play an important role in influencing the risk of  breast cancer recurrence and mortality.20, 21 
Obesity and high levels of  insulin and diabetes have been associated with increased breast cancer risk22, 23, 
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and physical activity is known to lower insulin levels and improve insulin sensitivity. Furthermore, it has 
been suggested that physical activity could result in a reduction in endogenous oestrogen levels and body 
fat, which could lead to slower progression of  breast cancer.24 Previous studies have also shown that obesity 
can lead to poorer breast cancer outcomes.21 Pierce et al. investigated interactions between specific lifestyle 
factors and mortality in breast cancer patients and found significant improvements in 10-year mortality in 
patients who were physically active and had a healthy dietary pattern, regardless of  BMI.5 Although we 
did not take into account dietary patterns, the interaction between BMI and physical activity in relation to 
outcome was not statistically significant and there was no statistically significant association between BMI, 
physical activity and survival. Of  note, in the older population, high BMI may even have a protective effect 
on overall survival, as was shown in a study by Reeves et al25, and which may reflect the absence of  an 
association in our results. 
Interestingly, the results based on the number of  MET-hours gave similar results to the analyses based 
on the absolute number of  hours. This implies that the intensity of  physical activity is not related to the 
association between physical activity and the improved overall survival. Presumably, any form of  physical 
activity is beneficial compared to a sedentary lifestyle. This could be of  major importance in developing 
future physical activity interventions for breast cancer patients.
Concerning the age-specific results, we found the strongest association between physical activity and overall 
survival in patients aged 65 years and older. This is of  particular interest in this  vulnerable population, as 
high age is associated with comorbidity and poor physical function.26, 27 In developed countries, over 40 
percent of  the breast cancer population is 65 years or older and this percentage is expected to increase even 
further in the upcoming years.28 Treatment of  breast cancer in older patients is still not evidence-based, due 
to the fact that older patients are often not included in clinical trials due to restrictions of  age, comorbidity 
and physical function.29 This leads to a large diversity in treatment strategies and poor adherence to 
guidelines among treating specialists.30 Consequently, breast cancer specific mortality increases with age, 
even amidst competing causes of  death in older patients.18 Therefore, new treatment strategies for elderly 
breast cancer patients are urgently needed. 
Although physical activity was not related to breast cancer outcome in our data, it could play an important 
role in preventing adverse-events and non-compliance to hormonal therapy in the older breast cancer 
population.31 Breast cancer in older patients is often hormone-receptor positive32, and consequently, 
many patients receive hormonal therapy. Aromatase inhibitors often cause side-effects such as arthralgia, 
musculoskeletal pain and diminished bone mineral density.31 Older patients are especially at increased risk 
for the development of  fractures after hormonal treatment.31 In the TEAM-study, older patients were more 
likely to be non-compliant within the first year of  hormonal treatment than younger patients. The most 
important reasons for non-persistence were adverse events.33 Therefore, maintaining physical activity levels 
might be extra beneficial in the older breast cancer population.
A G E  I N  R E L A T I O N  T O  P H Y S I C A L  A C T I V I T Y  A N D  S U R V I V A L  I N  P O S T M E N O P A U S A L  H O R M O N E 
R E C E P T O R - P O S I T I V E  B R E A S T  C A N C E R  P A T I E N T S  –  R E S U L T S  O F  T H E  T E A M - L I F E S T Y L E  S T U D Y
91
Strengths and limitations
A major strength of  this study is its prospective design. Data were registered at various timepoints during 
follow-up using validated questionnaires, resulting in a homogeneous study population with well-registered, 
reliable data. Furthermore,  patients in this side study were a representative subset of  the international 
TEAM trial, as demonstrated in an earlier report by Voskuil et al.12 To our knowledge, this is the first study 
to investigate differences in PA levels on survival outcomes in older breast cancer patients compared to 
younger patients. Needless to say, our study is limited by the number of  events, which was relatively small 
when compared with other studies.4, 15, 34 Furthermore, patients who exercise regularly may also be more 
likely to adopt other healthy lifestyles.35 The more favourable outcomes demonstrated in patients older than 
65 may therefore be the result of  selection, as patients who are capable of  participating in physical activity 
are fit enough to be able to exercise and hence survive for longer than unfit patients. In order to establish a 
causal relation between physical activity and breast cancer outcomes, randomized clinical trials should be 
performed, but inevitably, these kinds of  trials are not feasible. Therefore, data such as our present study 
can still be of  much value for investigating the association between physical activity levels and breast cancer 
outcomes.
Finally, the reported number of  hours of  physical activity was relatively high in comparison with other 
studies, and this may be due to over-reporting of  pre-diagnosis physical activity. Nevertheless, the Dutch 
population is known to engage in high levels of  physical activity, especially in walking, cycling, gardening 
and sports.16 Most women in the Netherlands (76%) spend at least 30 minutes on moderate-to-vigorous 
physical activity on at least 5 days of  the week.36
In conclusion, overall survival was better in patients who were active before and after diagnosis, while breast 
cancer recurrence and survival were not associated with physical activity. Especially in women over the age 
of  65, high physical activity levels before diagnosis were associated with an improved overall survival. These 
hypothesis-generating findings confirm the need for more studies investigating the use of  physical activity 
to supplement breast cancer treatment in older patients. Physical activity could play an important role in 
improving survival, maintaining physical function and improving quality of  life both during and after breast 
cancer treatment, especially in older patients. 
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Supplementary Table 1. Patient characteristics per quartile of  pre-diagnosis physical activity
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Supplementary Table 2. Survival analyses for post-diagnosis PA AND BMI combined
Supplementary Table 3. Causes of  death
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Background
Predictive models are an integral part of  current clinical practice and help determine optimal treatment 
strategies for individual patients. A drawback is that covariates are assumed to have constant effects on 
overall survival (OS), when in fact, these effects may change during follow-up. Furthermore, breast cancer 
patients may experience events that alter their prognosis from that time onwards. We investigated the 
‘dynamic’ effects of  different covariates on OS and developed a nomogram to calculate 5-year dynamic OS 
(DOS) probability at different prediction timepoints (tP) during follow-up. 
Methods
Dutch and Belgian postmenopausal, endocrine-sensitive, early breast cancer patients enrolled in the 
TEAM trial were included. We assessed time-varying effects of  specific covariates and obtained 5-year 
DOS predictions using a proportional baselines landmark supermodel. Covariates included age, histological 
grade, hormone receptor and HER2 status, T- and N-stage, locoregional recurrence (LRR), distant 
recurrence, and treatment compliance. A nomogram was designed to calculate 5-year DOS based on 
individual characteristics.
Results
2602 patients were included (mean follow-up 6.2 years). N-stage, LRR, and HER2 status demonstrated 
time-varying effects on 5-year DOS. Hazard ratio (HR) functions for LRR, high-risk N-stage(N2/N3) and 
HER2 positivity were HR=(8.427∙0.583tP), HR=(3.621∙0.816tP) and HR=(1.235∙0.851tP), respectively. 
Treatment discontinuation was associated with a higher mortality risk, but without a time-varying effect 
(HR 1.263 (95%CI 0.867-1.841)). All other covariates were time-constant.  
Conclusion
The current nomogram accounts for elapsed time since starting adjuvant endocrine treatment and optimises 
prediction of  individual 5-year DOS during follow-up. The nomogram can facilitate in determining 
whether further therapy will benefit an individual patient.
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I N T R O D U C T I O N
Breast cancer comprises a heterogeneous disease with diverse features that can interact with outcomes, 
making it difficult to obtain estimations of  individual prognoses. The overwhelming popularity of  tools 
such as Adjuvant! or the Nottingham Prognostic Index (NPI) illustrates the importance of  prediction 
models for physicians and patients, providing guidance for adjuvant treatment decisions.1, 2 Most prediction 
models, however, cannot be used for cancer patients at specific timepoints during the follow-up period, as 
these models have been designed for use immediately after diagnosis. Apart from the caveats associated 
with available ‘static’ prediction models, there are some important reasons why these models may give 
misleading results when used during follow-up. First, the fact that patients have already survived a number 
of  years after diagnosis may change a patient’s prognosis. For instance, breast cancer recurrence rates peak 
at 1-2 years after diagnosis and decline thereafter, resulting in an improved prognosis.3-5 Second, in the 
time between diagnosis and the moment of  prediction, important events may have taken place, such as 
locoregional recurrence (LRR) and/or distant recurrences (DR) or premature discontinuation of  treatment, 
which may alter a patient’s prognosis. Third, some variables included in current models may exhibit time-
varying effects on outcome, resulting in a change in mortality risk as time progresses. Consequently, too 
much emphasis may be placed on variables with a strong impact on outcome early in the follow-up period, 
whereas this effect might be much smaller later on. 
Available static models are based on probabilities of  survival at the time of  diagnosis and may not accurately 
portray a patient’s survival probability later on in the follow-up period. The concept of  updating survival 
probabilities by both incorporating time-varying covariates and allowing for time-varying effects is called 
dynamic prediction. By design, these variables are not included in the static risk prediction models, and 
these considerations illustrate a need for better prediction models for cancer patients. 
To investigate the clinical applicability of  dynamic prediction, we utilized a dataset from a large randomized 
clinical trial of  postmenopausal hormone receptor-positive early breast cancer patients treated with 
endocrine treatment (ET) in the Netherlands and Belgium. The aim of  the current analysis was to develop 
a clinically applicable nomogram to facilitate the prediction of  an individual patient’s probability of  
surviving an additional 5 years at any prediction timepoint (tP) up to three years after starting adjuvant ET. 
This concept of  continually updating 5-year overall survival (OS) from a certain tP is referred to as 5-year 
dynamic overall survival (DOS). We designed a dynamic predictive model, taking into account various 
patient- and tumor-specific covariates with time-varying and time-constant effects during follow up. 
M A T E R I A L S  A N D  M E T H O D S
The Tamoxifen Exemestane Adjuvant Multinational (TEAM) trial is a randomized, phase III, multinational, 
open-label study conducted in postmenopausal women with hormone receptor-positive breast cancer, who 
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were eligible for adjuvant ET and randomized to either 5 years of  exemestane (25mg) or 2.5-3 years of  
tamoxifen (20mg) followed by exemestane (25mg) for 2.5-2 years.6 The TEAM trial protocol was approved 
by regulatory and ethics authorities of  all participating centers in all participating countries. The trial 
was registered in the Netherlands and Belgium with the Netherlands Trial register, NTR 267. All patients 
provided written informed consent. Details of  the study and data collection have been published previously.6
In the Netherlands and Belgium, 3168 postmenopausal, early breast cancer patients were enrolled in the 
TEAM trial. Patients who did not start randomized treatment (n=19) or had missing endpoint data (n=4), 
metastatic disease before the start of  ET (n=7), and patients with missing data regarding covariates used in 
the model (n=528) were excluded (Figure 1). Patients with estrogen receptor (ER) and progesterone receptor 
(PR)-negative disease (n=8) were excluded. 
The primary outcome of  the present investigation was OS, which was the time from randomization to the 
date of  death or last recorded follow-up. LRR was defined as any breast cancer recurrence in the ipsilateral 
breast and/or lymph nodes as well as in supraclavicular lymph nodes. DR comprised all other accounts of  
breast cancer recurrence. 
Figure 1. CONSORT diagram of  patients included in the analyses
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Statistical analysis
Statistical analyses were performed using the programs SPSS (version 20) and R (version 2.15.1). We used the 
proportional baselines landmark supermodel7, 8 to obtain dynamic predictions of  the 5-year DOS probability. 
The model requires a number of  landmark timepoints (tLM); in the current model tLM was established at every 
third month between 0 and 3 years after the start of  ET. A prediction model for 5-year DOS at a specific tLM is 
constructed by selecting the individuals at risk at that tLM and incorporating the values of  any time-dependent 
covariates at that respective tLM in a Cox proportional hazards model.9 The landmark prediction models at 
different tLMs may be combined into a single supermodel (Appendix 1). Using this analysis in the clinical 
setting, we can obtain DOS predictions at any prediction timepoint, tP, between 0 and 3 years after starting 
adjuvant ET. For this specific model, the prediction window was set to 5 years after the established tP .
Baseline patient- and tumor-specific factors included in the model comprised age at diagnosis (continuous, 
linear and quadratic terms), Bloom&Richardson (BR) histological grade (I,II,III), tumor stage (1,2,3/4), 
nodal stage (N0,N1,N2/N3), ER and PR status (positive,negative), HER2 status (positive,negative, missing), 
most extensive surgery (mastectomy,breast conserving surgery), radiotherapy (yes,no), chemotherapy 
(yes,no). ER and PR status were considered positive if  at least 10% of  tumor cells stained positively following 
immunohistochemical staining, as defined by the Dutch breast cancer treatment guidelines.10 
The model also included three dynamic variables whose values may change during ET, namely current ET 
status (on versus off  ET), LRR (yes,no) and DR (yes,no). To assess whether a patient had stopped treatment, 
we used the last treatment date, as reported on the case-report forms. If  no last treatment date was available, 
the patient was assumed to be on-treatment. According to the TEAM trial protocol, patients with LRR or 
DR discontinued or switched ET.
In order to test for time-varying covariate effects, interactions between covariates and tLM (both linear and 
quadratic) were included in the model. A backward selection procedure was then performed in two steps. 
In the first step all quadratic tLM interactions with the covariates were tested. Non-significant quadratic 
interactions were removed, and those covariates which did not have significant interactions in the first step 
were then tested in the second step for linear tLM interactions. Again, only significant interactions were 
retained. Wald-tests, based on robust standard errors, were used and a p-value of  0.05 was considered 
statistically significant (Appendix 1). Main effects of  the covariates and of  tLM and tLM2 were included, 
irrespective of  statistical significance. The model was then validated by internal calibration using the 
heuristic shrinkage factor by van Houwelingen et al.11 The model’s ability to correctly discriminate between 
patients was evaluated using the dynamic cross validated c-index. A c-index of  1 resembles a model that can 
perfectly discriminate between patients, while with a c-index of  0.5, the prediction is as good as chance.7 
 
Nomogram 
The nomogram is a user-friendly tool for calculating survival probabilities based on a prediction model, and 
graphically computes 5-year DOS based on an individual patient’s unique characteristics. For each prognostic 
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factor, a number of  risk points are assigned to each corresponding covariate, which can be read off  the 
nomogram. The sum of  the risk points represents a total risk point score, from which the corresponding 5-year 
DOS probability can be assessed at any tP (between 0 and 3 years) after the start of  ET. 
R E S U L T S
In total, 2602 TEAM trial patients with a median age of  64.8 years (range 38-92 years), were included in 
the analyses (Figure 1). Baseline characteristics of  included patients are depicted in Table 1. The majority of  
patients included in this trial had adjuvant radiotherapy (66%) and did not receive adjuvant chemotherapy 
(68%). Figure 2 provides an overview of  the total number of  patients in the landmark datasets at successive 
tLMs in relation to treatment compliance and disease recurrence status. 
Table 1. Baseline characteristics of  patients included in the cohort (n=2602)
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Table 2 depicts the regression coefficients and hazard ratios (HR) with 95% confidence intervals (95% CI) of  
the covariates included in the model. Covariates with time-constant effects and covariates with time-varying 
effects on 5-year DOS are shown. Age at diagnosis demonstrated a time-constant effect, with 5-year DOS 
being a quadratic function of  age (Appendix 2). Interestingly, high-risk nodal stage (N2/N3), compared 
to N0, demonstrated a significant time-varying effect on 5-year DOS with each successive tP, while nodal 
stage N1 did not (Figure 3A). To illustrate, the HR of  a patient with nodal stage N2/N3 immediately 
after primary treatment compared to a patient with nodal stage N0 (reference) is 3.621, (calculated by the 
following formula: HR=[(constant) ∙ (time-varying effect)tP]=3.621 ∙ 0.8510)(Table 2), but decreases to 2.411 
(HR=3.621 ∙ 0.8512 =2.411) at two years after the start of  ET. HER2 positive status also demonstrated a 
significant time-varying effect on 5-year DOS (Table 2, Figure 3B).
Next, covariates whose status have the potential to change over time (i.e. treatment compliance status and 
disease recurrence) were investigated for their influence on 5-year mortality risk. Patients who went off-treatment 
during the follow-up period had a higher residual mortality risk compared to patients who remained compliant, 
although this was not statistically significant. The effect of  treatment discontinuation was constant over time 
(Table 2). Simultaneously, LRR had a time-varying influence on 5-year DOS, revealing a subsiding  mortality risk 
with each successive tLM (Figure 3C). Compared with no LRR, having a LRR at 1, 2, and 3 years after the start 
of  ET increased 5-year mortality risk with HR=4.913 (2.444-9.877), HR=2.864 (1.851-4.431), and HR=1.670 
Figure 2. Number of  patients at risk in relation to follow-up time since the start of  endocrine treatment
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(1.005-2.773), respectively (Table 2). In contrast, developing distant metastases (versus no distant metastases) was 
associated with an increased 5-year mortality risk, with a constant effect over time (HR=15.018 (9.934-22.705)). 
Figure 4 illustrates differences in the 5-year DOS in the event of  a LRR in a patient who presents with 
the most commonly occurring baseline characteristics (average patient) found in this cohort, as well as in a 
high-risk patient. In the absence of  a LRR, 5-year mortality probabilities are approximately 3% and 10%, 
respectively, at all tPs. However, in case of  a LRR, 5-year mortality probabilities in both the average patient 
and the high-risk patient are initially high, and decrease with time. 
Internal model validation
The heuristic shrinkage factor was 0.995, indicating good calibration of  the model. Furthermore, the model’s 
discriminatory accuracy had a dynamic cross validated c-index of  0.70, 0.72, 0.76 and 0.79 at 0, 1, 2 and 3 
years respectively. 
tP , prediction timepoint; LRR, Locoregional Recurrence.
Hazard ratios for nodal stage, HER2 status and locoregional recurrence status as time since the start of  endocrine treatment (tP) 
increases (depicted as a hazard ratio with 95% confidence interval).
Figure 3. Time-varying hazard ratios for Nodal stage, HER2 status and Locoregional Recurrence status
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Using the nomogram
The nomogram (Figure 5) provides estimates for 5-year DOS probabilities at different tPs from the start of  
ET and onwards, provided that adequate surgery has been performed. The probabilities can be calculated 
by adding the risk points for each covariate corresponding to the patient’s individual characteristics. For 
each characteristic, the number of  associated risk points can be determined by drawing a vertical line 
straight up from the covariate’s corresponding value to the axis with risk points (0 to 80). While the majority 
of  covariates are considered ‘static’ and defined at the start of  ET, some covariates are ‘dynamic’, such as 
treatment compliance status and the occurrence of  LRR or distant metastases during follow-up. In addition, 
three covariates (nodal stage (N2/N3), HER2 status (positive) and LRR) demonstrated time-varying effects 
on 5-year DOS. Hence, 5-year DOS for these specific covariates depends on the tP, and for these specific 
covariates each subgroup has an individual time-interaction axis. 
Figure 4. Change in 5-year dynamic probabilities of  death based on the occurrence of  a locoregional recurrence in 
two example patients
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The sum of  the risk points is equal to the total risk point score, which is depicted on the axis of  the 
nomogram entitled “Total Points”. From here, a vertical line can be drawn towards the axis labelled “5 Year 
Survival Probability”, which is the corresponding 5-year DOS at that specific tP. 
Table 2. The dynamic prediction model with time-constant and time-varying covariates
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To illustrate, we consider a 69-year-old postmenopausal woman (14 points) who has been using ET for two 
years (tP=2, 5 points). She had a grade III tumor (13 points) with a diameter of  1.5cm (0 points), ER-positive 
(0 points), PR-positive (0 points) and HER2-negative (0 points), and 5 tumor-positive lymph nodes (at tP=2, 
55 points). The patient has undergone breast conserving surgery (2 points) with adjuvant radiotherapy (0 
points) and adjuvant chemotherapy (0 points). She is still on-treatment (0 points) and disease-free (0 points) 
(no locoregional or DR). To calculate her 5-year DOS probability, we take her total risk point score (89 
points) and draw a vertical line down to the ‘5-year survival probability’ axis. For this patient, the 5-year 
DOS is 94%. If  our patient had developed a LRR in the 2-year period since ET, one must add an additional 
40 points  (total=129 points) to her total risk prediction score, resulting in a 5-year DOS of  84%. 
 
 
D I S C U S S I O N
To our knowledge this is the first dynamic prediction model in clinical oncology, designed to optimise the 
prediction of  the 5-year DOS at specific timepoints after the start of  adjuvant ET. The key advantage of  
this model is that it takes into account dynamic factors that can influence a patient’s prognosis after some 
time has passed since starting ET, including treatment compliance and the occurrence of  LRR or distant 
metastases. Moreover, covariates with time-varying effects are also accounted for in the model, including 
high-risk nodal stage (N2/N3) and HER2 positive status. 
Current nomograms are suboptimal for cancer patients, because their reference point is commonly the time 
of  diagnosis or the start of  adjuvant ET. Aiming at further personalized breast cancer treatment, continuous 
re-evaluation of  the residual risk of  breast cancer recurrence and mortality during follow-up is crucial. Patients 
may develop disease recurrences or discontinue ET before the pre-designated end-date, which may alter a 
patient’s prognosis from that timepoint onwards. Additionally, the effect of  a covariate on 5-year survival 
probabilities may not be constant over time. These changes are more prominent than current statistical models 
account for, which could lead to the risk of  developing less effective treatment guidelines. Therefore, survival 
prediction models need to be adapted for long-term outcome prediction in individual patients. Specifically, 
dynamic prediction models can be used to determine whether a patient will benefit from further adjuvant 
systemic therapy or, conversely, whether ET can be discontinued at a certain timepoint during follow-up. 
The current nomogram can be applied to postmenopausal, hormone receptor-positive breast cancer patients 
undergoing adjuvant ET and have had an axillary lymph node dissection in case of  macrometastases. For 
patients who have had breast-conserving surgery, the model assumes that the breast was irradiated. The 
current nomogram also assumes that disease relapse implies discontinuation of  ET from that moment 
onwards. In case of  disease recurrence, data on subsequent treatment were not available for all patients, 
hence our ability to draw conclusions for this subgroup is limited.
LRR is considered a ‘dynamic’ covariate, as patients can develop a LRR at any moment during follow-up. 
LRR also had ‘time-varying’ properties, as the event of  a LRR revealed a changing impact on 5-year DOS 
at different timepoints after starting ET. Our findings parallel those of  several other studies, which have 
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Figure 5. Nomogram for dynamic prediction of  the 5-year survival probability
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shown that early LRRs convey a worse prognosis than late LRRs.12-16 It can therefore be of  major clinical 
importance to include this factor in dynamic survival prediction. Moreover, this model could potentially 
help evaluate the need for additional adjuvant chemotherapy in case of  LRR. Data on the benefit of  
additional chemotherapy are still relatively lacking, although the nomogram could be useful in this setting. 
The current model also revealed a time-varying relationship between high nodal stage (N2/3) and 5-year 
DOS probability. A similar time-varying effect was shown with regard to 5-year DOS in HER2-positive 
patients, although no patients received anti-HER2 treatment. To our knowledge, no prior reports have 
investigated the time-varying effects of  these two prognostic factors, hence warranting further investigation. 
Our dynamic prediction model also accounts for the effect of  early treatment discontinuation for reasons 
other than breast cancer relapse. Although the effect of  treatment discontinuation did not reach statistical 
significance, possibly due to the low number of  patients who discontinued treatment within three years 
(Figure 2, left panel), we retained this data in our model, as an earlier review revealed the importance of  
treatment compliance on survival outcomes.17
The number and site(s) of  DR are known to be prognostic for subsequent survival.18-20 The dynamic prediction 
model incorporates the occurrence of  distant metastases, but does not include this in the nomogram due to 
insufficient data concerning first site of  DR and subsequent treatment. For this reason, it is not advised to use 
the dynamic prediction model for patients with distant metastases as first site of  disease recurrence.
Internal validation demonstrated that the model had a good ability to discriminate between patients. To elucidate, 
internal validation of  Adjuvant! showed a c-index of  0.71 for discriminatory accuracy (the ability for the model to 
distinguish patients who will versus those who will not die from breast cancer) and a predictive accuracy of  0.73 at 
diagnosis, which is similar to that of  our prediction model.21 The predictive accuracy of  Adjuvant! after diagnosis 
has not been studied; in contrast, our dynamic prediction model showed a cross-validated c-index that improved 
from 0.70 to 0.79 three years after the start of  adjuvant ET. Further external validation of  the prediction model 
is required in greater (non-trial) cohorts to allow for full applicability in the clinical setting. A web-based dynamic 
prediction tool is currently underway to facilitate decision making in clinical practice. 
C O N C L U S I O N
The importance of  using dynamic prediction models for clinical guidance, not only at the start of  
treatment, but also during follow-up, permits continuous revision of  a patient’s residual mortality risk and 
can help motivate a patient to continue treatment, improve compliance, and ultimately improve survival. 
This proof-of-principle study demonstrates a novel technique for performing dynamic prediction of  breast 
cancer survival probabilities over time, enabling a more individualized prediction of  the 5-year DOS in 
individual patients at various timepoints during adjuvant ET. The most important advantage of  this model 
is that it takes into account factors that can influence an individual patient’s prognosis after some time has 
passed since starting adjuvant ET. Notwithstanding the feasibility of  our dynamic prediction model, further 
external validation with longer follow-up is necessary to enable implementation in clinical practice.
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Appendix 2. 5-year dynamic overall survival (DOS) as a quadratic function of  age at diagnosis
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A B S T R A C T
Background
Tamoxifen and aromatase inhibitors are associated with different side effects which can significantly impact 
quality of  life (QOL). We assessed QOL in Dutch patients receiving tamoxifen or exemestane in the 
Tamoxifen Exemestane Adjuvant Multinational (TEAM) Trial. 
Methods 
A total of  2754 Dutch postmenopausal early breast cancer patients were randomized between five years of  
exemestane or 2·5-3 years of  tamoxifen followed by 2·5-2 years of  exemestane. A total of  742 patients were 
invited to participate in the QOL side-study and complete questionnaires at one (T1) and two (T2) years 
after start of  endocrine treatment. Questionnaires comprised the EORTC QLQ-C30 and BR23 validated 
questionnaires, supplemented with FACT-ES questions.
Results
543 patients completed questionnaires at T1 and by 454 patients (84%) at T2. For both treatment arms, 
overall QOL improved during follow-up. Most functioning scales improved over time, except for physical 
functioning, sexual functioning and sexual enjoyment. The only clinically relevant and statistically significant 
treatment difference between the treatment types concerned insomnia, with exemestane-treated patients 
reporting more insomnia than patients using tamoxifen (8 points difference at both timepoints; p=0·001). 
Discussion
Certain QOL issues are treatment- and/or time-specific and deserve attention by oncology health care 
providers. Patients using exemestane reported more insomnia compared to patients using tamoxifen. There 
is a need for careful inquiry into QOL issues by those prescribing endocrine treatment to optimize QOL 
and ensure treatment adherence.
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I N T R O D U C T I O N
The majority of  breast cancer patients is diagnosed at postmenopausal age and most have hormone-
receptor positive tumors. Over time, adjuvant endocrine therapy has increasingly been used to reduce 
disease recurrence and improve survival.1 Presently, optimal endocrine therapy consists of  at least five years 
of  treatment including an aromatase inhibitor (AI), either given upfront or as part of  a sequential treatment 
regimen following tamoxifen.2 Both regimens are appropriate treatment options for postmenopausal 
hormone receptor positive breast cancer patients.2, 3 However, many patients on endocrine therapy are 
confronted with adverse effects, which may negatively impact quality of  life (QOL), treatment compliance, 
and may then lead to a reduced survival.4, 5 The impact of  long-term endocrine treatment on QOL in 
postmenopausal breast cancer patients may therefore be an important issue of  deliberation regarding the 
choice for a specific adjuvant treatment strategy.
Both tamoxifen, a selective estrogen receptor modulator, and AIs, which potently inhibit the aromatase 
enzyme (involved in the conversion of  androgens to estrogen), are associated with a variety of  adverse 
effects. Tamoxifen is associated with thromboembolic complications and endometrial cancer while AIs 
show fewer life-threatening side effects but more readily give rise to sometimes invalidating symptoms such 
as hot flashes, arthralgias, vaginal dryness and osteoporosis.6, 7 Variations in the types and severities of  
adverse effects associated with the use of  either tamoxifen or an AI may result in differences in the domains 
of  QOL affected in patients using either endocrine treatment.
So far, several trials have investigated QOL in patients using adjuvant endocrine therapy, but only four have 
compared QOL in patients treated with tamoxifen versus an AI.8-12 It is difficult to compare these studies 
due to variations in trial design, starting time of  the AI and type of  AI used. To our knowledge, the ATAC 
QOL study is the only large trial that compared QOL from the start of  endocrine therapy in patients treated 
with tamoxifen versus an AI upfront.9 In the Tamoxifen Exemestane Adjuvant Multinational (TEAM) trial 
(Netherlands Trial Register NTR267), postmenopausal, hormone receptor-positive early breast cancer 
patients were randomized to either 5 years of  exemestane upfront or 2.5-3 years tamoxifen followed by 
2-2.5 years of  exemestane.2 There was a major participation in the TEAM study from the different hospitals 
throughout the Netherlands, therefore, this study provided a good opportunity for studying the effects of  
exemestane and tamoxifen on QOL in a homogeneous cohort of  Dutch breast cancer patients. Moreover, 
we were able to relate relevant QOL issues reported by patients in this side study to the adverse events 
involved with these issues reported by the same patients in the main study using the registered adverse 
events.
P A T I E N T S  A N D  M E T H O D S
Study design
The study design and patient eligibility criteria for the TEAM trial have been described previously.2 In the 
Netherlands, the study was initiated in 76 hospitals and details also have been described previously.13 The 
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TEAM QOL side study was an open, multicenter study in which 45 Dutch TEAM centers participated. 
The side study protocol was approved separately by central and local ethics authorities before the enrollment 
of  patients.
Patients and data collection
Patients who were randomized between January 2nd, 2003 and December 29th, 2004 and were event-
free were invited to participate in the TEAM QOL side study. Patients received a letter together with 
the first QOL questionnaire one year after treatment randomization (further referred to as timepoint 
1; T1). Participating patients who returned the first questionnaire and were disease-free two years after 
randomization received the second questionnaire one year after T1 (further referred to as timepoint 2; 
T2). Patients included in the sequential arm received the second questionnaire before the switch from 
tamoxifen to exemestane. No questionnaire was sent at baseline (time of  diagnosis and treatment) as the 
results regarding QOL may potentially be biased, due to the recent knowledge of  breast cancer diagnosis 
and impending treatment, which is known to have a negative impact on QOL. Furthermore, treatment 
was allocated by randomization, hence there is essentially no indication for baseline imbalance in QOL 
data between both treatment arms.14 Patient, tumor, treatment and survival data were collected through 
the main TEAM Datacenter in Leiden, the Netherlands. In the main trial, patients were seen every three 
months in the first year, twice yearly in the second year and at least yearly thereafter. 
Questionnaires
Data on QOL were obtained using the European Organization for Research and Treatment of  Cancer 
Quality of  Life Questionnaire Version 3.0 (EORTC QLQ-C30) and the EORTC Breast Cancer Module 
questionnaire (QLQ-BR23), both translated into Dutch and previously validated.15, 16 Both questionnaires 
were used after authorization by the EORTC Quality of  Life Study Group. The EORTC QLQ-C30 is 
composed of  five functioning scales (physical functioning, role functioning, cognitive functioning, emotional 
functioning, and social functioning), a global health status/QOL scale, three symptom scales (fatigue, pain, 
nausea/vomiting), and six single items (dyspnea, appetite loss, sleep disturbance, constipation, diarrhea 
and financial impact). The EORTC QLQ-BR23 is a validated tool designed for breast cancer patients 
with varying disease stages and treatment modalities and consists of  23 items that assess disease symptoms, 
side effects, body image, sexual functioning, future perspectives, therapy side effects, breast and arm 
symptoms and hair loss. Items that specifically assess side effects of  chemotherapy were not applicable 
for the current study. In addition, the Functional Assessment of  Cancer Therapy – Endocrine Subscale 
(FACT-ES) questionnaire was designed and validated to measure QOL in breast cancer patients treated 
with endocrine therapies.17 Of  the 18 items, 13 were included in our questionnaire (as other items were 
already included through the EORTC QLQ-C30 or BR23 questionnaires), resulting in three endocrine 
symptom scales (menopausal complaints, weight complaints, and vaginal complaints).
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Based on standard EORTC scoring procedures, all scales were linearly converted to a zero-to-100 scale. 
Missing data were treated according to published recommendations.18 For scales evaluating global health 
and functioning, higher scores represent higher levels of  functioning and health status. For the evaluation of  
symptoms, higher scores correspond to more problems and higher levels of  complaints.
Relevant patient-reported outcomes
Regarding QOL, the following items were investigated: (1) the difference between the QOL scores for 
patients using tamoxifen versus exemestane, (2) the difference between the two timepoints (T1 and T2), and 
(3) the interaction between treatment arm and time. A difference in score of  at least eight points between 
groups was considered clinically relevant, and has been demonstrated to be a reasonable cut-off  for clinical 
significance for a range of  QOL endpoints.19 Prior surgery was taken into account for analyses of  body 
image, sexual functioning and sexual enjoyment.
 
Statistical analysis
All data were analyzed using the statistical package SPSS for Windows 17.0 (SPSS Inc, Chicago, IL, USA). 
Descriptive data are given as mean (SD) or median (range). The t-test was used to compare frequencies 
between groups. Linear mixed models were used to assess changes over time for overall QOL and for 
separate components of  QOL. 
R E S U L T S
Demographics
A total of  742 Dutch patients were invited to participate in the QOL side study (Figure 1). 543 patients 
(73%) completed the first questionnaire, of  which 454 (84%) also completed the second questionnaire. 
Baseline characteristics of  the responding patients and the total group of  Dutch TEAM patients are shown 
in Table 1. The distribution of  clinical, pathological and treatment characteristics of  patients participating 
in the QOL side study was similar to that of  the entire cohort of  Dutch TEAM trial patients, except for the 
distribution of  age, hormone receptor status and prior chemotherapy (yes/no). Of  the patients participating 
in the TEAM QOL side study, most were older than 60 years, had node-positive disease and underwent a 
sentinel lymph node procedure followed by an axillary lymph node dissection. Almost 50% of  the tumors 
were smaller than 20mm and approximately half  of  the patients were surgically treated by mastectomy.
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Table 1. Clinical and pathological data of  responders compared to all Dutch TEAM trial patients
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Figure 1. Patient selection 
 
Quality of  Life: Tamoxifen versus exemestane
The results regarding QOL items are shown in Table 2. In general, the scores for the various items did 
not differ significantly between patients using tamoxifen versus exemestane. Patients allocated tamoxifen 
showed superior scores for emotional functioning and sexual functioning (p=0.048 and p=0.024 respectively) 
than exemestane-users. Treatment with exemestane did not show superior results compared to tamoxifen 
for any of  the functioning scales. Regarding individual symptoms, patients who received tamoxifen had 
fewer complaints of  fatigue, dyspnoea, insomnia, and arm symptoms than patients receiving exemestane. 
For fatigue, the results were unrelated to the administration of  chemotherapy (data not shown). Only for 
insomnia, the differences between the two treatment types were clinically significant (more than 8 points 
difference between tamoxifen and exemestane), observed at both timepoints (Figure 2). The endocrine 
symptom scales that were assessed using the FACT-ES included menopausal, weight and vaginal complaints. 
These scores did not differ between the two treatment arms. 
The global health status scale represents an overall summary measurement of  QOL. With respect to either 
treatment group, there was no difference in global health status/overall QOL (Table 2). Interestingly, the 
reported overall QOL was higher than the reference value of  the EORTC QLQ-C30 (>75 versus 62 
points). 
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Figure 2. Insomnia in relation to treatment and time in the TEAM QOL side study
 
Quality of  Life: Changes over time
Changes in QOL items were assessed over the one-year period between T2 and T1 for the total group of  
patients, as there were no relevant differences between the two treatment arms. We found that over time, 
most functioning scales improved, except for physical functioning, sexual functioning and sexual enjoyment 
(p<0.01). Of  note, fewer patients completed the questions concerning sexual functioning and enjoyment 
compared to the other items (Table 2). Over time, neither improvement nor deterioration was observed for 
global health status. Concerning the individual symptom scales, a significant improvement was found for 
the following items: fatigue, nausea and vomiting, appetite, breast symptoms and side effects of  systemic 
therapy. Again, these results for fatigue were unrelated to the administration of  chemotherapy (data not 
shown). A clinically significant difference over time was only established for breast symptoms. 
Quality of  Life: Interaction between treatment arm and time
Irrespective of  treatment, most assessed items improved from T1 to T2. Only for the functioning scale 
‘Future perspective’, did an interaction exist between treatment and time: patients using exemestane 
improved more compared to patients using tamoxifen. 
D I S C U S S I O N
The impact of  adjuvant endocrine therapy on QOL is an ongoing discussion in the treatment of  breast 
cancer patients prescribed long-term endocrine therapy. The current standard of  practice advocating five 
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or more years of  endocrine treatment can therefore be considered cumbersome in those experiencing severe 
adverse effects. Both tamoxifen and AIs have been associated with the development of  various menopausal 
symptoms like sleeping disorders and sexual problems related to the depletion of  circulating estrogens, some 
of  which being severe to the point of  significantly diminishing QOL. The present investigation of  QOL 
in patients in the TEAM trial offers further insight into the impact of  either tamoxifen or exemestane on a 
woman’s QOL during endocrine therapy for breast cancer. 
In the present investigation, a clinically significant difference was found between the two treatment arms 
for insomnia, observed at both timepoints, indicating more problems for exemestane users versus those 
taking tamoxifen. In general, insomnia is underreported and frequently overlooked in the context of  
breast cancer treatment. Approximately half  of  all breast cancer patients experience sleeping disorders 
Table 2. Overview of  the different functioning and symptom scales by time and treatment arm
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up to several years post-diagnosis.20 The pathophysiological mechanism behind insomnia in breast cancer 
patients suggests a relation with nocturnal hot flashes.21 Both hot flashes and musculoskeletal symptoms 
have also been associated with the depletion of  circulating estrogens.22 As exemplified by the MA.17 trial, 
a significant increase in the incidence of  hot flashes and musculoskeletal symptoms was found in patients 
treated with letrozole compared to placebo.11 Our data regarding more sleeping disorders in exemestane-
users suggests that further lowering of  postmenopausal estrogen levels with exemestane may lead to more 
sleeping disorders. Unfortunately this cannot be verified with blood samples, as these were not collected for 
our cohort of  TEAM patients.
Patients using exemestane reported less sexual enjoyment and more sexual functioning problems than 
patients using tamoxifen. This is similar to the results as found after one year of  therapy in the US 
Oncology side study of  the TEAM trial concerning menopausal symptoms.10 Our data do show that also 
after 2-2.5 years of  therapy, menopausal symptoms persisted over time. In physiological menopause, the 
lack of  circulating estrogens reduces vaginal lubrication, resulting in vaginal dryness and, consequently, 
dyspareunia.23 Tamoxifen affects sexual functioning in terms of  decreased libido and the ability to become 
aroused and experience orgasm, while AIs cause vaginal dryness and dyspareunia. Although tamoxifen is 
known to have anti-estrogenic properties on breast tissue, it exerts an estrogen agonist effect on the female 
genital tract in postmenopausal women and increases the risk of  endometrial cancer.24 Furthermore, under 
tamoxifen treatment, the vaginal squamous epithelium is weakly stimulated and undergoes proliferation 
and maturation.25 It is possible that the abovementioned reasons explain why sexual functioning may be less 
affected in tamoxifen-treated patients than in those treated with exemestane. Another contributing factor 
may be that as already said, exemestane induces further lowering of  postmenopausal estrogens in breast 
cancer patients. Fewer reports investigated vaginal dryness and dyspareunia in studies with AIs, but Morales 
et al. suggest that AIs induce more symptoms of  vaginal atrophy (vaginal dryness and dyspareunia) than 
tamoxifen, which parallels our findings that exemestane-treated patients reported more sexual functioning 
problems than tamoxifen-treated patients.26
Other quality of  life studies
To date, only a few large randomized trials comparing adjuvant tamoxifen with AIs have reported on QOL 
data (Table 3).8-12  
Also, it is difficult to compare the different randomized trials with each other and with our QOL side study, 
due to differences in patient populations, countries of  residence, AIs used, timing and of  start of  treatment, 
and the instruments used to assess QOL. However, regardless of  these variations, no large differences in 
QOL were seen between tamoxifen and AIs. 
The planned nature of  the QOL side study using validated questionnaires as well as the high response rate 
for both T1 and T2 questionnaires lends confidence to our findings. The absence of  a baseline measurement 
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may be considered a shortcoming when assessing changes in QOL over time; notably, however, baseline 
measurements of  QOL are likely biased due to recent knowledge of  breast cancer diagnosis in our patient 
population at the start of  treatment. Due to the randomized nature of  this trial, differences in baseline QOL 
with respect to treatment arms are unlikely.14 
In summary, our findings indicate that overall QOL and most functioning scales improve with longer 
therapy duration, both for patients treated with tamoxifen and exemestane. Nevertheless, certain QOL 
issues are treatment-specific and deserve attention by oncology health care providers. Also, the large number 
of  patients who reported complaints of  sexual functioning, fatigue and insomnia in the QOL study was not 
mirrored by the reported adverse events related to these complaints in the main TEAM trial database. 
There is a need for careful inquiry by those seeing patients throughout the duration of  endocrine treatment 
in order to optimize QOL and ensure adherence to treatment.
Table 3. Overview of  other quality of  life studies in trials comparing tamoxifen with an aromatase inhibitor in 
postmenopausal early breast cancer patients
C H A P T E R  8128
1.  Davies C, Godwin J, Gray R et al. Relevance of  
breast cancer hormone receptors and other factors 
to the efficacy of  adjuvant tamoxifen: patient-
level meta-analysis of  randomised trials. Lancet 
2011;378(9793):771-784.
2.  Van de Velde CJ, Rea D, Seynaeve C et al. Adjuvant 
tamoxifen and exemestane in early breast cancer 
(TEAM): a randomised phase 3 trial. Lancet 
2011;377(9762):321-331.
3.  Regan MM, Neven P, Giobbie-Hurder A et al. 
Assessment of  letrozole and tamoxifen alone and in 
sequence for postmenopausal women with steroid 
hormone receptor-positive breast cancer: the BIG 
1-98 randomised clinical trial at 8.1 years median 
follow-up. Lancet Oncol 2011;12(12):1101-1108.
4.  Mortimer JE, Flatt SW, Parker BA et al. Tamoxifen, 
hot flashes and recurrence in breast cancer. Breast 
Cancer Res Treat 2008;108(3):421-426.
5.  Patterson RE, Saquib N, Natarajan L et al. 
Improvement in self-reported physical health 
predicts longer survival among women with a 
history of  breast cancer. Breast Cancer Res Treat 
2011;127(2):541-547.
6.  Burstein HJ. Aromatase inhibitor-associated 
arthralgia syndrome. Breast 2007;16(3):223-234.
7.  Fisher B, Costantino JP, Wickerham DL et al. 
Tamoxifen for the prevention of  breast cancer: 
current status of  the National Surgical Adjuvant 
Breast and Bowel Project P-1 study. J Natl Cancer 
Inst 2005;97(22):1652-1662.
8.  Fallowfield L, Cella D, Cuzick J, Francis S, Locker 
G, Howell A. Quality of  life of  postmenopausal 
women in the Arimidex, Tamoxifen, Alone or in 
Combination (ATAC) Adjuvant Breast Cancer 
Trial. J Clin Oncol 2004;22(21):4261-4271.
9.  Fallowfield LJ, Bliss JM, Porter LS et al. Quality 
of  life in the intergroup exemestane study: a 
randomized trial of  exemestane versus continued 
tamoxifen after 2 to 3 years of  tamoxifen in 
postmenopausal women with primary breast cancer. 
J Clin Oncol 2006;24(6):910-917.
10.  Jones SE, Cantrell J, Vukelja S et al. Comparison 
of  menopausal symptoms during the first year 
of  adjuvant therapy with either exemestane or 
tamoxifen in early breast cancer: report of  a 
Tamoxifen Exemestane Adjuvant Multicenter trial 
substudy. J Clin Oncol 2007;25(30):4765-4771.
11.  Muss HB, Tu D, Ingle JN et al. Efficacy, toxicity, 
and quality of  life in older women with early-stage 
breast cancer treated with letrozole or placebo after 
5 years of  tamoxifen: NCIC CTG intergroup trial 
MA.17. J Clin Oncol 2008;26(12):1956-1964.
12.  Whelan TJ, Goss PE, Ingle JN et al. Assessment 
of  quality of  life in MA.17: a randomized, 
placebo-controlled trial of  letrozole after 5 years of  
tamoxifen in postmenopausal women. J Clin Oncol 
2005;23(28):6931-6940.
13.  van Nes JG, Seynaeve C, Maartense E et al. 
Patterns of  care in Dutch postmenopausal 
patients with hormone-sensitive early breast 
cancer participating in the Tamoxifen Exemestane 
Adjuvant Multinational (TEAM) trial. Ann Oncol 
2010;21(5):974-982.
14.  Fayers P, King M. The baseline characteristics 
did not differ significantly. Qual Life Res 
2008;17(8):1047-1048.
15.  Aaronson NK, Ahmedzai S, Bergman B et al. 
The European Organization for Research and 
Treatment of  Cancer QLQ-C30: a quality-of-life 
instrument for use in international clinical trials in 
oncology. J Natl Cancer Inst 1993;85(5):365-376.
16.  Sprangers MA, Groenvold M, Arraras JI et al. 
The European Organization for Research and 
Treatment of  Cancer breast cancer-specific 
quality-of-life questionnaire module: first results 
from a three-country field study. J Clin Oncol 
1996;14(10):2756-2768.
17.  Fallowfield LJ, Leaity SK, Howell A, Benson S, 
Cella D. Assessment of  quality of  life in women 
undergoing hormonal therapy for breast cancer: 
validation of  an endocrine symptom subscale 
for the FACT-B. Breast Cancer Res Treat 
1999;55(2):189-199.
R e f e r e n c e  L i s t
Q U A L I T Y  O F  L I F E  I N  R E L A T I O N  T O  T A M O X I F E N  O R  E X E M E S T A N E  T R E A T M E N T  I N  P O S T M E N O P A U S A L 
B R E A S T  C A N C E R  P A T I E N T S  –  A  T E A M  T R I A L  S U B - S T U D Y
129
18.  Fayers PM. Interpreting quality of  life data: 
population-based reference data for the EORTC 
QLQ-C30. Eur J Cancer 2001;37(11):1331-1334.
 19.  Norman GR, Sloan JA, Wyrwich KW. 
Interpretation of  changes in health-related quality 
of  life: the remarkable universality of  half  a 
standard deviation. Med Care 2003;41(5):582-592.
20.  Savard J, Simard S, Blanchet J, Ivers H, Morin CM. 
Prevalence, clinical characteristics, and risk factors 
for insomnia in the context of  breast cancer. Sleep 
2001;24(5):583-590.
21.  Ohayon MM. Severe hot flashes are associated 
with chronic insomnia. Arch Intern Med 
2006;166(12):1262-1268.
22.  Stearns V, Ullmer L, Lopez JF, Smith Y, Isaacs C, 
Hayes D. Hot flushes. Lancet 2002;360(9348):1851-
1861.
23.  Semmens JP, Wagner G. Estrogen deprivation and 
vaginal function in postmenopausal women. JAMA 
1982;248(4):445-448.
24.  Nasu K, Takai N, Nishida M, Narahara H. 
Tumorigenic effects of  tamoxifen on the female 
genital tract. Clin Med Pathol 2008;1:17-34.
25.  Varras M, Polyzos D, Akrivis C. Effects of  
tamoxifen on the human female genital tract: review 
of  the literature. Eur J Gynaecol Oncol 2003;24(3-
4):258-268.
26.  Morales L, Neven P, Timmerman D et al. Acute 
effects of  tamoxifen and third-generation aromatase 
inhibitors on menopausal symptoms of  breast 
cancer patients. Anticancer Drugs 2004;15(8):753-
760.

HIGH NON-COMPLIANCE IN PATIENTS TREATED 
WITH EXTENDED ADJUVANT LETROZOLE. 
RESULTS FROM THE IDEAL RANDOMIZED TRIAL
Duveken BY Fontein, Johan WR Nortier, Gerrit-Jan Liefers, Hein Putter, 
Elma Meershoek-Klein Kranenbarg, Joan van den Bosch, Eduard Maartense, Emiel JT Rutgers, 
Cornelis JH van de Velde
C H A P T E R
9
European Journal of  Surgical Oncology, 2011
C H A P T E R  9132
A B S T R A C T
Background
The aim of  this study was to investigate non-compliance to aromatase inhibitors and factors associated with 
early treatment discontinuation in the extended adjuvant setting.
Methods
The IDEAL trial is a prospective, open-label phase-III trial comparing 2.5 with 5 years of  extended 
adjuvant letrozole in hormone receptor-positive postmenopausal early breast-cancer patients after 5 years 
of  adjuvant endocrine therapy. The purpose of  this study was to assess non-compliance in the first 2.5 years 
of  extended adjuvant therapy. Non-compliance was defined as early discontinuation of  letrozole for all 
reasons, excluding death or recurrence. 
Results
At 2.5 years, 1215 patients were included in the analysis. Overall non-compliance probability was 18.4%, 
of  which 85.1% discontinued due to toxicities. Analyses showed that patients with prior sequential 
therapy were less likely to discontinue treatment than when treated with an aromatase inhibitor (AI) or 
tamoxifen upfront (logrank-p=0.004). Longer treatment-free intervals also predicted more non-compliance 
(logrank-p=0.011). Age was not predictive of  non-compliance (p=0.571). Prior surgery (mastectomy 
vs breast conserving surgery), both with or without radiotherapy and/or chemotherapy were also not 
associated with early treatment discontinuation (p=0.228 and p=0.585 respectively). Although having fewer 
than four positive lymph nodes predicted more non-compliance (logrank-p=0.050), age, tumor-type and 
locoregional treatment did not. 
Conclusions
High non-compliance to extended adjuvant endocrine therapy was confirmed. Toxicities were the major 
reason for discontinuation, and this was not influenced by age. Longer treatment-free intervals and fewer 
positive lymph nodes predicted more non-compliance. Patients who underwent sequential therapy were 
least likely to discontinue extended adjuvant endocrine therapy.
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I N T R O D U C T I O N
Aromatase inhibitors (AIs) have shown improvements in reducing both mortality and recurrence rates in 
postmenopausal hormone receptor-positive early breast cancer patients.1-5 AIs are commonly prescribed as 
part of  a sequential treatment regimen for 2-3 years after 3-2 years of  tamoxifen, or as monotherapy for five 
years, although it has been suggested that more than five years of  adjuvant treatment provides an additional 
benefit, even after a period of  treatment discontinuation.6 Despite prominent developments in breast cancer 
therapy directed at improving survival and reducing recurrence, early discontinuation of  adjuvant endocrine 
therapy in the first five years of  treatment is persistently high.7, 8 Non-compliance rates are similar in patients 
treated with AIs, tamoxifen, or a sequence of  both, and ranges between 40-60%. Reports confirm that these 
high rates are largely attributable to the presence and severity of  adverse effects.8-12 
AIs function by inhibiting the enzyme aromatase, which plays a role in converting estradiol to estrogen. 
Estrogen deprivation by AIs has shown profound effects on breast cancer survival and a significant reduction 
in recurrence rates.13 However, inducing an early artificial menopausal status by depriving the body of  
circulating estrogens also gives rise to symptoms imitating menopause, including arthralgias, hot flashes, 
vaginal dryness, and osteoporosis.14, 15 Steps have been undertaken to reduce the number of  adverse effects 
that derive from the depletion of  estrogens. Third-generation AIs were developed to be more selective and 
potently lower plasma estrogen levels through near-complete suppression of  aromatase.13, 16 
Studies show that treatment duration is directly related to clinical outcome.17 Current standard of  care is 
tamoxifen or an AI only or a sequence of  both for the duration of  five years, although evidence suggests that 
continuing treatment after five years may be beneficial in terms of  survival.1, 6
Although data implies that treatment compliance is lower in patients who are older (≥85 years) or younger 
(<45 years), have a lower socio-economic status, experience side effects, and are prescribed therapy for 
longer duration, these associations are inconsistent across studies.18, 19 These differences may, in part, result 
from differences in study populations, as well as variations in definitions of  adherence. Patients’ personal 
perceptions and beliefs about their illness as well as the risks, benefits and costs of  their prescribed medication 
were found to be strong predictors of  non-compliance, and have been the focus of  investigations.18-20
To date, no other prospective clinical trial has studied non-compliance to extended adjuvant therapy in-depth. 
The MA.17 trial, one of  the first trials to investigate more than five years of  adjuvant endocrine treatment, 
conveyed high rates of  adverse effects, but medication adherence was not reported.21 In light of  determining the 
optimal duration of  adjuvant endocrine therapy, efficacy may be compromised when treatment is discontinued 
before the predetermined stop date is reached, in which case extended therapy is prescribed in vain.
This investigation discusses high rates of  non-compliance found in the extended adjuvant setting in a 
Dutch trial on prolonged endocrine therapy, and determines which patients are at risk of  early treatment 
discontinuation. Discerning which patients are at highest risk of  non-compliance is imperative for tackling 
this issue effectively.
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M A T E R I A L S  A N D  M E T H O D S
Patient selection
The Investigation on the Duration of  Extended Adjuvant Letrozole (IDEAL) trial is a prospective, 
randomized, open-label phase III trial evaluating the efficacy and safety of  2.5 with 5 years of  adjuvant 
letrozole in breast cancer patients after five years of  adjuvant endocrine therapy. The purpose of  the present 
study was to assess non-compliance in the first 2.5 years of  extended adjuvant therapy. Postmenopausal 
patients were diagnosed with hormone receptor-positive, early stage (I-IIIa) breast cancer, and adequately 
treated with five years of  adjuvant endocrine therapy. Patients were disease-free at time of  randomization. 
Adjuvant endocrine therapy consisted of  five years of  AIs only (anastrozole, exemestane or letrozole), or a 
sequence of  2-3 years of  tamoxifen followed by 3-2 years of  AIs. When AIs are contraindicated, five years 
of  tamoxifen monotherapy is warranted. The IDEAL trial is registered with the Netherlands Trial Register 
(NTR3077). Appropriate approvals from local ethical committees were obtained and all patients provided 
written informed consent. 1262 patients from 72 hospitals were included in the present analysis and were 
randomized to either 2.5 or 5 years of  letrozole (2.5mg once daily, orally) between April 2007 and April 
2011.
Non-compliance
Non-compliance was defined as early discontinuation of  letrozole before the predetermined end date 
for any reason, with the exception of  early discontinuation due to cancer recurrence or death. Switching 
to a different form of  endocrine therapy before the predetermined stop date was also considered non-
compliance. The duration of  letrozole therapy was determined by calculating the number of  days between 
the first and last dose of  letrozole during the first 2.5 years of  follow-up. An intermittent break from therapy 
was permitted for a maximum of  four weeks. Patients who died during the follow-up period and who had 
not reported treatment discontinuation before their death were considered compliant. Patients who never 
started letrozole were excluded from the analyses.
Patient and tumor characteristics
Tumor characteristics were recorded using clinical TNM classification (tumor size, regional lymph node 
metastases and distant metastases), estrogen receptor (ER), and progesterone receptor (PR) status. We 
collected data on tumor and pathological characteristics, including histological subtype, pathological grade 
and mitotic activity, and prior curative and locoregional therapy (type of  surgery, type and duration of  
chemotherapy, type and duration of  endocrine therapy). Patients were stratified by nodal status (node-
negative or node-positive), time from last dose of  prior endocrine therapy (0-<6, 6-<12, 12-27 months) and 
prior chemotherapy (yes/no). Treatment discontinuation was assessed during patient visits at 6 months, 1, 
2 and 2.5 years after starting extended adjuvant treatment with letrozole, or in case of  intermittent adverse 
events. Date of  last follow-up, cancer recurrence or death were used as censoring, and further administrative 
censoring was applied at 2.5 years after randomization. The date of  treatment discontinuation as well as 
reasons for non-compliance and (if  relevant) subsequent therapy were documented prospectively.
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Statistical analysis
Kaplan-Meier survival curves were used to demonstrate early discontinuation of  letrozole over the follow-
up period. We performed Cox regression analyses to identify factors associated with early treatment 
discontinuation. All analyses were performed with SPSS version 17.0 Statistical Software (SPSS Inc., 
Chicago Ill.).
 
Table 1. Baseline characteristics of  1215 patients who started letrozole
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Patient and treatment characteristics
1262 patients were randomized for 2.5 or 5 years of  treatment with letrozole. 1215 patients had at least 
one dose of  letrozole during the follow-up period. 31 patients (2.6%) had a recurrence and seven patients 
(0.6%) died over the follow-up period. Most patients (1069, 88%) started letrozole within six months of  the 
end of  prior adjuvant endocrine therapy. Prior treatment consisted of  five years tamoxifen (n=141) or an 
AI only (n=291), or sequential therapy of  2-3 years with an AI after 3-2 years of  tamoxifen (n=729) (Table 
1). Information about the number of  follow-up visits was available for 1103 patients. Compliant patients 
visited the breast unit more frequently than non-compliant patients (median 2.07 (range 0.79-10.53) versus 
2.03 visits (range 0.02-7.14), p=0.011). 
The overall non-compliance probability was 18.4% within the 2.5-year follow-up period. The median 
follow-up time for non-compliant and compliant patients was 1.88 years (range 0.19-2.50) and 1.11 
years (range 0.19-2.50) respectively, (p=0.003). Highest discontinuation rates were found in the first six 
months of  treatment with letrozole (49.7%). A vast majority of  patients (n=154, 85.1%) discontinued due 
to adverse events. Most commonly reported adverse events included musculoskeletal, neurological, and 
dermatological/skin disorders, based on the Common Terminology Criteria for Adverse Events (CTCAE) 
version 3.0 (Table 2). Other reasons for early discontinuation of  letrozole included treatment refusal (n=18), 
protocol deviation (n=4), intercurrent illness (n=1) and other reasons (n=4). No difference existed between 
the randomized treatment groups (2.5 years vs 5 years letrozole) (logrank p=0.695). 35 patients discontinued 
follow-up altogether (13 non-compliant and 22 compliant patients).
Table 2. Reasons for treatment discontinuation by adverse event*
* based on the Common Terminology Criteria for Adverse Events (CTCAE) version 3.0
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Risk factors for non-compliance
A significant difference was found between treatment discontinuation and prior endocrine treatment 
regimen (logrank p=0.004). Patients previously treated with sequential therapy of  2-3 years tamoxifen 
followed by an AI for 3-2 years had the lowest probability of  treatment discontinuation after 2.5 years 
(Figure 1a). There was no difference between the two 5-year therapies (p=0.829). Patients who had used 
letrozole earlier, either five years upfront or after switching from tamoxifen, were most likely to persevere 
Figure 1. Kaplan-Meier curve of  early treatment discontinuation based on prior endocrine treatment regimen and 
treatment-free interval after 5 years of  adjuvant endocrine therapy.
Figure 1a. Early treatment discontinuation based on prior endocrine treatment regimen
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with letrozole in the extended adjuvant setting (3.5% non-compliance, hazard ratio (HR) 0.170 (95%CI 
0.066-0.437); logrank p=0.001) compared to tamoxifen only. No significant difference existed between the 
other treatment groups (data not shown). A significant difference was also found in the number of  patients 
discontinuing treatment early based on the treatment-free interval between the last dose of  prior endocrine 
therapy and the first dose of  letrozole (logrank p=0.011). Longer intervals predicted more non-compliance 
(Figure 1b).
Patients were categorized by age (<55, 55-65, 65-75, >75 years), tumor size and nodal status based on the 
TNM classification, prior surgery and prior chemotherapy. No differences in early discontinuation rates 
between older and younger postmenopausal patients could be established (p=0.571) (data not shown). 
Tumor size did not show any differences in early discontinuation rates (logrank p=0.370). However, there 
was a barely significant difference in non-compliance based on the number of  positive lymph nodes; having 
fewer than four positive lymph nodes predicted more non-compliance (logrank p=0.050) (Figure 2). 
Figure 2. Early discontinuation of  letrozole based on nodal status 
Figure 2. Number of  positive lymph nodes and treatment discontinuation
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Type of  surgery (mastectomy or breast conserving surgery (BCS)) was not associated with non-compliance 
(logrank p=0.822). Non-compliance was not associated with prior adjuvant chemotherapy (logrank 
p=0.585) or radiotherapy (logrank p=0.383) separately. We investigated whether the combination of  surgery 
type with or without radiotherapy were correlated with non-compliance. Only nine patients received BCS 
without radiotherapy and were therefore grouped together with other breast conserving surgery patients. 
No differences were established between the different treatment groups (logrank p=0.228). Additional 
analyses were performed where patients who switched to another AI were also considered compliant. 
Patients with mastectomy and radiotherapy were more compliant than patients who underwent mastectomy 
without radiotherapy or BCS with or without radiotherapy (HR 1.740 (95%CI 1.047-2.892) and HR 1.785 
(95%CI 1.113-2.864); logrank p=0.043 for the two treatment combinations respectively).  After termination 
of  letrozole, most patients discontinued extended therapy altogether (78.5%). 35 patients continued with 
another AI (4 patients unknown). 32 out of  35 patients switched back to the AI used prior to starting 
letrozole (14 exemestane, 18 anastrozole). 
D I S C U S S I O N
Risk factors for non-compliance 
Non-compliance to adjuvant endocrine therapy can be detrimental for women in their treatment of  
hormone-receptor positive early breast cancer. More than half  of  the patients prescribed adjuvant AIs 
discontinue treatment before the five-year regimen has passed.9, 11, 22 The present study shows that even 
after persisting five years of  endocrine therapy, approximately 15% of  patients still choose to discontinue 
treatment with AIs. Longer intervals between adjuvant and extended adjuvant treatment, prior endocrine 
therapy with tamoxifen or AI only, and fewer than four positive lymph nodes were associated with more 
non-compliance.  
Research on non-compliance in the extended adjuvant setting after enduring five years of  endocrine 
therapy is lacking. We found several factors that were predictive of  early treatment discontinuation. The 
kind of  endocrine therapy was an independent predictor of  non-compliance. Patients previously treated 
with letrozole only or as part of  a sequential treatment regimen were more likely to persist treatment than 
patients who had previously been treated with a different agent. The most plausible reasoning lies in the fact 
that patients are accustomed to letrozole and its toxicities.
Evidence for the impact of  certain patient- and therapy-related factors on treatment non-compliance is 
variable. Previous reports indicate that older and younger breast cancer patients have higher rates of  early 
treatment discontinuation.19 Increased age is often associated with multiple comorbidities, which also affects 
treatment compliance.19, 23  Non-compliance probability did not differ significantly based on age in our 
cohort. It should be taken into consideration that the current population may differ from other populations 
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reported in prior literature. Perceived benefit of  extended adjuvant treatment may also be the cause of  the 
obliterated differences in non-compliance based on age commonly described in previous studies.18, 19 In 
addition, the present study population consists of  patients who could be considered more compliant than 
the general population of  postmenopausal early breast cancer patients with hormone-receptor positive 
disease, due to the fact that they have already completed five years of  endocrine therapy. 
Partridge et al. indicated that patients who underwent mastectomy instead of  BCS had higher rates of  
tamoxifen non-compliance.19 On the other hand, Owusu et al. reported more treatment discontinuation in 
patients who received BCS without radiotherapy.22 Our results were similar to those reported by Owusu et al. 
only after considering patients who switched from letrozole to another AI as being compliant: patients who 
underwent mastectomy with radiotherapy were more compliant than those who underwent mastectomy 
without radiotherapy or BCS. Although mortality rates do not differ between BCS and mastectomy, a 
pooled analysis of  randomized trials found more locoregional recurrences in patients with BCS.24 It is 
therefore disquieting to discover that patients who underwent BCS with or without radiotherapy are at 
greater risk of  non-compliance. 
The observed protective effect of  more positive lymph nodes on non-compliance starkly contrasts findings 
by Fink and colleagues.18 Fink et al. investigated tamoxifen discontinuation in women 65 years and older 
with newly diagnosed hormone receptor-positive breast cancer and discovered that patients with four 
or more positive nodes had a two and a half  times greater likelihood of  discontinuing tamoxifen than 
patients with no positive nodes. Contrary to these findings, our study showed that patients with four or 
more positive lymph nodes were more compliant than patients with fewer positive nodes. This discovery 
suggests that patients’ perceptions on the benefit of  treatment and the knowledge of  risk factors for disease 
recurrence could influence treatment persistence, as was demonstrated in earlier investigations of  the role of  
patients’ beliefs on treatment adherence.18 All patients in our study already persisted five years of  adjuvant 
endocrine therapy. Accordingly, patients who discontinued treatment in the first five years were not included 
in the present analysis. Differences between the two populations may thus explain the dissimilarity in the 
observations by Fink and colleagues.18 
Adverse effects
Previous studies have recognized that non-compliance is largely attributable to the presence and severity of  
adverse effects.9, 10, 19 Treatment efficacy can be compromised when AIs are not taken for the full prescribed 
duration.17 Adverse events were the cause of  85.1% of  the cases of  early treatment discontinuation, which 
is consistent with other studies on non-compliance in the first five years of  endocrine therapy, where adverse 
events also posed the greatest threat to non-compliance.9, 10, 19 
It has also been suggested that adherence to endocrine therapy is at least partially dependent on the (lack 
of) communication between patients and their physicians, who fail to adequately explain the importance 
of  enduring adjuvant endocrine therapy and the potential adverse effects of  the prescribed therapy.25 As 
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adverse effects are a major contributor to early treatment discontinuation, it is crucial that physicians and 
nurse practitioners take the time to explain and prepare the patient for the possibility of  adverse effects. 
Greater adherence was found in patients previously prescribed a sequential treatment regimen than those 
with upfront treatment regimens. One might infer that active reinforcement of  the importance of  endocrine 
treatment when a patient visits her physician to switch from tamoxifen to an AI provides an additional 
advantage to treatment adherence, because the importance of  therapy is reiterated. This supposition is 
based on reported methods of  improving adherence, which include adequately explaining and reinforcing 
the benefits and side effects of  the prescribed medication.25
Several methods have been proposed to objectively measure drug compliance, including self-reports, 
pill counts, prescription analysis, serum or urine drug levels and microelectronic monitoring systems.26 
Although one or more of  these methods is unmistakably more effective for objectively assessing compliance 
while on treatment, this was not possible in the current study. Given the results of  the present analysis, 
however, it is more important to reflect whether prescribing endocrine therapy for 2.5 years or longer will 
be advantageous if  almost 20% of  patients already discontinue treatment within 2.5 years.
After discontinuing letrozole, most patients stopped treatment altogether. The decision to discontinue 
treatment may be a relief  for patients experiencing adverse effects that interfere with daily functioning and 
quality of  life. Conversely, other patients are more reluctant to stop treatment, given the knowledge that a 
growing number of  studies are finding that longer treatment with AIs provide additional survival benefit. 
The Dutch treatment guidelines currently recommend five years of  adjuvant endocrine therapy for 
patients with hormone receptor-positive disease. Extended adjuvant therapy is not yet standard practice, 
and physicians and patients may therefore decide to discontinue treatment completely rather than switch 
to another AI. On the other hand, almost 20% of  patients who discontinued letrozole did persist with 
another AI, which suggests that outside of  clinical trials physicians are already prescribing AIs for longer. 
Information on drug adherence and treatment duration after switching from letrozole to another AI were 
not available, and is therefore a limitation of  this study. Additionally, information on why non-compliant 
patients had fewer follow-up visits per year was not reported. It is therefore not possible to conclude 
whether missing a follow-up visit was due to adverse events or due to other reasons unrelated to treatment 
compliance.
Treatment efficacy and drug metabolism
Although endocrine therapy is known to cause multiple toxicities of  varying severity, not all patients report 
adverse effects. With respect to tamoxifen, patients may differ in their metabolic responses to convert 
tamoxifen into the active metabolite endoxifen, depending on the activity of  the Cytochrome P450 2D6 
(CYP2D6) enzyme.27 Treatment efficacy seems highest in patients considered extensive metabolizers.27-29 
Goetz and colleagues found that extensive metabolizers had the highest rates of  adverse effects such as hot 
flashes.28 If  this also holds true for AIs, it is important to determine which patients are at highest risk of  non-
compliance resulting from adverse events based on their metabolic characteristics. If  differences in drug 
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efficacy are associated with variations in AI metabolism, and treatment toxicities are subsequently linked to 
these variations in AI metabolism, one can infer that patients with more severe adverse reactions will derive 
additional benefit from AI therapy. Simultaneously, these are the same patients who will have the greatest 
risk of  non-compliance. To date, this has only been demonstrated in CYP2D6 metabolism studies with 
tamoxifen.27-29 Considering that an individual-tailored approach to endocrine treatment of  postmenopausal 
breast cancer patients is most favourable, it is crucial that future studies determine which patients are at 
highest risk of  adverse events, and consequently, non-compliance. 
Patients are frequently prescribed adjuvant therapies to further reduce the risk of  relapse. However, 
reductions in recurrence can only be attained when patients comply with the prescribed treatment and 
duration. Despite promising reports of  superior efficacy when endocrine treatment duration exceeds five 
years, many patients are plagued by adverse effects, and the risk of  non-compliance raises questions on the 
efficacy of  extended treatment in all patients. 40-60% of  patients have discontinued treatment after five 
years of  treatment 19, and an additional 18% stop in the extended adjuvant setting. This alarmingly high 
non-compliance reiterates the need for tackling this issue effectively. Furthermore, it is important to discern 
which patients are most likely to encounter adverse effects and prevent their non-compliance, as it is likely 
that these patients may derive most benefit from extended adjuvant endocrine therapy with AIs.
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Introduction
Many adverse events (AEs) associated with aromatase inhibitors (AI) involve symptoms related to the 
depletion of  circulating estrogens, and may be related to efficacy. We assessed the relationship between 
specific AEs (hot flashes (HF) and musculoskeletal AEs (MSAE)) and survival outcomes in Dutch and 
Belgian patients treated with exemestane in the Tamoxifen Exemestane Adjuvant Multinational (TEAM) 
trial. Additionally, the relationship between hormone receptor expression and AEs was assessed 
Methods
Efficacy endpoints were relapse-free survival (RFS), overall survival (OS) and breast cancer-specific 
mortality (BCSM), starting at 6 months after the start of  exemestane treatment. AEs reported in the first 6 
months of  treatment were included. Specific AEs comprised HF and/or MSAE. Landmark analyses and 
Cox proportional hazards models assessed survival differences up to 5 years. 
Results
1485 exemestane patients were included. Patients with HF had a better RFS than patients without HF 
(multivariate HR 0.393 (95%CI 0.19–0.813); p=0.012). The occurrence of  MSAE versus no MSAE did not 
relate to better RFS (multivariate HR 0.677 (95%CI 0.392–1.169); p=0.162). Trends were maintained for 
OS and BCSM. Quantitative hormone receptor expression was not associated with specific AEs. 
Discussion
Some AEs associated with estrogen depletion are related to better outcomes and may be valuable biomarkers 
in AI treatment.  
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I N T R O D U C T I O N
Five years of  adjuvant treatment with third-generation aromatase inhibitors (AI) have shown improvements 
in disease-free survival, distant disease-free survival, and contralateral breast cancer, without significant 
improvements in overall survival, when compared with tamoxifen in postmenopausal hormone receptor-
positive breast cancer patients. This has been observed in several large trials.1, 2 In addition, superiority of  AIs 
has also been shown when used as part of  a sequential treatment regimen, following 2-3 years of  tamoxifen, 
including survival benefit in the IES study.3-5 Although the toxicity profile shows fewer acute and potentially 
life-threatening adverse events (AEs) than tamoxifen, such as  pulmonary embolisms  and endometrial cancer, 
AIs are also associated with inconvenient adverse effects, mostly related to the body’s depletion of  circulating 
estrogens such as hot flashes (HF), vaginal dryness, osteoporosis and musculoskeletal symptoms (MSAE) such 
as arthritis, arthrosis, arthralgia and myalgia.6 Adverse effects of  AIs also play an important role in treatment 
compliance and, essentially, treatment efficacy.7 
By virtue of  their mechanism of  action, aromatase inhibitors decrease the levels of  circulating postmenopausal 
estrogens.8 Polymorphisms in the aromatase gene, CYP19A1, have also been described and are associated with 
variations in circulating estrogen levels.9. In addition, it has been suggested that a relationship exists between 
CYP19A1 polymorphisms and efficacy of  aromatase inhibitors based on alterations in aromatase activity.10. 
The presence of  specific AEs including HF and MSAE may also be related to lower levels of  circulating 
estrogens.11-13 Based on this assumption, AEs may be a predictor and valuable biomarker of  treatment 
efficacy of  AIs.14-16 Regarding tamoxifen, it has also been suggested that patients who developed vasomotor 
symptoms during tamoxifen treatment had a lower risk of  breast cancer relapse, and were CYP2D6 extensive 
metabolizers, but data are inconclusive and immature to implement preemptive CYP2D6 testing in the 
clinic.15-18 Cuzick and colleagues assessed the relationship between endocrine symptoms and breast cancer 
recurrence in both tamoxifen- and anastrozole-treated patients in the ATAC study, and found that the presence 
of  specific endocrine symptoms were predictive of  a better response to endocrine therapy.14 
The level of  hormone receptor expression is possibly also predictive of  response to endocrine therapy. Results 
from the TransATAC and TEAM trials showed that higher levels of  estrogen receptor (ER) expression were 
beneficial in terms of  longer time to relapse in both patients treated with aromatase inhibitors and tamoxifen; in 
highly hormone-sensitive patients AIs were more effective than tamoxifen.19, 20 Quantitative hormone receptor 
expression may therefore be predictive of  the occurrence of  specific adverse effects related to the depletion of  
circulating estrogens, and thus influence treatment efficacy in patients treated with exemestane. We hypothesized 
that more specific AEs would be present in patients with higher levels of  hormone receptor expression. 
In the current investigation in postmenopausal hormone-sensitive breast cancer patients using exemestane 
therapy, we assessed the relationship between the occurrence and types of  AEs and efficacy, as well as the 
association between specific AEs and quantitative ER and progesterone receptor (PR) expression based on the 
Allred score. For this purpose, data from hormone-receptor positive Dutch and Belgian early breast cancer 
patients treated with the steroidal aromatase inhibitor, exemestane, in the Tamoxifen Exemestane Adjuvant 
Multinational (TEAM) trial was utilized.
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M A T E R I A L S  A N D  M E T H O D S
The TEAM trial is a randomized, phase 3, multinational, open label study conducted in postmenopausal 
women with ER and/or PR positive tumors who were eligible for adjuvant hormonal treatment. 
Patients were randomized to receive either exemestane 25 mg once-daily for five years or tamoxifen 
20 mg once-daily for 2.5–3 years, followed by exemestane 25 mg once-daily for 2.5–2 years, for a total 
of  five years.21 Participants were enrolled in nine countries worldwide. The TEAM Trial protocol 
was approved by the regulatory and ethics authorities of  all participating centers in all participating 
countries. The trial was registered in the Netherlands and Belgium with the Netherlands Trial Register, 
NTR 267. All patients provided written informed consent, and additional consent was obtained from 
patients in the tamoxifen group for the switch to exemestane. Details of  eligibility criteria have been 
published in earlier reports.21 
In the Netherlands and Belgium, 3167 patients were randomized in the TEAM study. 1584 patients 
were allocated to 5 years of  exemestane. Patients randomized to the sequential treatment arm 
(tamoxifen to start with, n=1583) and patients who did not start randomized treatment (n=8) were 
excluded from the current analyses. Furthermore, patients who had an event (recurrence or death) 
(n=8) and/or discontinued the randomized therapy within six months of  treatment initiation (n=94) 
were also excluded as patients had to fulfill the first six months of  treatment in order to be included 
in the follow-up. All AEs reported in the first six months of  starting adjuvant endocrine therapy were 
included in the analyses.
Data collection was performed by case report forms and transferred to the central data center in Leiden, 
the Netherlands. For almost all Dutch, and a subset of  the Belgian patients, ER and PR expression on the 
tumor blocks were reviewed centrally in Edinburgh, United Kingdom, as has been reported by Bartlett 
and colleagues.20 Quantitative ER and PR expression were evaluated as binary categories according to the 
Allred score, PR-poor ≤4 versus PR-rich ≥5; ER-poor ≤6 versus ER-rich ≥7.20 Only those patients whose 
ER and PR expression could be reviewed centrally were included in the analyses with quantitative HR 
expression. Patients with unknown ER Allred scores (n=212) or unknown PR Allred scores (n=231) were 
excluded.
Complete follow-up data was available for the first five years, and was carried out every 3 months in the first 
year, and twice yearly until year 5 (end of  randomized therapy). All AEs were obtained from patient responses 
during follow-up visits, a symptom checklist was not utilized. Severity of  AEs was assessed using the National 
Cancer Institute Common Toxicity Criteria, and were centrally recoded using the Medical Dictionary for 
Regulatory Activities (version 12.1).21 HF was defined as a subjective and transient sensation of  heat, including 
night sweats. MSAE included all accounts of  arthralgia, arthritis, arthrosis and myalgia. For the current 
analysis, osteoporosis was not considered an MSAE. Due to the fact that both HF and MSAE are specifically 
related to the immediate decrease in concentration of  circulating estrogens, the symptoms combined are 
referred to as ‘specific’ AEs. Specific AEs of  all severities reported within the first 6 months of  treatment were 
included in the analyses. 
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The endpoints of  the current analyses were relapse free survival (RFS), overall survival (OS), and breast cancer-
specific mortality (BCSM) starting as of  six months after start of  exemestane therapy. RFS was defined as the 
time on treatment to the earliest documentation of  disease relapse (local or distant recurrence, contralateral 
breast cancer or death from breast cancer, as defined on the case report form), or end of  follow-up (5 years). 
Breast cancer mortality was confirmed by medical record review and categorized into 1 of  10 pre-specified 
groups, and classification was verified by the TEAM central datacenter. If  patients had distant metastases at 
the time of  death, the cause of  death was considered breast cancer-related. 
Statistical analysis
Statistical analyses were performed using SPSS 17.0 (SPSS, Chicago, IL). Landmark analyses were conducted, 
with follow-up starting at 6 months after randomization. Kaplan-Meier curves were plotted for time-to-
relapse. Cox Proportional Hazard Models with 95% confidence intervals (CI) were used to assess survival 
differences with respect to the presence or absence of  HF or MSAE. Multivariate survival analyses were 
adjusted for age at diagnosis, tumor size, nodal status, histological grade, most extensive surgery, radiotherapy 
and chemotherapy. Interaction terms between HF and age, size, nodal status, histological grade, surgery, prior 
radiotherapy and prior chemotherapy, and between MSAE and age, size, nodal status, histological grade, 
surgery, prior radiotherapy and prior chemotherapy were incorporated in the Cox model to test for the 
presence of  effect modification. 
 
R E S U L T S
Study population
In total, 1485 exemestane patients were included. Median age was 63.7 years (range 44-93 years), and further 
patient characteristics are shown in Table 1. Supplementary Figure 1 portrays the reported treatment-related 
AEs within the predetermined 6-month period by age. Of  note, the majority of  patients did not report any 
AEs, while 39.3% of  the patients reported any AE within the first six months of  starting exemestane. Specific 
AEs were reported by 23.7% of  the patients. Specific AEs were more frequently reported by younger patients 
(chi-squared p<0.001). The number of  patients who discontinued exemestane because of  AEs during the 
follow-up period (starting as of  six months post-randomization) was 95 (6.4%). No difference was found in 
discontinuation rates between patients with and without HF. However, in the presence of  MSAE, significantly 
more patients discontinued exemestane therapy than when no MSAE were experienced (18.9% versus 11.4%, 
p=0.029). 
Adverse events and breast cancer recurrence
Characteristics of  patients who reported specific AEs versus none or nonspecific AEs are shown in Table 2. 
Younger patients and patients who had also been treated with chemo- and/or radiotherapy generally reported 
more specific AEs. 
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Using univariate Cox regression analyses, the presence of  HF versus no HF (with or without MSAE) was not 
significantly associated with a lower risk of  disease relapse (21 versus 144 events), although the hazard ratio 
(HR) was much reduced (HR 0.704 (95% confidence interval (CI) 0.441-1.123); p=0.141) (Table 3). However, 
after correcting for age at diagnosis, histological grade, T-stage, nodal stage, ER and PR status, type of  surgery, 
radiotherapy and chemotherapy in multivariate analyses, patients with HF showed a significantly lower risk of  
disease recurrence (HR 0.393 (95%CI 0.19-0.813); p=0.012) (Figure 1). 
The presence of  MSAE versus no MSAE (with or without HF) was not associated with a better RFS (15 versus 
150 events), using both univariate and multivariate Cox regression analyses (HR 0.727 (95%CI 0.427-1.236); 
Table 1. Baseline characteristics in patients treated with exemestane
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p=0.239 and HR 0.677 (95% CI 0.392-1.169); p=0.162 respectively). No significant correlation was found 
between RFS and the severity of  AEs.(Figure 1)
Patients who received chemotherapy reported HF and MSAE more frequently than patients not treated with 
chemotherapy: (HF, 20.2% versus 14.0%, p=0.002 and MSAE, 20.4% versus 7.6%, p<0.001) (Supplementary 
Table 1). Because earlier studies described a relationship between adjuvant chemotherapy and menopausal 
symptoms, we also tested for effect modification by chemotherapy, but this did not influence the relationship 
between specific AEs and survival (logrank p=0.688).
Table 2. Characteristics of  patients with and without specific adverse events
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Figure 1. Relation between adverse event and severity and relapse-free survival for hot flashes and musculoskeletal 
adverse events
MSAE, musculoskeletal adverse events 
 
When investigating the association between disease relapse and specific AEs (HF and/or MSAE) versus 
nonspecific (all other AEs) or no AEs, as reported within the first six months of  exemestane treatment, we 
found that patients reporting specific AEs had a lower risk of  disease relapse than patients who reported 
none or nonspecific AEs in the univariate analysis (Figure 2) (specific AEs: HR 0.608 (95%CI 0.404-0.914); 
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nonspecific AEs: HR 0.638 (95%CI 0.4-1.015); no AEs (ref); overall p=0.019). Even more so, multivariate 
analyses (correcting for the same variables as previously mentioned), also showed a significant correlation 
between specific AEs and better RFS (specific AEs: HR 0.559 (95%CI 0.368-0.849); nonspecific AEs: HR 
0.583 (95%CI 0.365-0.931); no AEs (ref); overall p=0.005).
Figure 2. Relapse-free survival for specific adverse events versus nonspecific or no adverse events
AEs, adverse events
We also investigated whether the trends were maintained when analyses were performed for OS and BCSM. 
There was a significant relationship between patients who reported specific AEs versus nonspecific or no AEs 
with respect to OS and BCSM.(Table 3) Assessed separately, however, neither HF nor MSAE was significantly 
associated with a better outcome for OS or BCSM. 
During the follow-up period of  the current analysis, 95 patients (6.4%) still discontinued exemestane treatment 
because of  AEs (both specific and nonspecific). Most patients who discontinued exemestane due to toxicities 
reported no or nonspecific AEs (n=64, 67.4%). When looking at the group discontinuing therapy due to 
specific AEs, results were similar for patients experiencing HF only (n=13, 13.7%), MSAE only (n=11, 11.6%) 
or both HF and MSAE (n=7, 7.4%). Prior chemotherapy (yes/no) did not influence the results (chi-squared 
p=0.267). 
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Quantitative hormone receptor expression using Allred scores
Although PR and ER Allred scores were predictive of  RFS based on earlier findings by Bartlett and 
colleagues20, no association was found in our analysis between PR and ER Allred scores and the occurrence of  
specific versus nonspecific or no AEs (Supplementary Table 2), or with the occurrence of  HF and/or MSAE 
separately (data not shown). Therefore, PR and ER Allred scores were not predictive of  better RFS.
Table 3.  Relation between adverse events and outcomes
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D I S C U S S I O N
This analysis in Belgian and Dutch patients participating in the TEAM trial and randomized to exemestane 
therapy investigated the relationship between the occurrence of  specific AEs related to the depletion of  
(circulating) estrogens and RFS. Only AEs reported while on-treatment and occurring within six months 
of  starting exemestane treatment were considered for the analyses, in order to ascertain that the AEs were 
attributed to the study medication. 
In the cohort of  exemestane treated patients, HF were strongly associated with improved RFS, while MSAE 
were not predictive of  better RFS. Currently, we did not find any evidence from previous clinical studies 
that estrogen levels were correlated with improved survival in patients treated with aromatase inhibitors. 
Nevertheless, variations in circulating estrogens may occur due to polymorphisms in the aromatase gene in 
postmenopausal women.10  
HF are a commonly reported toxicity of  aromatase inhibitors, and  are strongly related to the degree of  lowered 
estrogen levels occurring both naturally during menopause, and artificially in relation to chemotherapy and with 
aromatase inhibitors for breast cancer.13 MSAE include arthralgia, arthritis, arthrosis, myalgia, bone pain and 
joint disorders, and are also frequently prevalent in postmenopausal patients. The mechanism behind MSAE 
is relatively unknown, although several studies have also demonstrated an association with decreased estrogen 
levels.12, 22 Felson and colleagues reported that estrogen has antinociceptive effects and that the depletion of  
circulating estrogens influences the sensitivity to pain in articular structures.12 It is also suggested that lowered 
estrogen levels increase levels of  pro-inflammatory cytokines.23 The inflammation of  joints subsequently gives 
rise to increased levels of  prostaglandins and bradykinin, thereby activating receptors on peripheral nociceptors 
and enhancing their sensitivity to pain.12 We could not demonstrate an association between the presence of  
MSAE and treatment efficacy, although there is some evidence in support of  this hypothesis. 
MSAE and HF may both be associated with decreased estrogen levels, and may thus be valuable biomarkers 
for treatment efficacy. Our study’s finding that patients on exemestane therapy who reported specific AEs had a 
lower risk of  disease recurrence is supported by Cuzick et al. in a previous study. 14 In contrast, however, Cuzick 
et al. found an association between breast cancer recurrence and both vasomotor and joint symptoms, with the 
presence of  MSAE being more predictive of  RFS than HF, the latter not being in accordance with our data. 
Nevertheless, a trend showing a better RFS in our patients with MSAE was seen. Of  note, we assessed MSAE 
arising in the first 6 months of  treatment, and results might be different when MSAE occurring over the full 
duration of  the follow-up period were included. Cuzick et al. investigated patients who had been treated with 
either an aromatase inhibitor or tamoxifen; as we investigated a subgroup of  the patients randomized to 
exemestane in the TEAM trial, this may lead to some degree of  selection bias, although baseline characteristics 
and adverse events reported did not differ between the two randomized treatment groups (data not shown).  
The effect of  chemotherapy on the relationship between specific AEs and survival is difficult to assess due to 
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possible confounders such as age and disease stage. Our findings revealed that patients who have previously 
been treated with adjuvant chemotherapy reported more MSAE and HF than patients who did not undergo 
prior chemotherapy. It is well-known that chemotherapy is correlated with more menopausal symptoms24, and 
for this reason our analyses were adjusted for prior chemotherapy. With respect to MSAE, a relationship has 
also been found between plasma levels of  inflammatory cytokines and musculoskeletal symptoms in breast 
cancer patients undergoing paclitaxel chemotherapy in a previous study.25 However, this study only investigated 
short-term symptoms, while evidence is relatively lacking with respect to late-onset musculoskeletal symptoms 
in patients who received prior chemotherapy. Nevertheless, it is plausible to assume a relationship with the 
prolonged suppression of  circulating estrogens, and subsequent increases in nociception and circulating 
inflammatory cytokines.12, 23
All patients who were treated and event-free for at least six months were included in the analyses. The number 
of  patients who discontinued treatment during the follow-up period was similar for both HF and MSAE or 
both, and lower than previously reported. Noncompliance is known to be similar in patients treated with AIs, 
tamoxifen, or a sequence of  both, and can be as high as 50%.26  These high rates are largely attributable to the 
presence and severity of  adverse effects.26  As such, if  RFS is superior in patients who experience specific AEs, 
but who are also at greatest risk of  noncompliance, there is a clinically relevant paradox that those patients 
who may potentially derive most benefit from adjuvant endocrine treatment have a significant risk of  disease 
relapse because of  treatment discontinuation. The absence of  a relationship between MSAE on RFS may 
therefore be explained by the fact that patients experiencing MSAE discontinued treatment early, whereas this 
did not occur for patients with HF. When dealing with AEs, it is therefore important to ask patients specifically 
about their symptoms, as not all patients will report toxicities spontaneously, and may not link their complaints 
with the study medication. The absence of  checklists for complaints in the TEAM study may have led to some 
degree of  under-reporting of  AEs in this trial. Nonetheless, in clinical practice it is important to effectively 
inform and warn patients of  possible toxicities. In addition, treatment compliance should be actively promoted 
by all health care providers in order to optimize treatment. 
There was no correlation with the occurrence of  specific AEs in patients with PR- or ER-rich tumors in our 
analyses. It is suggested that in the presence of  any level of  ER, tumors expressing high levels of  PR increase 
the benefit of  endocrine treatment, and consequently patients may encounter more specific side effects.27 
However, we could not confirm these findings with the current data.
Patients using adjuvant AIs who experience specific AEs may have a better RFS than patients without these 
specific AEs. However, not all patients undergoing endocrine treatment for breast cancer experience specific 
AEs, and therefore, individual genetic factors may also play a role in the response to therapy and the emergence 
of  specific AE based on differences in drug metabolism. The most logical explanation would be that these 
specific AEs act as a surrogate marker for estrogen depletion and thus treatment efficacy. The aromatase 
enzyme is the most prominent candidate enzyme. It is encoded by the CYP19A1 gene and is involved in the 
R E L A T I O N S H I P  B E T W E E N  S P E C I F I C  A D V E R S E  E V E N T S  A N D  E F F I C A C Y  O F  E X E M E S T A N E  T H E R A P Y  I N 
P O S T M E N O P A U S A L  E A R L Y  B R E A S T  C A N C E R  P A T I E N T S
157
peripheral conversion of  androgens to estrogens.28 Several reports suggest that variations in CYP19A1 may 
influence AI treatment efficacy and also the incidence of  specific AEs in hormone-positive early breast cancer 
patients, although this requires further investigation.10, 22 
To conclude, although these results are hypothesis-generating, our findings suggest that the side effects caused 
specifically by the depletion of  estrogens predict a better outcome and may thus act as a valuable biomarker in 
AI treatment. Future studies on biomarkers predictive of  treatment outcome are eagerly warranted, eventually 
aiming at further personalization of  therapy.
 
Supplementary Figure 1. Adverse events occurring within 6 months in patients treated with Exemestane by age
 
C H A P T E R  1 0158
Supplementary Table 1. Relationship between prior chemotherapy and hot flashes and musculoskeletal adverse events
Supplementary Table 2. Adverse events according to PR and ER Allred score
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Introduction
Specific adverse events (AEs) associated with endocrine therapy and related to depletion or blocking of  
circulating estrogens may be related to treatment efficacy. We investigated the relationship between 
survival outcomes and specific AEs including vasomotor symptoms (VMS), musculoskeletal adverse events 
(MSAE) and vulvovaginal symptoms (VVS) in postmenopausal breast cancer patients participating in the 
international Tamoxifen Exemestane Adjuvant Multinational (TEAM) trial. 
Methods
Primary efficacy endpoints were disease-free survival (DFS), overall survival (OS) and distant metastases 
(DM). VMS, MSAE and VVS arising in the first year of  endocrine treatment were considered. Patients 
who did not start or who discontinued their allocated therapy and/or had an event (recurrence/death) 
within one year after randomization were excluded. Landmark analyses and time-dependent multivariate 
Cox proportional hazards models assessed survival differences up to five years from the start of  treatment. 
Results
9325 patients were included. Patients with specific AEs (versus nonspecific or no AEs) had better DFS and 
OS (multivariate hazard ratio (HR) (95% confidence interval (CI)) for DFS: VMS 0.731 (0.618-0.866); 
MSAE 0.826 (0.694-0.982); VVS 0.769 (0.585-1.01); multivariate HR (95%CI) for OS: VMS 0.583 
(0.424-0.803); MSAE 0.811 (0.654-1.005); VVS 0.570 (0.391-0.831)) and fewer DM (VMS 0.813 (0.664-
0.996); MSAE 0.749 (0.601-0.934); VVS 0.687 (0.436-1.085)) than patients not reporting these symptoms. 
Increasing numbers of  specific AEs were also associated with better survival outcomes. Outcomes were 
unrelated to treatment allocation.
Discussion
Certain specific AEs are associated with superior survival outcomes, and may therefore be useful in 
predicting treatment responses in breast cancer patients treated with endocrine therapy.
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I N T R O D U C T I O N
Since the 1980s, adjuvant endocrine therapy by means of  tamoxifen, a selective estrogen receptor modulator, 
has been a beneficial agent for breast cancer patients, being most effective in hormone-sensitive breast 
cancer.1, 2 Later, five years of  tamoxifen therapy became the gold standard for adjuvant endocrine treatment. 
Over the last 15 years, several studies have been performed to assess the value of  third-generation aromatase 
inhibitors, showing benefit in terms of  overall survival (OS), disease-free survival (DFS), distant disease-
free survival and contralateral breast cancer (CBC) recurrence in postmenopausal breast cancer patients 
with hormone receptor positive disease when compared with tamoxifen.3-5 Other studies showed beneficial 
effects of  a sequential treatment regimen consisting of  2-3 years of  tamoxifen followed by 2-3 years of  an 
aromatase inhibitor when compared with tamoxifen alone.3, 4, 6, 7 
Both tamoxifen and aromatase inhibitors are associated with inconvenient and sometimes debilitating 
adverse effects resembling menopausal symptoms, and which may be related to lower levels of  peripherally 
circulating estrogens or the blocking of  the estrogen receptor (ER) in particular tissues, depending on the type 
of  endocrine therapy used.8-11 Some relevant and commonly reported adverse events (AEs) associated with 
adjuvant endocrine therapy for early breast cancer comprise vasomotor symptoms (VMS), musculoskeletal 
and joint symptoms (MSAE), and vulvovaginal symptoms (VVS). After menopause, estrogen production 
is derived from peripheral tissues including adipose tissue, muscle, liver, skin, brain, bone marrow and 
breast tissue.12, 13 VMS are a well-known side effect of  estrogen deprivation, occurring both naturally 
during menopause and artificially in relation to chemotherapy and endocrine therapy administered in early 
breast cancer patients.11 Estrogen is considered a factor that affects temperature regulation by promoting 
vasodilation, which influences blood flow to the skin.14 Through decreased estrogen  levels associated with 
endocrine therapy, the body lacks the ability to maintain normal body temperatures.15 Estrogen deprivation 
has also been linked to the development of  MSAE in patients on endocrine therapy.9 Estrogen has 
antinociceptive effects that influence the body’s sensitivity to pain in articular structures as well as increased 
levels of  pro-inflammatory cytokines, which is thought to be associated with MSAE.9, 16 With respect to 
VVS, aromatase inhibitors (further) lower postmenopausal estrogen levels, causing vaginal atrophy, and 
possibly resulting in vaginal dryness and dyspareunia.17, 18 Tamoxifen, on the other hand, has known agonist 
effects on the uterus.19, 20 
Adverse effects during long-term treatment can significantly impact quality of  life as well as treatment 
compliance. Earlier studies on adjuvant breast cancer therapy recognized that non-compliance is largely 
attributable to the presence of  adverse effects.21-25 Furthermore, treatment outcomes can be compromised 
when adjuvant endocrine treatment is not taken for the full prescribed duration.26 
In earlier reports, the relationship between VMS as well as MSAE and breast cancer recurrence in patients 
treated with adjuvant endocrine therapy was investigated.27, 28 The presence of  both symptoms was 
predictive of  fewer breast cancer recurrences. Recently, we reported results of  Dutch and Belgian patients 
treated with exemestane alone, and found a significant relapse-free survival (RFS) benefit in patients who 
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reported VMS and MSAE.29 Similarly, a recent investigation by Huober and colleagues in the BIG 1-98 trial 
found associations between arthralgia, myalgia and vasomotor symptoms and improved DFS.30 Stearns and 
colleagues, however, also investigated the association between endocrine symptoms and RFS in the MA.27 
trial, but did not find a benefit in patients who reported VMS and/or MSAE.31 Another issue is that patients 
treated with either tamoxifen or aromatase inhibitors commonly complain of  VVS. Vaginal dryness was 
addressed in the study by Huober et al., which was considered a VVS. To the author’s knowledge, no other 
reports exist on the relationship between VVS and breast cancer recurrence.
In the present analysis, we investigated the relationship between specific AEs (VMS, MSAE and VVS) 
arising in the first year of  endocrine therapy and treatment efficacy in postmenopausal early breast cancer 
patients enrolled in the Tamoxifen Exemestane Adjuvant Multinational (TEAM) trial. In addition, the 
influence of  early treatment discontinuation within the five-year treatment period in relation to outcome in 
patients with and without specific AEs was assessed. 
M A T E R I A L S  A N D  M E T H O D S
TEAM trial
The TEAM trial is a randomized, phase 3, multinational, open label study conducted in postmenopausal 
women with ER and/or PR positive breast cancer and who were eligible for adjuvant endocrine treatment. 
Patients were randomized to receive either exemestane 25mg once-daily for five years or tamoxifen 20mg 
once-daily for 2.5-3 years, followed by exemestane 25mg once-daily for 2.5-2 years (sequential regimen).6 
Participants were enrolled in 599 hospitals in nine countries worldwide (Belgium, France, Germany, Greece, 
Japan, the Netherlands, UK and Ireland, and the USA.6 Similar trial protocols were used in all countries, 
with minor differences to accommodate the regional treatment guidelines; the TEAM trial protocols were 
approved by the regulatory and ethics authorities of  all participating centers in all participating countries.6 
All patients provided written informed consent, and additional consent was obtained from patients using 
tamoxifen for the switch to exemestane. The study was conducted in compliance with the guidelines of  
the Declaration of  Helsinki, International Conference on Harmonisation and Good Clinical Practice. 
Appropriate approvals from the ethical committee were obtained.6  Data collection was performed locally 
by case report forms and regularly transferred to a local data center, after which the Central Statistical and 
Data Center collected and analyzed the pooled data. Follow-up was carried out every three months in the 
first year, and twice yearly until year 5 (end of  randomized therapy), with yearly mammography. Details of  
eligibility criteria have been published in earlier reports.6 
In the TEAM trial, 9766 patients were allocated to five years of  exemestane or to a sequential treatment 
with tamoxifen followed by exemestane for a total of  five years in the TEAM trial. For the current analyses, 
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we excluded patients who did not start the randomized treatment, who discontinued their allocated therapy 
within the first year, or who had an event (recurrence or death) within the first year of  starting endocrine 
therapy. 
Adverse events
All AEs reported in the first year of  starting adjuvant endocrine therapy were included in the analyses. AEs 
were obtained from patient responses during follow-up visits, and a standard symptom checklist was not 
utilized. Severity of  AEs was assessed using the National Cancer Institute Common Toxicity Criteria, and 
were centrally recoded using the Medical Dictionary for Regulatory Activities (version 12.1).6  VMS were 
defined as a subjective and transient sensation of  heat, including hot flashes and night sweats. MSAE were 
all accounts of  arthralgia, arthritis, arthrosis, myalgia and bone pain. For the current analysis, osteoporosis 
was not considered a MSAE due to the fact that osteoporosis is a long-term process, likely to take more 
than 1 year to become evident. VVS included all accounts of  vaginal dryness/itching, vaginal discharge, 
dyspareunia, endometrial and libido disorders.
Endpoints
The efficacy endpoints of  the present investigation were DFS, OS, and distant metastases (DM), starting as 
of  the second year of  therapy. DM comprised all cases of  metastases of  the skeleton, skin, liver, lung, brain, 
and contralateral lymph nodes, and excluded locoregional recurrences (including ipsilateral breast cancer, 
ipsilateral lymph nodes, ipsilateral chest wall recurrences), CBC and new primary tumors. DFS was defined 
as the time on-treatment to the earliest documentation of  disease relapse or death (all-causes) or end of  
follow-up, whichever came first. OS was defined as the time on-treatment to the date of  death. 
The relationship between the occurrence of  specific AEs (VMS, MSAE and VVS) and survival and 
recurrence outcomes was assessed. Furthermore, we evaluated the relationship between outcome measures 
and the sum of  the different kinds of  specific AEs reported per patient.
Statistical analysis
Statistical analyses were performed using SPSS 17.0 (SPSS, Chicago, IL). It was possible to combine the 
patients in the two treatment groups, as the primary efficacy analysis found no differences in outcome 
between the two treatment arms.6  Landmark analyses were conducted, with follow-up starting at one year 
after randomization. Accounts of  specific AEs reported in the first year after randomization were used to 
classify patients into the yes/no cohorts for VMS, MSAE and VVS. Kaplan-Meier curves were plotted for 
time-to-event. Early treatment discontinuation is an important factor in patients who experience AEs of  
endocrine treatment, as shorter time on-treatment may negatively influence outcomes.26  Multivariate time-
dependent Cox Proportional Hazards Models with specific adverse event (yes/no), on-treatment (yes/no), 
and their interaction assessed differences in survival with respect to the presence or absence of  VMS, MSAE 
and VVS, in relation to time on-treatment. All multivariate analyses were adjusted for age at diagnosis, 
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country, histological grade, tumor size, nodal stage, most extensive surgery, radiotherapy and chemotherapy. 
Interaction terms between the AEs and all abovementioned adjusted variables were incorporated in the 
Cox model to test for the presence of  effect modification. 
R E S U L T S
Study population
In total, 9325 patients (95%) were included in the current analyses; reasons for exclusion are shown in 
Figure 1. We excluded patients who never started treatment or who had an unknown start date (n=93), and 
patients who discontinued their allocated therapy (n=174) or who had an event (recurrence or death) within 
the first year of  treatment (n=174). 4694 patients were allocated to receive 5 years of  exemestane and 4631 
patients were allocated to receive the sequential treatment regimen. Median follow-up was 5.13 years (range 
0.01 – 9.23 years), and median age was 63.8 years (range 34.9 – 96.1 years). Baseline characteristics were 
similar between the two treatment groups.6
Figure 1. Patients included in the analyses of  adverse events and breast cancer outcomes
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Table 1. Baseline characteristics for specific versus none or nonspecific adverse events
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Baseline characteristics of  the patients who reported specific AEs versus none or nonspecific AEs are 
shown in Table 1. Overall, there was no difference in the presence of  specific versus none or nonspecific 
AEs between randomized treatments. Assessed separately, patients allocated sequential treatment reported 
fewer VMS and MSAE, but more VVS (chi-squared p-value<0.001 for all comparisons). Younger patients 
were more likely to report specific AEs, while older patients were more likely to report nonspecific AEs 
(<60/60-<75/≥75 years: 16.3%/22.2%/31.5% nonspecific AEs reported respectively). In addition, 
patients who reported specific AEs more frequently had well-differentiated and low-grade tumors, node- 
negative disease, underwent breast-conserving surgery, and had adjuvant radiotherapy and chemotherapy 
when compared with patients who did not report specific AEs. Within the first year of  treatment, 3003 
patients (32.2%) reported VMS (with or without other specific or nonspecific adverse effects), 2635 patients 
reported MSAE (28.3%) and 1150 patients reported VVS (12.3%). 
Disease-free survival
DFS outcomes are depicted in Table 2 and Figure 2. Using both univariate and multivariate Cox 
regression analyses (adjusted for age at diagnosis, country, histological grade, tumor size, nodal stage, most 
extensive surgery, radiotherapy and chemotherapy), patients who reported VMS or MSAE had a better 
DFS than those who did not report these symptoms (multivariate hazard ratio (HR) for VMS: 0.731 ((95% 
confidence interval (CI) 0.618-0.866); MSAE: 0.826 (95%CI 0.694-0.982)). DFS was significantly better 
in patients who reported VVS after univariate analyses, and borderline significant following multivariate 
analyses (univariate HR 0.566 (95%CI 0.437-0.733); multivariate HR 0.769 (95%CI 0.585-1.01)). 
Overall survival
Figure 2 shows OS outcomes for VMS, MSAE and VVS respectively. Both univariate and multivariate 
Cox regression analyses showed that patients who reported VMS or VVS had better outcomes in terms of  
OS than those who did not report these symptoms (multivariate HR for VMS: 0.583 (95%CI 0.424-0.803); 
for VVS: 0.570 (95%CI 0.391-0.831)). There was a borderline significance for improved OS with respect 
to MSAE versus no MSAE after multivariate analyses (multivariate HR 0.811 (95%CI 0.654-1.005)).
(Table 2)
Distant metastases
Further investigations into the occurrence of  VMS and MSAE in relation to DM revealed that patients 
who reported these symptoms had fewer accounts of  DM than when these symptoms were not reported 
(for VMS, multivariate HR 0.813 (95%CI 0.664-0.996); MSAE 0.749 (95%CI 0.601-0.934)). VVS were 
associated with significantly fewer DM following univariate analyses, but not for multivariate analyses.
(Table 2) There was no effect modification for treatment discontinuation and the risk of  DM for VMS, 
MSAE and VVS.(Table 2)
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Figure 2. Outcomes for disease-free survival, overall survival and distant metastases in relation to specific adverse events
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Table 2. Survival outcomes and distant metastases for vasomotor symptoms, musculoskeletal adverse events and 
vulvovaginal symptoms
Early Treatment discontinuation
Time-dependent Cox regression analyses were performed to investigate the relationship between time on-
treatment and survival outcomes. Pertaining to VMS and MSAE, treatment discontinuation did not affect the 
improved DFS and OS in patients who reported these specific AEs. Therefore, even if  patients discontinued 
treatment before the pre-designated stop-date (which was five years after the start of  randomized therapy), 
a survival benefit persisted in those who reported specific AEs. This was also the case for DFS in relation to 
VVS, but not for OS (p for interaction=0.016).(Table 2)
Sum of  specific adverse events
A patient could have a maximum of  3 types of  specific AEs, which was the sum of  VMS, MSAE and VVS 
(yes/no outcome). Improved outcomes for DFS, OS and DM were found for increasing numbers of  specific 
AEs reported.(Table 3/Figure 3)
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Figure 3. Outcomes for disease-free survival, overall survival and distant metastases based on the number of  
specific adverse events reported
Table 3. Outcome based on the number of  specific adverse events reported
Adjuvant chemotherapy in relation to specific adverse events
Patients who received adjuvant chemotherapy more frequently reported specific AEs when compared with 
patients who had not been treated with adjuvant chemotherapy (56.3% versus 43.7%, p<0.001). There is a 
known relationship between adjuvant chemotherapy and menopausal symptoms, although the relation with 
late-onset symptoms has not been fully investigated.32 We tested for effect modification by chemotherapy for 
VMS and VVS and MSAE. No effect could be demonstrated (data not shown). 
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The present analyses showed that postmenopausal breast cancer patients who received at least one year 
of  adjuvant endocrine therapy and who reported one or more treatment-related AEs during the first year 
of  treatment had better subsequent outcomes in terms of  DFS and OS, and fewer DM than patients 
who do not report these symptoms. The strongest effect on distant recurrence and survival outcomes was 
observed for VMS. A decreasing incidence of  DM, disease relapse and death was noted in patients reporting 
increasing numbers of  different specific AEs. Furthermore, even if  patients who reported specific AEs were 
not on-treatment for the full duration, they still had better outcomes than patients who were on-treatment 
for longer, but did not experience specific AEs. No difference in effect was found between the two TEAM 
trial treatment arms. 
The present investigation only included patients who reported symptoms in the first year of  endocrine 
therapy. Due to the unplanned nature of  these analyses, pre-existing symptoms were not recorded. The 
effect observed may therefore be larger when the occurrence of  specific AEs over the entire follow-up 
period is considered. Reporting of  AEs may not be uniform across countries or study centers within 
countries, therefore it is conceivable that results may be influenced by reporting bias. The incidence of  
reported specific AEs varied considerably by country and survival outcomes were better in countries 
where more specific AEs were reported (Supplementary Table 1). These results must be interpreted with 
caution, as no information was available for individual study centers. All AEs were patient-reported AEs 
and no standardized symptom checklist was utilized. Cultural differences between countries may therefore 
also reflect differences in reporting of  AEs. A symptom checklist that actively inquires about a patient’s 
symptoms and severity thereof  will undoubtedly lead to a more accurate assessment and potentially observe 
a stronger relationship between specific AEs, severity, and improved outcomes. Also of  note, characteristics 
of  patients reporting specific versus no or nonspecific AEs revealed that patients with specific AEs were 
younger, more frequently had lower-grade tumors, node-negative disease, underwent breast-conserving 
surgery and adjuvant radiotherapy and chemotherapy. Although it is conceivable that older patients may 
be less likely than younger patients to report any AE at all, older patients reported more nonspecific AEs 
than younger patients in our cohort. Nonetheless, even after adjusting for these possible confounders, the 
correlation between specific AEs and superior outcomes was still present. 
Previously, a relationship was found between VMS and MSAE and disease recurrence in breast cancer 
patients participating in the ATAC trial27, and between hot flashes and outcomes in tamoxifen-treated 
patients in a study by Mortimer and colleagues.28 Our earlier manuscript regarding Dutch and Belgian 
exemestane users reports a relationship between MSAE and VMS and disease recurrence.29 In the current 
analyses, we aimed to assess whether results varied in a much more heterogeneous population. Minor 
variations in protocols between countries accommodated regional treatment guidelines. Additionally, in 
the context of  cultural differences between countries, variations in reporting may exist. Most importantly, 
however, we address time on-treatment in relation to the occurrence of  AEs. In contrast to what is generally 
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expected, Cuzick and colleagues noted a better treatment adherence in patients experiencing vasomotor 
and joint symptoms. Yet noncompliance resulting from side effects plays an important role in adjuvant 
endocrine therapy for postmenopausal, hormone receptor-positive breast cancer patients, and several 
studies have reported that patients who discontinue treatment before the pre-designated end-date do so 
largely because of  AEs21-25 Patients who discontinue the prescribed treatment regimen may not enjoy the 
full benefit of  treatment due to shorter time on-treatment.26 Pritchard sharply points out that the reporting 
of  AEs may depend on the kind of  patient who reports these symptoms; this may be related to treatment 
compliance, which would hence explain improved treatment outcomes in these patients.33 Similarly, patients 
who do not report specific AEs may not have taken the prescribed treatment. Therefore, we performed 
a time-dependent Cox regression analysis for time on- and off-treatment. The positive effect of  specific 
AEs on outcomes did not change for patients who went off-treatment. Accordingly, even if  patients who 
experience specific AEs discontinued treatment before the designated stop-date, they still had a survival 
benefit over patients who did not experience specific AEs. 
Although our results must be considered hypothesis generating, our findings show an association between 
specific side effects caused by endocrine therapy and outcomes, and may thus potentially be a valuable 
predictor and biomarker for treatment efficacy. Future prospective studies, however, are warranted in order 
to advance the personalization of  treatment strategies for breast cancer patients. 
 
Supplementary Table 1. Disease-free and overall survival outcomes for specific adverse events versus nonspecific 
adverse events by country
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Background
Musculoskeletal adverse events (MSAE) and vasomotor symptoms (VMS) are known side-effects of  
aromatase inhibitors (AIs), and may be related to genetic variations of  the aromatase gene (CYP19A1). We 
investigated the relationship between these specific AEs and single nucleotide polymorphisms (SNPs) in the 
CYP19A1 gene in postmenopausal, hormone receptor-positive early breast cancer patients treated with 
adjuvant exemestane for five years.
Methods
Dutch patients who were randomized to receive 5 years of  exemestane in the Tamoxifen Exemestane 
Adjuvant Multinational (TEAM) trial were included. A tagging SNP approach was performed, covering 
80% of  variations of  the CYP19A1 gene with 30 SNPs. Logistic regression analyses were used to assess the 
risk of  reporting VMS or MSAE in relation to genotypes within selected SNPs.  
Results
Of  737 included patients, 281 patients reported at least one MSAE (n=210) or VMS (n=163). Homozygous 
AA genotype of  rs934635 was associated with a significantly higher odds of  MSAE (multivariate odds 
ratio (OR) 4.66, p=0.008) and VMS (multivariate OR 2.78, p=0.044). Regarding both rs16964189 and 
rs7176005, the homozygous variant genotypes (TT) were associated with a higher odds of  VMS, but not 
MSAE (OR 1.758,  p=0.025 and OR 6.361, p=0.021 respectively). 
Discussion
Our exploratory analysis demonstrated that some CYP19A1 gene variations may be associated with MSAE 
and/or VMS. Specifically, patients with the homozygous variant rs934635 genotype reported more MSAE 
and VMS. Although further confirmatory studies are warranted, genomic profiling can help identify 
patients at an increased risk of  reporting these specific AEs, potentiating further personalized breast cancer 
treatment. 
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I N T R O D U C T I O N
Aromatase inhibitors (AIs) are well-integrated in the treatment of  post-menopausal patients with 
hormone-sensitive breast cancer, and have shown improvements in both mortality and recurrence rates 
in the adjuvant as well as the palliative setting.1 The mechanism of  action of  AIs consists of  the inhibition 
of  the aromatase enzyme, which plays a significant role in estrogen biosynthesis in postmenopausal 
women.2 The inhibition of  the aromatase enzyme causes a significant decline in estrogen levels in this 
setting, thus having its positive effect on breast cancer suppression in postmenopausal women.  
Joint pain and hot flashes have emerged as major side-effects in patients treated with AIs.3, 4 In the 
clinical setting 30-40% of  the patients report musculoskeletal adverse events (MSAE) and these AI-
associated adverse events (AEs) contribute to a decrease in patient function5 and compliance to therapy, 
affecting both quality of  life and drug effectiveness. The precise pathophysiological mechanism of  
AI-induced MSAE remains unclear. The marked estrogen deprivation in postmenopausal breast 
cancer patients is hypothesised to play an important role. This hypothesis has been strengthened by 
the fact that the time from menopause is associated with the incidence of  MSAE, with a shorter 
time since the last menstruation being predictive of  more MSAE.6 In addition, hot flashes and night 
sweats, collectively known as vasomotor symptoms (VMS), are common side effects associated with 
endocrine therapy, and have been related to the degree of  lowered estrogen levels occurring both 
naturally during menopause, and artificially in relation to chemotherapy and endocrine therapy for 
the treatment of  breast cancer.7 Recent studies8, 9 demonstrated that the occurrence of  MSAE and/
or VMS predicted for improved efficacy of  AI treatment, reinforcing the hypothesis that estrogen 
deprivation in postmenopausal patients may be one of  the major factors in the development of  specific 
AEs during AI treatment. 
Variation in the CYP19A1 gene coding for the aromatase enzyme is associated with altered estrogen 
levels in serum and urine10 and increased breast cancer risk according to several studies.11, 12 Furthermore 
it was demonstrated that polymorphisms in CYP19A1 cause a different in-vitro response to AIs and 
alter aromatase activity in postmenopausal women.13, 14 It is thus possible that polymorphisms in the 
CYP19A1 gene are associated with different responses to AIs in patients. This differential response may 
be influenced by the degree of  estrogen deprivation and may affect the efficacy of  AI treatment and the 
development of  AEs. 
The objective of  this study was to evaluate whether single nucleotide polymorphisms (SNPs) in the 
CYP19A1 gene were associated with AEs in postmenopausal early breast cancer patients treated with 
adjuvant exemestane. We performed a genetic analysis in patients enrolled in the TEAM (Tamoxifen 
Exemestane Adjuvant Multinational) trial in the Netherlands.
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Study design and patient population
Patients were selected from the cohort of  Dutch TEAM patients (n=2754) only. Patients who received five 
years of  exemestane (n=1379) and who had available tumor tissue were eligible (n=808). After genotyping, 
71 patients were excluded because of  genotyping failures (Figure 1). In total 737 Dutch patients who were 
treated with five years of  adjuvant exemestane were available for analysis. 
The TEAM trial is a randomized, phase III, multinational, open-label study conducted in postmenopausal 
women with estrogen receptor (ER-) and/or progesterone receptor (PR)-positive tumors who were eligible 
for adjuvant endocrine therapy. Patients were allocated to receive exemestane (25 mg once-daily for 5 years) 
or tamoxifen (20 mg once-daily for 2.5-3 years), followed by exemestane (25 mg once-daily for 2.5-2 years), 
for a total of  5 years.15 Study participants were enrolled in nine countries worldwide. Details of  eligibility 
criteria have been published in an earlier report.15 Data were collected locally and transferred to the central 
datacenter in Leiden, the Netherlands. Complete follow-up data were available for at least the first five years 
from the start of  treatment, with follow-up visits performed every 3 months in the first year. Medical history 
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Figure 1. Flow diagram of  patients included in the current study
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issues were classified according to the International Classification of  Diseases (ICD), version 10 (http://
apps.who.int/classifications/icd10/browse/2010/en). 
Outcome measurements
The objective of  the current study was to evaluate whether SNPs in the CYP19A1 gene were associated 
with AEs in patients treated with exemestane. The primary endpoint was the occurrence of  MSAE and 
VMS during the first year of  treatment in relation to CYP19A1 SNPs. All AEs were obtained from patient 
responses during follow-up visits, and a standard symptom checklist was not used. AE severity was assessed 
using the National Cancer Institute’s Common Terminology Criteria for Adverse Events (v3.0) and was 
centrally recoded using the Medical Dictionary for Regulatory Activities (version 12.1). MSAE included 
arthralgia, arthritis, and osteoarthritis, myalgia and other musculoskeletal problems. Osteoporosis was not 
considered a MSAE. VMS were defined as subjective and/or transient sensations of  heat, including night 
sweats.
Selection of  polymorphisms and genotyping procedures
Thirty polymorphisms in the CYP19A1 gene were selected using a tagging SNP approach, aiming for an 
80% coverage of  variation in the gene. CYP19A1 data was gathered from HapMap, with 200Kb distance 
from the start and end of  the gene. Pairwise tagging with a minimal distance between two SNPs of  50Kb 
was used to narrow the selection. This approach captured 211 SNPs with an R2 of  0.8 or higher. The 80% 
coverage consisted of  28 SNPs with a mean R2 of  0.962. Polymorphisms with a minor allele frequency 
below 5% were excluded. Two SNPs (rs7176005 and rs6493497) were included because of  a suggested 
association.14
DNA was isolated from paraffin embedded tissue samples with the Maxwell 2000 system (Promega Leiden, 
the Netherlands). Taqman assays were obtained from Life Technologies (Life Technologies, Nieuwerkerk 
aan den Ijssel, the Netherlands) for 26 polymorphisms. All those SNPs were initially determined by the 
LC480 system (Roche, Almere, the Netherlands) according to the manufacturer’s protocol. Taqman assays 
were unavailable for 4 SNPs, and a pyrosequence (Qiagen, Venlo, the Netherlands) assay was designed. Both 
platforms yielded comparable results. Since tumor tissue was used, a preamplification step was introduced. 
Details of  this procedure have been published elsewhere.16
Genotyping validity
Two assays were excluded because of  assay failure. Failed samples were repeated once on the same platform 
and were considered genotyping failures if  a re-run generated poor results for a second time. On the 
occasion of  more than 10 genotyping failures in an individual patient, this patient was excluded. The 
average success rate of  the other 28 assays and the individual samples was 98.4%. The lowest success rate of  
an individual assay was 92%. For quality control, 10% of  all DNA samples were genotyped in duplicate for 
all SNPs. No inconsistencies were observed. The allelic frequencies of  the 28 included SNPs with adequate 
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assays were tested for Hardy-Weinberg equilibrium (HWE). Six genotype assay results did not meet HWE. 
However, of  four of  these, frequencies were comparable with allelic frequencies as reported on the National 
Center for Biotechnology Information website (NCBI, http://www.ncbi.nlm.nih.gov) for the Caucasian 
population. Of  the two remaining SNPs, no frequencies were available from the NCBI Web site. The 
homozygote wild-type frequencies of  both SNPs were allowed for the analysis because of  a low number of  
homozygous patients and good quality controls. We assessed whether HWE deviation was caused by loss of  
heterozygosity (LOH).17 Almost all patients were heterozygous for at least one SNP in the CYP19A1 gene, 
therefore we rejected the possibility of  LOH. Furthermore, there is currently no available evidence that 
LOH is a relevant issue in the CYP19A1 gene. 
Since germline DNA was not available, tumor DNA was utilized, extracted from paraffin embedded tissue. 
Prior research has demonstrated the concordance between germline DNA and tumor DNA in multiple 
genes and numerous SNPs, although there is no direct evidence available with regard to the CYP19A1 
gene.18, 19 In addition, solid evidence of  an association between CYP19A1 polymorphisms and breast cancer 
risk is still lacking.
Statistical analysis
Statistical analyses were performed using SPSS 17.0 (SPSS, Chicago, IL). Chi-squared tests initially 
compared proportions of  VMS versus no VMS and proportions of  MSAE versus no MSAE for different 
genotypes. Univariate and multivariate logistic regression analyses assessed whether the occurrence of  
VMS and MSAE differed with respect to CYP19A1 genetic variants. The primary analysis was performed 
using a general model, after which the most appropriate model was fitted (general, dominant or recessive). 
With respect to both MSAE and VMS, our multivariate logistic regression analyses were adjusted for age, 
body-mass index (BMI), and adjuvant chemotherapy. Data on patient ethnicity was not taken up in the 
trial protocol and was therefore not included in the multivariate analyses. Any musculoskeletal and/or 
vasomotor symptoms that were reported to have occurred before the start of  treatment were excluded from 
the analyses. The explained variance was tested for using the Nagelkerke R2 test. Due to the exploratory 
nature of  these analyses, which comprises testing multiple hypotheses of  which a selection will require 
further investigation, we did not correct for multiple testing.20
RESULTS
Successful DNA extraction from tumor samples was achieved in 737 patients, who were subsequently 
included in the analyses. Table 1 provides an overview of  the baseline characteristics of  these 737 patients. 
Median age was 64 years (range 45-91 years) and median BMI (kg/m2) was 26.6 (range 16.9-47.8) There 
were no statistically significant differences in patient, tumor, or treatment characteristics between included 
and excluded patients (Supplementary Table 1). There was a borderline proportional difference with respect 
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to prior chemotherapy being administered in 27.1% and 32% respectively (chi-squared p=0.05). Only one 
patient who received adjuvant chemotherapy and reported MSAE and VMS was treated with taxanes.
Table 1. Baseline characteristics of  patients included in the analyses
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Musculoskeletal adverse events
MSAE were reported by 210 patients during the first year of  exemestane treatment (Table 1). 98 patients 
(47.6%) reported mild symptoms, while 108 patients (52.4%) reported moderate/severe MSAE. The 
genotype of  one SNP (rs934635) consisting of  a G>A polymorphism, was associated with MSAE (Table 
2), although genotype was not associated with AE severity (chi-squared p=0.15). Figure 2 shows that 
homozygous AA patients reported more MSAE compared to wild-type GG and GA, with an odds ratio 
(OR) of  4.62 (95% confidence interval (CI) 1.79-12.0) following univariate analysis (p=0.007). Multivariate 
analyses were adjusted for age, BMI and adjuvant chemotherapy and revealed an OR of  5.08 (95%CI 1.8-
14.3) (p=0.007). No association was found with regard to the other SNPs (Supplementary Table 2).
Figure 2. Percentage of  specific adverse events according to genotype
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Supplement for Figure 2
Vasomotor symptoms
163 out of  737 patients experienced VMS during the first year of  exemestane treatment, of  which the 
majority (69.1%, n=112) were mild and 30.9% were moderate/severe (n=50). Associations with VMS were 
found for three SNPs, namely rs934635, rs7176005, and rs16964189 and are depicted in Figure 2. With 
respect to rs934635, the homozygous AA genotype was found to be associated with VMS, revealing an OR 
of  2.86 (95%CI 1.12-7.27) following univariate analysis (p=0.044) and an OR of  2.78 (95%CI 1.02-7.56) 
after multivariate analysis (p=0.044), which were also adjusted for age, BMI and adjuvant chemotherapy. 
There was no correlation between genotype and AE grade (data not shown). In addition, both univariate 
and multivariate analyses showed a statistically significant association with rs7176005 (Table 2). Patients 
with a homozygous TT genotype reported more VMS than patients with at least one C allele (univariate 
OR 6.36 (95%CI 1.5-27.0) (p=0.021) and multivariate OR 4.9 (95%CI 1.02-23.5) (p=0.06)). 
Lastly, the rs16964189 SNP was associated with the occurrence of  VMS for the homozygous TT genotype 
(univariate OR 1.76 (95%CI 0.79-3.92) (p=0.025) and multivariate OR 1.86 (95%CI 0.76-4.59) (p=0.06)). 
No other SNPs demonstrated an association with VMS (Supplementary Table 2).
Explained variance
The explained variances (R2) for rs934635, rs16964189 and rs7176005 were 0.074, 0.054 and 0.057 
respectively for MSAE and VMS combined. Assessed separately, the respective R2 values were 0.077, 
0.060, and 0.057 for MSAE and 0.043, 0.043 and 0.044 for VMS. Sensitivity analyses revealed increased 
R2 values with the addition of  more covariates in the regression model (data not shown). 
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Table 2. Single nucleotide polymorphisms of  the aromatase (CYP19A1) gene associated with musculoskeletal 
adverse events and vasomotor symptoms
 
D I S C U S S I O N
Our analyses suggest an association between three CYP19A1 SNPs, namely  rs7176005 (TT genotype), 
rs934635 (AA genotype), and rs16964189 (TT genotype), and the increased incidence of  MSAE and/
or VMS in the first year of  adjuvant exemestane treatment in postmenopausal hormone receptor-positive 
breast cancer patients. MSAE and VMS associated with endocrine treatment can influence patient function 
and compliance to AI therapy and can significantly affect quality of  life. Simultaneously, these specific 
AEs have been related to lowered levels of  circulating estrogens.7, 21 Although our findings are limited by 
the unavailability of  estrogen levels in our cohort, clinical data have shown associations between MSAE 
and VMS and breast cancer outcome, also in the TEAM trial.8, 9 Differential responses to AIs and the 
incidence of  these specific AEs may result from genetic variations in the genes encoding the drug target or 
drug-metabolizing enzymes. With respect to treatment with AIs, the aromatase gene comprises a multitude 
of  SNPs, some of  which may be relevant for predicting treatment response and/or variations in drug 
metabolism leading to the presence or absence of  treatment toxicities. 
It is widely accepted that higher estrogen levels in postmenopausal women are associated with augmented 
breast cancer risk, and are related to increased transcription of  aromatase.22, 23 An earlier study showed 
that two SNPs of  the CYP19A1 gene, rs6493497 and rs7176005, were associated with increased plasma 
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estrogen levels, which plays an important role in promoting the growth of  estrogen-sensitive breast cancer.14, 
24 Another study investigated sex hormone levels in relation to genetic polymorphisms of  the aromatase 
gene, finding lower estrone concentrations in women with multiple SNPs.25 Finally, Wang et al. showed 
that variations in CYP19A1, including rs6493497 and rs7176005 caused changes in the transcription of  
aromatase in tumor tissue, causing a greater decrease in aromatase activity in AI-treated patients.14 To add, 
rs7176005, was associated with higher estradiol levels in patients both before and after AI treatment.14
As mentioned previously, both MSAE and VMS have been linked to lower levels of  circulating estrogens in 
AI users. Ingle and colleagues demonstrated the existence of  a strong correlation between four SNPs in the 
TCLA1 gene and MSAE in a genome wide association study26, and associations have also been found in 
relation to osteoporosis.27, 28 Although these SNPs are different from those in our analyses, the relationship 
that was found between CYP19A1 SNPs and MSAE (and osteoporosis) suggest that genetic variations may 
have an effect on circulating estrogens in AI users. No reports exist on genetic variations in relation to VMS 
specifically, although reports have verified variations in circulating sex hormone levels in relation to SNPs 
of  CYP19A1.10, 13, 25 Straume et al. suggested that the variant allele of  the rs7176005 was associated with 
enhanced CYP19 transcription in breast cancer patients, possibly resulting in higher plasma and tissue 
estrogen levels.24 The effect of  treatment with AIs on triggering AEs may, in this case, be influenced by 
baseline estrogen levels. 
Both AEs and clinical outcomes have been linked to a number of  SNPs previously 14, 26-31, with several SNPs 
showing endocrine treatment benefit in both the adjuvant and neoadjuvant settings.31, 32 Results with respect 
to the SNP rs7176005, however, are still somewhat inconclusive. Analyses by Ghimenti et al.33 failed to show 
an association with response to neoadjuvant anastrozole treatment.
A major advantage of  the tagging-SNP approach is that it allows for a systematic investigation of  associated 
SNPs, providing almost complete coverage of  the entire CYP19A1 gene. Although tumor material may 
not truly represent a patient’s germline genetic profile, the CYP19A1 gene is reported to be quite stable 
and identical to that in the patient’s non-breast cancer tissue.14 Furthermore, the large number of  patients 
used in this study (737 patients) strengthens the assertion that specific SNPs could be associated with more 
MSAE or VMS following treatment with exemestane. To our knowledge, this is currently the largest study 
to date investigating the association between SNPs in CYP19A1 and treatment toxicities. Although many 
patients did not have tumor material available for assessment (n=808), characteristics of  subjects with 
available tumor material (n=737) did not differ from excluded patients (Supplementary Table 1). Despite 
the substantial size of  our cohort, the number of  patients with homozygous variants for specific SNPs was 
low and limited the ability to draw definite conclusions about the results and the implication for clinical 
practice. Consequently, further validation of  these SNPs is eagerly awaited.
Our study did not reveal an association between AE severity and genotype. All AEs were obtained from 
spontaneous patient reports and specific responses during follow-up visits. No standard symptom checklist 
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was utilized, which could imply relative under-reporting of  AEs in this study. It is therefore conceivable that 
our findings may be influenced by reporting bias and the effect observed may be stronger if  inquiry into 
specific MSAE- and VMS-severity was standardized. Previously, we also found that patients who reported 
MSAE and VMS had better outcomes following endocrine treatment than patients who did not report 
these symptoms.9 Although speculative, drug metabolism might vary between patients, indicating a possible 
dose-response relationship with regard to endocrine treatment. As patients who develop AEs also risk early 
treatment discontinuation, dose reduction to minimize AEs while maintaining treatment benefit may be 
an acceptable approach to optimising treatment in these patients. Likewise, patients who receive adjuvant 
endocrine therapy, but do not develop toxicities may require a higher dosage to maximize their benefit. 
Despite the large number of  patients in our study, the low number of  homozygous variants limits our 
interpretations. Nevertheless, patients with a heterozygous genotype for rs934635 also showed an increased 
odds of  reporting specific MSAE and VMS, albeit less striking. The clinical benefit of  identifying these 
patients susceptible to AEs following AI treatment is especially important given the influence of  treatment 
compliance on breast cancer outcomes. Consequently, these personalized approaches can enable clinicians 
to find the optimal treatment for their patients that balances toxicities, compliance and effectiveness of  
endocrine therapy. 
These hypothesis-generating results provide the prospect of  using variations in the CYP19A1 gene to 
facilitate decision-making for a particular adjuvant endocrine therapy in postmenopausal breast cancer 
patients. Future studies on SNPs associated with variations in responses to endocrine treatment are eagerly 
awaited and will have to be performed in large cohorts of  patients. It is hopeful that this will  lead to 
better ways of  predicting optimal treatment strategies in postmenopausal breast cancer patients who are 
candidates for adjuvant endocrine therapy. 
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Supplementary Table 1. Characteristics of  included and excluded exemestane-treated patients
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Supplementary Table 2. Specific adverse events in relation to single nucleotide polymorphisms of  the aromatase 
(CYP19A1) gene   
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A B S T R A C T
In recent years, studies investigating neoadjuvant therapies have been emerging, because of  the additional 
benefits it provides in terms of  facilitating less extensive surgery and the possibility of  investigating tumor 
biological features and response. Neoadjuvant hormonal therapy (NHT) is, in general, considered to be 
a suitable option for hormone receptor-positive patients who are unfit for chemotherapy or surgery, and 
is increasingly being utilized to achieve tumor downsizing before surgery in postmenopausal women. 
Studies investigating NHT were reviewed for tumor response data. NHT demonstrated similar efficacy to 
neoadjuvant chemotherapy (NCT) in hormone receptor-positive breast cancer patients. Clinical responses 
ranged from 13.5-100%, with treatment periods between 3-24 months. In studies comparing tamoxifen 
with aromatase inhibitors, the latter were superior in terms of  tumor response and rates of  breast-
conserving surgery (BCS). In most studies with treatment durations longer than 3 months, tumor response 
rates increased. Therefore, longer durations of  NHT are feasible and should be considered as an alternative 
to NCT in selected patients. 
N E O A D J U V A N T  H O R M O N A L  T H E R A P Y  F O R  E N D O C R I N E  S E N S I T I V E  B R E A S T  C A N C E R : 
A  S Y S T E M A T I C  R E V I E W
199
I N T R O D U C T I O N
Targeted treatment for breast cancer was described as early as 1895, when Beatson performed an 
oophorectomy on a woman with extensive breast cancer, inspired by techniques for promoting lactation 
in cattle.1 Today, breast cancer treatment has adopted a multifactorial approach, combining surgery, 
systemic therapy and radiotherapy as main treatment modalities. Early studies investigated neoadjuvant 
chemotherapy (NCT) in women with large, operable breast cancer, revealing tumor shrinkage that 
facilitated more breast-conserving surgery (BCS), while survival rates were unaffected when compared 
with postoperative chemotherapy.2 More recently, neoadjuvant hormonal therapy (NHT) trials have been 
emerging and its clinical application is gaining recognition. During the 13th St. Gallen International Breast 
Cancer Conference, 94% of  breast cancer experts’ consensus panel voted for the use of  NHT in patients 
with hormone receptor-positive breast cancer.3 A great advantage of  preoperative systemic therapy is the 
prospect of  downsizing and downstaging large tumors, facilitating the possibility of  rendering inoperable 
tumors operable and achieving more BCS. Moreover, neoadjuvant studies can efficiently provide insight 
into the effects of  drugs on biochemical, molecular and histological tumor features, on the basis of  which 
surrogate prognostic biomarkers can be identified. Moreover, research questions can be answered sooner 
and in fewer patients. In recent years, several targeted systemic treatments have been developed, using 
molecular and biological tumor characteristics to further guide treatment decisions.4 For example, adjuvant 
chemotherapy is less effective in hormone receptor-positive than hormone receptor-negative tumors.5, 6 
It is therefore plausible to assume similar efficacy profiles in the neoadjuvant setting. Here, we provide a 
systematic review of  studies reporting response to NHT.
M A T E R I A L S  A N D  M E T H O D S
Search method
Studies were identified through systematic review of  the available literature in the PubMed database up 
to February 13th, 2013. PubMed was searched using a set of  search terms which described breast cancer 
and neoadjuvant hormonal therapy with different agents. The specific search strategy used is outlined in 
Appendix 1 and was conducted with the help of  the institution’s information specialist (J.S.). Additional 
articles were included after searches through reference lists of  selected articles. 
Selection criteria
Two independent reviewers (D.F. and A.C.) selected studies for inclusion in the systematic review. Only 
reports written in English were eligible. Articles included original studies in which NHT was investigated 
in relation to tumor response. Studies were included if  the primary or secondary outcome was related to 
our research questions. In the case of  an update of  previously published data or multiple reports of  a single 
study, only the most recent publication was selected. In the case of  disagreement, the independent reviewers 
discussed the study and, where necessary, the decision was made by a third independent reviewer (J.M). 
Only studies including patients with nonmetastatic breast cancer were included.
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Data extraction
Data extraction was performed by two independent reviewers (D.F. and A.C.). Relevant data was 
determined prior to reading of  the selected articles. For all studies, we documented the type of  study, year 
of  publication, patient and treatment characteristics, primary and (where possible) secondary endpoints, 
treatment duration, tumor response evaluation method(s), and study results. Data from each study was 
documented and independently reviewed and verified by the two independent reviewers. 
R E S U L T S
Study selection
A total of  228 unique articles were identified in the original database search. 153 studies were excluded based 
on our predefined inclusion criteria after reading the abstracts. 46 articles were fully read and evaluated for 
reporting of  clinical and/or pathological response data. Three additional manuscripts were included after 
a manual search through the reference lists of  the selected studies. 26 studies were deemed eligible for our 
systematic review. The study selection process is summarized in Figure 1. 
Selected studies included 13 single-armed studies,7-19 4 studies investigating an aromatase inhibitor (AI) 
versus tamoxifen,20-23 5 studies comparing different AI regimens 24-28 and 4 studies that compared NHT with 
NCT.29-32 
Figure 1. Selection of  studies included in this review
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Overall responses
26 studies were included in our analyses (Table 1). 23 studies investigated clinical response based on calliper 
measurement or palpation.7, 9-14, 16, 18-32 Clinical responses ranged from 13.5% to 100% for endocrine therapy, 
with treatment durations between 3 and 24 months. Radiological responses, as measured with ultrasound or 
mammography ranged from 20% to 91.7% and 16% to 85.4% respectively. Table 1 provides an overview 
of  the clinical responses based on measurement modality. The lowest clinical response rate was found in a 
study that included both hormone receptor-positive and hormone receptor-negative patients.18
Chemotherapy versus hormonal therapy
Four studies compared NHT with NCT.31-34 Overall clinical response rates for the NHT arm ranged from 
48%-89% and from 64% to 85% for the NCT arm. Three studies included hormone receptor-positive 
patients only.29-31 Results from the large comparative study by Semiglazov et al. (n=239) showed that NHT 
is at least as effective as NCT with regard to response rate.31 Furthermore, BCS was performed slightly more 
often in the NHT arm (33% vs. 24%, p=0.058). Likewise, Alba et al. did not find a significant difference in 
clinical response following NHT when compared with NCT in a retrospective analysis of  95 luminal breast 
cancer patients (p=0.075).29
Tamoxifen versus aromatase inhibitors
In four phase III trials, differences in neoadjuvant treatment outcomes between AIs and tamoxifen were 
studied.20-23 Clinical response rates ranged from 38% to 70% for AIs and from 36% to 51% for tamoxifen. In 
two studies,21, 22 AIs were as least as effective as tamoxifen, and in two other studies,20-23 AI treatment resulted 
in a significantly better clinical response. The first published phase III trial comparing an AI to tamoxifen 
was a study by Eiermann and colleagues.21 This double-blind double-dummy, randomized, multicenter study 
compared four months of  letrozole with tamoxifen in women with hormone receptor-positive tumors who were 
ineligible for BCS. Letrozole was found to be more effective than tamoxifen in terms of  clinical and radiologic 
(ultrasound and mammography) response rates, and in relation to BCS. The advantage of  letrozole was higher 
in estrogen receptor (ER)-positive and HER2-positive breast tumors. Although most studies focused on AI 
treatment for postmenopausal women, Masuda et al.22 conducted a neoadjuvant study with premenopausal 
patients, all treated with ovarian suppression with goserelin, and who were randomized to treatment with 
either anastrozole or tamoxifen. Clinical response was observed more frequently with anastrozole than with 
tamoxifen (70.4% vs. 50.5%, p=0.004). Similarly, ultrasound and MRI response was significantly better in 
the anastrozole group. In all four studies, AIs rendered tumors more suitable for BCS. Higher BCS rates were 
observed in favour of  AIs in two studies, although only significant in the study by Eiermann et al.21, 22
Only one study was prospectively planned to investigate differences between four months of  neoadjuvant 
treatment with exemestane, anastrozole or letrozole in the ACOSOG Z1031 trial.24 Although letrozole 
exhibited the highest response rate (74.8%), this was not significantly different from that of  exemestane 
or anastrozole (62.9% and 69.1% respectively). Also, BCS rates were not significantly different for the 
letrozole, exemestane, and anastrozole arms (60.8%, 67.8%, and 77% respectively; 52%, 50% and 57.7% 
were lumpectomy candidates before neoadjuvant therapy).
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Duration
In most studies investigating NHT, patients were treated for 3 to 4 months prior to surgery. We identified eight 
studies that reported responses following treatment periods longer than 3-4 months.(Table 2)  In one study by 
Dixon et al.12 postmenopausal patients (median age 78) with operable or locally advanced ER-positive breast 
cancer received neoadjuvant letrozole for 3 months or longer. Treatment was continued after three months in 63 
of  the 182 patients for reasons including insufficient response for operability (n=15) or BCS (n=26), patients were 
unfit or unsuitable for surgery (n=13) or refused surgery (n=9).12 A continued clinical reduction in volume was 
observed hereafter. The overall response rate increased from 69.8% at three months to 83.5% after prolonged 
treatment in 63 patients. Importantly, the overall BCS rate improved from 60% to 72%. Several other studies 
also attempted to identify the optimal duration of  NHT.7, 11 In the phase II trial by Llombart-Cussac et al., the 
median time to objective response was 3.9 months and the median time to maximum response (i.e. time until 
the lesion had reached stabilization at evaluation) was 4.2 months. A third of  the responders reached maximum 
reduction in tumor volume after 6 months, although few responders were reported hereafter. In another study, 
patients were treated with neoadjuvant letrozole for up to 8 months.11  While only 50% of  patients were initially 
considered to be eligible, BCS was performed in 68% of  the patients after 4 months of  neoadjuvant letrozole. 
Hormone receptor status and histological subtype
All but three studies included hormone receptor-positive patients only. In these three studies17, 18, 32, clinical 
response rates were as low as 34.5% and 13.5% for early-stage and late-stage breast cancer respectively. No 
reports existed on quantitative hormone receptor-expression in patients treated with NHT. 
Eight studies reported the inclusion of  both ductal and lobular breast cancer patients.8, 10, 11, 14, 16, 26, 30, 35 None 
of  these studies discriminated between lobular and ductal subtypes of  breast cancer in their analysis of  
response. Only one single-armed study by Dixon reported on NHT in patients with lobular breast cancer 
exclusively and found response rates of  almost 92% after more than three months of  treatment. The mean 
reduction in tumor volume at 3 months was 66%.9
D I S C U S S I O N
NHT is gaining popularity and is becoming standard of  care in hormone receptor-positive breast cancer 
patients with large inoperable tumors, and in patients deemed unfit for NCT. With the prospect of  an 
additional modality for downsizing large tumors as well as providing an early measurement tool for 
evaluating response to endocrine therapy, NHT is increasingly becoming an integral part of  preoperative 
breast cancer management. Here we present a systematic overview of  the available studies involving NHT 
to date. Compared to NCT, our evidence suggests that NHT has comparable response rates. AIs have 
demonstrated superior results when compared with tamoxifen in postmenopausal patients. In a majority 
of  studies, NHT duration was between 3 and 4 months. Where data on longer treatment duration were 
available, continuing NHT beyond 3-4 months demonstrated additional clinical responses and further 
reductions in tumor size.
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One of  the main benefits of  neoadjuvant systemic treatment is the higher chance that BCS is feasible in 
patients initially opting for mastectomy. In most studies investigating NHT, patients were treated for 3 to 4 
months prior to surgery. One of  the first investigators to study longer durations of  NHT was Dixon et al., 
who treated elderly patients for up to 24 months.12 Extending treatment beyond the predefined end-date 
revealed further reductions in tumor size in several studies, and in one study, response rates reached 100% 
when extending treatment indefinitely.27 The 13th St. Gallen Breast Cancer Expert Panel recently (March 
2013) voted in favor of  a preferred maximal response duration beyond 4 to 8 months (62%).3 With ever 
increasing data suggesting that longer treatment durations are suitable7, 8, 12, 17, there is a growing interest 
in using NHT in (older) breast cancer patients deemed unfit for NCT or surgical intervention. Prolonged 
NHT could therefore be a valid alternative, and an earlier meta-analysis showed no differences in overall 
survival in elderly breast cancer patients treated with NHT alone versus surgery.35 An additional advantage 
is the relatively mild toxicity profile of  NHT when compared with NCT.29, 31 Semiglazov and colleagues 
found more adverse events in NCT-treated patients than in NHT-treated patients.31 In contrast to NCT-
treated patients, no serious adverse events were reported by patients undergoing NHT. Therefore, NHT 
could be a safe alternative to NCT for certain patients for whom a low toxicity profile is preferred, especially 
in the elderly hormone receptor-positive breast cancer population. Although several studies are integrating 
NHT into their study design, available data on trials addressing the question of  whether NCT is superior to 
NHT before surgery in hormone receptor-positive breast cancer patients is limited to a single trial (NEST 
trial, NCT01622361), whose completion is expected in 2016.36 Trials with combined NHT and targeted 
therapy are also expected soon. Our study group recently completed a phase II trial with 6 months of  
neoadjuvant exemestane, in postmenopausal hormone receptor-positive breast cancer patients (TEAM IIA 
trial, ISRCTN17633610). Results of  this trial will be available shortly. Considering the limited evidence 
comparing NCT to NHT, further trials are warranted, especially focusing on the question of  neoadjuvant 
treatment duration for NHT and NCT. A comparative study of  6 months NHT versus standard durations 
of  NCT could be feasible, keeping in mind that the objective is to downsize tumors for surgery.
In the adjuvant setting, studies have shown that hormonal therapy is more effective than chemotherapy when 
treating hormone-receptor positive breast cancer.37, 38 Previously, an association was demonstrated between 
higher levels of  ER expression and efficacy of  endocrine therapy.39 Petit and colleagues demonstrated 
an inverse relation between ER expression and pathological complete response following neoadjuvant 
chemotherapy in hormone receptor-positive breast cancer patients.37 In the current investigation, all but 
three studies included hormone receptor-positive patients only. In the two single-arm studies, relatively lower 
response rates were observed when compared with the other single-arm studies.17, 18 Ciatto et al. observed a 
strong association between response and ER content. While 100% had progressive disease in patients with 
no tumor immunostaining, only 6% of  tumors with >60% immunostaining progressed.17 These findings 
suggest that NHT could be a valuable substitute to NCT in ER-rich breast cancer patients. Furthermore, 
in clinical-decision making, the percentage of  ER-immunostaining might be a more predictive number 
for treatment efficacy than a dichotomous ER-status based on a cut-off  value of  1 or 10%. The majority 
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of  studies have not reported on the effects of  NHT on different tumor subtypes, such as invasive lobular 
carcinoma. Consequently, the effect of  NHT in patients with hormone receptor-positive breast cancer may 
reveal an even greater benefit in specific subgroups. Invasive lobular breast carcinomas, in particular, may 
be best off  when treated with NHT rather than NCT, due to the fact that they commonly present with large, 
ER-rich tumors relatively insensitive to NCT.9, 39-41 
A superior efficacy for AIs over tamoxifen was found in a majority of  the comparative studies.20-23 Previously, 
it has been suggested that tamoxifen resistance in ErbB1- and ErbB2-positive tumors may play an important 
role in hormone-receptor positive patients.42 Therefore, in postmenopausal hormone receptor-positive 
patients, we recommend NHT treatment with an AI rather than tamoxifen.
Because of  the heterogeneity of  the data collected and the use of  varying classifications of  tumor response 
(e.g. WHO and UICCC criteria)43, 44, it was not possible to perform a pooled meta-analysis of  the reported 
response rates. Hence, we have provided a comprehensive overview of  the studies investigating response to 
NHT. In addition, it is difficult to draw conclusions for BCS rates, as baseline assessments of  BCS versus 
mastectomy candidates differed between studies.
An additional feature of  neoadjuvant therapy is facilitating investigations of  possible predictive biomarkers. 
It has been suggested that measurements of  the proliferation marker Ki-67 can be used to tailor neoadjuvant 
treatment shortly after starting treatment.45 Dowsett et al. found that in patients treated with letrozole, the 
change in Ki-67 level after two weeks of  treatment was of  prognostic value for relapse-free survival (RFS), 
rather than baseline Ki-67 levels.46 Ellis et al. concluded that a single tumor Ki-67 assessment 2 to 4 weeks after 
initiating AI treatment can identify ER-positive breast cancer patients with poor outcomes.47 Furthermore, 
since the neoadjuvant setting provides a convenient model for examining tumor biology, post-neoadjuvant 
data may be used in preparation of  further adjuvant studies or to predict outcomes in the adjuvant setting.48 
For example, post-treatment Ki67 can be of  prognostic value, as shown by Ellis et al., who developed a 
preoperative endocrine prognostic index (PEPI) score for the prediction of  RFS. The PEPI score incorporates 
post-treatment pathological tumor size, pathological node status, ER status and Ki6749 Results from biomarker 
studies like these will help pave the way to a more personalized approach using neoadjuvant therapy. 
NHT rivals NCT in its potential for downsizing primary tumors and rendering them operable, as well as 
increasing conversion rates from mastectomy to BCS in postmenopausal, hormone receptor-positive breast 
cancer patients. Moreover, the favourable toxicity profile of  NHT makes it a very suitable treatment option for 
patients unfit for chemotherapy. Studies have shown that AIs, rather than tamoxifen, are the preferred agents 
for NHT in postmenopausal patients. Longer treatment durations demonstrated greater clinical responses 
and BCS rates with acceptable tolerability, and our findings are largely supported by the St. Gallen Breast 
Cancer Expert Panel 2013.3 Treatment with AIs can still be optimised by selecting the most potent agent and 
by defining optimal treatment durations. Furthermore, in our endeavour for more personalized approaches to 
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breast cancer management, investigations into subgroups of  patients most likely to attain a beneficial clinical 
response to NHT are needed. Results from future neoadjuvant trials in which these subgroups are studied will 
unquestionably contribute to further establishment of  optimized treatment regimens in individual patients.
 
Appendix 1. PubMed search algorithm for relevant studies
PubMed was searched using a set of  search terms which described breast cancer and neoadjuvant hormonal 
therapy according to the following algorithm:
 
(“neoadjuvant hormonal therapy” OR “preoperative hormonal therapy” OR “neoadjuvant endocrine 
therapy” OR “preoperative endocrine therapy” OR “primary endocrine therapy” OR “primary hormonal 
therapy” OR “primary hormone therapy” OR ((“Antineoplastic Agents, Hormonal”[Pharmacological 
Action] OR “Aromatase Inhibitors”[Pharmacological Action] OR “anastrozole”(Supplementary Concept) 
“ICI D1033” OR “ZD-1033” OR ZD1033 OR Arimidex R “exemestane”(Supplementary Concept) OR 
“FCE 24304” OR “FCE-24304” OR Aromasil OR Aromasin OR “letrozole”(Supplementary Concept) OR 
Femara OR “CGS 20267” OR “CGS-20267” OR “Tamoxifen”[mesh] OR ICI47699 OR Zitazonium OR 
Soltamox OR Tomaxithen OR “ICI-46474” OR “ICI 46474” OR ICI46474 OR “ICI-46,474” OR “ICI 
46,474” OR “ICI46,474” OR Nolvadex OR “hormonal therapy” OR “hormone therapy” OR “endocrine 
therapy”) AND (“Neoadjuvant Therapy”[Mesh] OR Neoadjuvant OR “primary systemic” OR “primary 
therapy”))) AND (“Breast Neoplasms”[mesh] OR “breast cancer”) AND (“Clinical Trial”[Publication 
Type] OR “Comparative Study” [Publication Type]).
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A B S T R A C T
Introduction
Neoadjuvant hormonal therapy (NHT) is playing an increasing role in the clinical management of  breast 
cancer and may improve surgical outcomes for postmenopausal, estrogen receptor (ER)-positive breast 
cancer patients. However, there is currently no consensus on the optimal duration of  NHT before surgery. 
Here, we present the outcomes of  the TEAM IIA trial, a multicentre, phase II trial investigating the efficacy 
of  six months of  neoadjuvant exemestane in postmenopausal, strong ER-positive (≥50%) breast cancer 
patients. 
Methods
102 patients (stage T2-T4ac) were included in the study after exclusion of  ineligible patients. Primary 
endpoint was clinical response at 3 and 6 months as measured by palpation. Secondary endpoint was 
radiological response as measured by MRI, mammography and/or ultrasound. Linear mixed models 
(95%confidence interval (CI)) were used to compare changes in mean tumor size (in mm) between baseline, 
3 and 6 months after the start of  hormonal therapy. Conversion rates from mastectomy to breast-conserving 
surgery (BCS) were evaluated.
Results
Median age of  all patients was 72 years (range 53-88). Overall response rate by clinical palpation was 64.5% 
in all patients with a final palpation measurement. 4 patients had clinically progressive disease. 63 patients 
had both 3-month and >3-month palpation measurements. Overall response was 58.7% at 3 months and 
68.3% at final palpation (>3 months).  Mean tumor size by clinical palpation at T=0 was 39.1mm (95%CI 
34.8-43.4mm), and decreased to 23.0mm (95%CI 18.7-27.2mm) and 16.7mm (95%CI 12.6-20.8) at T=3 
and T>3 months respectively (p=0.001).  Final radiological response rates at the end of  treatment for 
MRI (n=37), ultrasound (n=77) and mammography (n=56) were 70.3%, 41.6% and 48.2% respectively. 
Feasibility of  BCS improved from 61.8% to 70.6% (McNemar p=0.012). 
Discussion
6 months of  neoadjuvant exemestane therapy helps reduce mean tumor size further in strongly ER-positive 
breast cancer patients without significant side effects compared to 3 months. Nevertheless, some patients 
still experience disease progression under exemestane. Feasibility of  breast conservation rates improve by 
almost 10%.
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I N T R O D U C T I O N
Neoadjuvant hormonal therapy (NHT) with aromatase inhibitors has been gaining recognition due to its 
ability to improve surgical outcomes for hormone sensitive breast cancer patients with stage II or III breast 
cancer. In recent years, NHT has come to play a major role in the treatment of  large breast tumors, attesting 
its ability to render inoperable tumors suitable for mastectomy and for breast conservation in patients who 
would otherwise undergo ablative surgery.1 Moreover, NHT provides the prospect of  investigating the 
effects of  hormonal treatment, with or without new targeted antitumor agents, on biochemical, molecular 
and histological tumor response features, which can help guide subsequent treatment decisions.2 
Although long-term survival benefit of  adjuvant chemotherapy do not differ between ER-positive and ER-
negative tumors based on an Early Breast Cancer Trialists’ Collaborative Group (EBCTCG) meta-analysis3, 
neoadjuvant studies have demonstrated that ER-positive tumors are less sensitive to chemotherapy than 
ER-negative tumors in terms of  pathological Complete Response (pCR).4-7
In estrogen receptor-positive, postmenopausal breast cancer patients, NHT is an appropriate option for patients 
who are considered unfit for neoadjuvant chemotherapy. Not infrequently, NHT is also prescribed for long-term 
treatment in elderly patients who are too fragile to undergo surgical intervention. During the 13th St. Gallen 
International Breast Cancer Consensus Conference, the majority of  the breast cancer experts’ consensus panel 
voted in favour of  the use of  NHT for postmenopausal patients with highly endocrine-responsive disease.8 
Currently, the most commonly applied treatment duration of  NHT in early breast cancer patients with 
large inoperable tumors is three months. Arguably, however, this may be too short a period for aromatase 
inhibitors to work to their full potential, as tumor response may continue if  treatment is extended.9, 10 
Importantly, the St. Gallen 2013 preliminary summary of  the consensus discussion reported that 62.2% of  
panelists were in favour of  continuing NHTtreatment until maximal response8, with only 11% of  panelists 
recommending a treatment duration of  3-4 months.11 26.7% of  panelists were in favour of  a treatment 
duration of  4-8 months.11 Clinical studies investigating the optimal duration of  NHT in order to optimize 
operability of  large tumors otherwise unsuitable for breast conservation are still relatively lacking.2, 12 We 
report the results of  the TEAM IIA study,  a nationwide, multi-institutional, phase II trial that investigated 
six months of  neoadjuvant therapy with exemestane on tumor response in strongly endocrine-sensitive 
breast cancer patients, which was developed to address the optimal duration of  NHT.
M A T E R I A L S  A N D  M E T H O D S
Trial design
The TEAM IIA  trial was originally designed as a phase III, randomized clinical trial investigating three versus 
six months of  neoadjuvant exemestane therapy on clinical response. Due to unexpectedly slow accrual, the 
TEAM IIA trial protocol was changed to a phase II single-arm study investigating six months of  NHT on 
clinical response following an amendment in June 2009. The TEAM IIA trial was conducted in 11 hospitals 
throughout the Netherlands between March 2007 and May 2012. Database lock was on October 15th, 2013. 
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Patients
107 patients were enrolled in the study. 20 patients were randomized to 3 months of  neoadjuvant treatment 
with exemestane before the amendment. 87 patients were included after the amendment and were allotted 
6 months of  NHT.(Figure 1) Patients randomized to 3 months and on-treatment were offered to continue 
until 6 months. Eligibility criteria included postmenopausal patients with histologically confirmed invasive 
adenocarcinoma (stage I-III) of  the breast that was strongly ER-positive (≥50% based on core biopsies) and 
≥2cm in diameter. Patients with metastatic disease (M1) were considered ineligible. In addition, patients 
with multicentric,  bilateral, or inflammatory (cT4d) breast cancer were ineligible. 
Figure 1. CONSORT diagram showing patients included in the study. 
The protocol as well as the amendment were reviewed and approved by each participating institution and 
registered with the Netherlands Trial Register (NTR785) in compliance with the Declaration of  Helsinki 
and Good Clinical Practice guidelines. All patients provided written informed consent.
Tumor response was assessed monthly by clinical palpation and at 3-month intervals for MRI, bidirectional 
mammography or ultrasound. Clinical palpation response was measured in terms of  the largest diameter 
(in millimetres). For radiological response, perpendicular dimensions of  the largest measurable primary 
tumor and lymph nodes were measured. Cut-off  points for response categories included complete 
response (disappearance of  all target lesions), partial response (≥30% decrease in tumor size), stable 
disease (<20% increase or ≤30% decrease in tumor size), and progressive disease (≥20% increase in 
tumor size, as well as an absolute increase of  at least 5mm), and were based on the Response Evaluation 
Criteria in Solid Tumors (RECIST) version 1.1.13 
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Endpoints
The primary endpoint was overall clinical response at three and six months, as measured by clinical 
palpation. Only patients who enrolled in the study after the implementation of  the amendment are included 
in these analyses. 
Secondary endpoints consisted of  objective radiological response; imaging modality was opted by the 
treating physician. Other secondary endpoints included pCR of  the primary breast cancer and lymph 
nodes, and the feasibility of  breast conserving surgery in all patients. pCR was defined as the absence of  
invasive tumor cells in the resection specimen and dissected lymph nodes (pT0/pN0) as reported by the 
pathology laboratories.
Tumor pathology data
Core biopsies were obtained before the start of  treatment and resection specimens were acquired at final 
surgery. Biopsies were evaluated by immunohistochemistry with conventional light microscopy at pathology 
laboratories. 
Assessment of  safety
Patient-reported toxicities were assessed at 1-month intervals. The National Cancer Institute Common 
Terminology Criteria for Adverse Events, version 3.0, was used to classify adverse events following 
exemestane treatment. 
Statistical analyses
Cross tabs with McNemar tests for paired samples were used to assess palpability and clinical response at 
baseline, three and six months. If  treatment was discontinued before six months due to progressive disease or 
due to patient or investigator request, response up to the last clinical examination was used. Mean changes 
in tumor size from baseline to 3 months and 6 months after the start of  exemestane were assessed in linear 
mixed models with 95% confidence intervals (CI) for clinical palpation, MRI, bi-directional mammography, 
and/or ultrasound. All available radiological modalities were included in the analyses. If  more than one 
modality was used for tumor size measurement, we used radiological modality in order of  accuracy (MRI 
followed by mammography, followed by ultrasound).13 
R E S U L T S
Study population
107 patients were included in the study, of  which 20 patients were allocated 3 months of  exemestane before 
implementation of  the protocol amendment. After exclusion of  ineligible patients (n=5), the final cohort 
comprised 102 (stage T2-T4a-c) patients.(Figure 1) Median treatment time for all patients was 5.78 months 
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(mean 5.32, range 0.89-9.11 months) and 3.33 months (mean 3.46, range 2.22-5.78 months) for patients 
randomized to 3 months of  treatment before the amendment. The scatter plot that makes up Figure 2 
reveals the percentage change in tumor size as measured by palpation in relation to time on exemestane 
treatment for all patients in the cohort. Mean age was 72 years (range 53-88). Baseline characteristics 
of  patients at the start of  treatment (T=0) are presented in Table 1, with primary tumor characteristics 
representing the results following core needle biopsy. 
Tumor downstaging
Clinical response to exemestane was quantified and classified as complete response, partial response, 
stable disease and progressive disease. Overall response rates at the end of  treatment for palpation, MRI, 
ultrasound and mammography are shown in Table 2. At the end of  neoadjuvant exemestane treatment, 
overall clinical response (complete response + partial response) was 64.5% (51 out of  79 evaluable patients). 
There were 22 complete clinical responses, 29 partial responses, 24 stable diseases and 4 progressive diseases 
according to palpation assessments. Of  the 4 patients with progressive disease based on clinical palpation, 
only 2 were also radiologically confirmed progressive diseases (2 stable disease). Mean percentage reduction 
in tumor size was 47.35% (range -63% - 100%). 63 patients had palpation measurements at 3 months and 
Figure 2. Scatter plot of  the percentage change in tumor size as measured by palpation in relation to time on 
treatment (months) in patients treated with neoadjuvant exemestane in all included patients.
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a final measurement at the end of  neoadjuvant treatment (>3 months). At the end of  treatment, overall 
clinical palpation response (compared to 3 months) increased from 58.7%to 68.3% at last palpation. 
(McNemar p=0.031).
Mean tumor size was 39mm at the start of  treatment, and decreased significantly after 3 and >3 months of  
exemestane treatment (Table 3). Mean reductions in tumor size at 3 and >3 months were 16mm and 22mm 
respectively (p<0.001). After >3 months of  neoadjuvant treatment, there was a statistically significant 
decrease in tumor size when compared with 3 months of  treatment (p=0.003). 
Table 1. Baseline characteristics of  patients included in this study
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Radiological assessment
93 patients had a radiological assessment (91.2%). Based on radiological assessment, overall clinical response 
rate was 54.8%. There were 11 complete responses (11.8%), 40 partial responses (43%), 35 stable diseases 
(37.6%) and 7 patients with progressive disease (7.5%). Patients who had MRI measurements (n=37) 
had larger tumors at palpation than patients without MRI measurements (n=65) (35mm versus 47mm, 
p=0.003). In the MRI group there was a greater proportion of  invasive lobular carcinomas (45.7%) than in 
the group without MRI measurements (20.3%). Patients who had both MRI in addition to mammography 
or ultrasound measurements did not have larger tumors on MRI than on mammography or ultrasound 
(independent samples T-test p=0.694 and p=0.142). Figure 3 shows the mean tumor sizes (95% confidence 
interval, CI) for individual radiological modalities. In addition, Table 3 depicts mean reductions in tumor 
Table 2. Overall response at final assessment in all patients, as determined by clinical palpation, MRI, mammography 
and ultrasound.
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size for each radiological modality separately. For all modalities, there was a significant decrease in mean 
tumor size over time. Mean tumor size was not statistically significantly lower after 6 months of  exemestane 
than after 3 months (p>0.05). 
8 patients (8.8%) had confirmed HER2-positive disease after surgery, of  whom 5 had clinical response 
assessments available (2 complete responses (25%), 1 partial response (12.5%), 2 stable diseases (25%)). All 
patients had radiological response data available, which showed 1 complete response (12.5%), 1 partial 
response (12.5%), 3 stable diseases (37.5%) and 3 progressive diseases (37.5%).
Feasibility of  breast-conserving surgery
Median time to surgical intervention was 28 weeks (range 8 – 47 weeks). Tumor and nodal stage, grade, 
histology, and hormone receptor status were also determined after final surgery and are presented in 
Supplementary Table 1. The number of  patients with feasible BCS increased from 63 before treatment 
to 72 at the end of  treatment (McNemar p=0.012) (Table 4). A total of  98 patients (96.1%) underwent 
surgical resection of  their tumor. Primary surgery consisted of  BCS in 58 patients (56.9%) and mastectomy 
in 40 patients (39.2%). 9 patients (9.2%) deemed ineligible for BCS at the start of  treatment had successful 
breast conservation. 9 patients (8.8%) required a re-excision (5 mastectomy, 4 BCS) following tumor-positive 
resection margins (invasive carcinoma and/or carcinoma in situ). 
Table 3. Mean tumor size and mean change in tumor size at 3 months and at the end of  neoadjuvant exemestane 
treatment in patients enrolled after protocol amendment
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Patient preference for either mastectomy or BCS was also assessed. 79 patients reported a surgical preference 
at baseline and at the end of  treatment. Patient preference regarding the type of  breast surgery shifted from 
13.7% in favour of  mastectomy (n=14) at the start of  treatment to 23.5% (n=24) in favour of  mastectomy 
at the end of  treatment. Preference for BCS was 66.7% (n=68) at baseline and decreased to 63.7% (n=65) 
at the end of  exemestane treatment.
Sentinel lymph node biopsy
25 out of  102 patients (24.5%) had clinically or cytologically confirmed node-positive disease at the start 
of  exemestane treatment. In total, 71 patients underwent a sentinel lymph node biopsy (SLNB) (9 patients 
before neoadjuvant therapy and 62 patients after neoadjuvant therapy). Three out of  the 25 patients (12%) 
who were clinically node-positive before the start of  exemestane became pathologically node-negative after 
neoadjuvant treatment. Forty-two out of  62 patients (67.7%) who had a SLNB after neoadjuvant treatment 
were also node-negative (pN0 or pN0(i+)).
Figure 3. Mean change in tumor size after 3 and 6 months after the start of  neoadjuvant treatment in patients 
enrolled after protocol amendment.
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Safety and toxicities
Adverse events were graded according to the CTC-AE version 3.0. All toxicities that make up >1% of  all 
reported adverse events (n=188) are included in Supplementary Table 2. Only 10 toxicities (4.1%) were 
reported to be grade 3-4 toxicities. Pain, fatigue, and sensory neuropathy make up the majority of  grade 
III-IV toxicities reported in this study. Importantly, only three patients  discontinued exemestane due to 
toxicities. There were no serious unexpected adverse events.  
D I S C U S S I O N
Six months of  neoadjuvant exemestane resulted in improved clinical and radiological responses, without 
an increased risk of  toxicity. Overall clinical response rate was 64.5% after 6 months of  neoadjuvant 
exemestane. Radiologically confirmed progressive disease was limited to four patients. In addition, 
neoadjuvant treatment resulted in a greater feasibility of  breast conservation, although the number of  
patients who required a re-excision for tumor-positive margins was 8.8%. 
Two earlier studies have shown that in patients with ER-positive breast cancer, hormonal therapy may be at 
least as effective as chemotherapy for inducing tumor response.14, 15 In the last decade, neoadjuvant therapy 
has gained popularity, owing to the prospect of  downsizing tumors to facilitate breast conservation and 
to evaluate biological features associated with tumor response to treatment.2 Neoadjuvant chemotherapy 
Table 4. Feasibility of  breast conserving surgery before and after neoadjuvant treatment in all patients
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(NCT) with several cycles comprising around 4 months (e.g. TAC chemotherapy for 6 x 3-week cycles), of  
which it is suggested that early clinical response to the first few cycles is predictive for survival after surgery.16 
Conversely, however, NHT demonstrates a more gradual tumor response rate and may thus require longer 
treatment durations in order to attain maximum effect.9 Our investigation revealed that prolonged treatment 
with neoadjuvant exemestane therapy results in sustained tumor response, with a reduction in mean tumor 
size of  more than 2cm at the end of  treatment.
Previous prospective, randomized studies have investigated the feasibility of  aromatase inhibitors in 
inducing tumor downsizing in  endocrine-sensitive breast cancer patients. The P024 and PROACT studies 
investigated 4 months of  aromatase inhibitor therapy compared with tamoxifen therapy and found response 
rates of  55% and 50% respectively in the aromatase inhibitor arm.17, 18 Similarly, the IMPACT study by 
Smith and colleagues reported a response rate of  37% following 3 months of  anastrozole.19 Aromatase 
inhibitor therapy in these phase III studies showed lower response rates than those found in our study, 
possibly related to the longer treatment duration in our cohort.
For practical purposes, tumor size assessed by clinical palpation defined the primary endpoint of  this study. 
There was a steady decrease in the number of  patients with palpable tumors between baseline and 6 
months of  NHT. Although the greatest decrease in tumor size was observed between baseline and 3 months 
of  treatment, tumor size continued to fall after more than 3 months of  NHT, suggesting that prolonged 
treatment duration may be required to achieve maximum response to optimize surgery. In an earlier report 
by Dixon and colleagues, more than a third of  the patients included in the study continued NHT beyond 
3-4 months for various reasons, causing a rise in overall response rates to more than 80% and facilitating 
more BCS.9 Furthermore, maximum response in other studies was achieved approximately 4-6 months after 
the start of  NHT.20, 21 Similar results were recently reported in a study by Carpenter et al, who showed that 
the median duration of  neoadjuvant letrozole to allow for BCS in patients otherwise ineligible for breast 
conservation was 7.5 months.22 These findings demonstrate that extended duration of  NHT achievable 
optimal tumor response and is well-accepted by patients. 
Radiological response as measured by MRI is considered the best available response assessment modality followed 
by mammography.13, 23 Although our study is limited by the inconsistent use of  MRI to assess tumor response, the 
highest overall response rate was observed with MRI (70.2%), suggesting that the lower response rates measured 
by mammography and ultrasound may underestimate the true response to NHT. Although recommended, the 
use of  MRI was not required and was up to the local investigator. The RECIST criteria (1.1) were used to 
evaluate MRI data in this study.13 It must be noted that those tumors which were reduced to scattered fragments 
should be regarded as responders to NHT, although accurate response assessment based on RECIST is not 
possible. In 2012, the ACRIN 6657/I-SPY study concluded that volumetric assessment of  breast tumors is a 
better predictor of  response than measuring the longest tumor diameter in patients treated with neoadjuvant 
chemotherapy.24 Since the patients in this study were included between 2010 and 2012,  routine volumetric 
assessments were not yet standard of  care, but should be considered for use in clinical practice.
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Our study comprised strongly ER-positive breast cancer patients, as studies have shown that the degree of  
quantitative ER expression might be a valuable discriminating factor to predict hormonal therapy efficacy. In 
this study, we utilized percentage of  positively staining tumor cells (according to the Dutch National Breast 
Cancer guidelines)25 to select our patients. The ACOSOG Z1031 study selected ER-positive patients based on 
the Allred score (Allred score 6-8), which may be of  added value in predicting response to hormonal therapy.26 
When considering staining intensity in addition to percentage of  positively staining cells when selecting eligible 
patients, response rates may be even higher than those reported in the current study and deserves further 
investigation. In the adjuvant setting, efficacy of  hormonal therapy was superior with incremental increases 
in ER expression.27-30 NHT may be a valid alternative to neoadjuvant chemotherapy in strong ER-positive 
patients, and quantitative ER expression may aid the decision to opt for NHT as opposed to NCT. Petit et 
al. found an inverse relation between ER expression and pCR in hormone receptor-positive breast cancer 
patients treated with neoadjuvant chemotherapy.31 NHT provides the prospect of  improving operability of  
large tumors, thereby opening up new domains for further improvements in breast cancer care.
pCR is a frequently used endpoint in patients treated with NCT. In our study, however, only one patient 
had a pCR in both tumor and regional lymph nodes. Accordingly, it is questionable whether pCR should 
be the aim in breast cancer patients undergoing NHT. Apart from much longer time to maximal response 
when compared with NCT, one must bear in mind that the primary objective of  preoperative treatment is 
to allow for adequate tumor downsizing to enable breast conservation in patients who would alternatively 
require mastectomy, and breast surgery in otherwise inoperable patients.1 As patients may differ in the time 
to maximum response, monitoring tumor downsizing up to response stagnation may be more important in 
anticipation of  surgical resection as opposed to determining a set treatment duration.
Feasibility of  BCS improved from 61.8% (n=63) to 70.6% (n=72) after completion of  NHT, although breast 
conservation was performed in 58 patients. Of  note, BCS can be considered a challenging endpoint for 
determining NHT efficacy and must be interpreted with caution, as type of  surgery can also be driven by several 
other factors than post-treatment tumor size alone (i.e. patient preference, surgeon preference and/or experience). 
A major advantage of  NHT is its application in translational research, especially with regard to predicting 
efficacy of  hormonal therapy.32 Measurements of  the proliferation marker Ki-67 can be used to tailor 
neoadjuvant treatment soon after the initiation of  treatment.33 In patients treated with letrozole, the change 
in Ki-67 level after two weeks of  treatment was of  prognostic value for RFS, as was demonstrated in an 
earlier study.33 Ellis et al. concluded that a single tumor Ki-67 assessment after 2 to 4 weeks after initiating 
aromatase inhibitor treatment might identify ER-positive breast cancer patients with poor outcomes.34 
Although this is not always feasible in daily clinical practice, results from biomarker studies like these will 
help pave the way to a more personalized treatment approach pertaining to hormonal therapy. 
The conversion of  our study from a double-arm phase III study investigating 3 versus 6 months of  NHT to a 
single-arm phase II study of  the efficacy and safety of  6 months of  NHT is in part related to slow accrual and 
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limits the assertion of  our findings. During the early phases of  this study, the reluctance to treating patients with 
NHT resulted in much resistance in the inclusion of  patients in our trial. More than half  of  the patients allocated 
to 3 months of  NHT continued for more than 3 months, suggesting that longer treatment duration has already 
gained acceptance by patients in clinical practice. Of  crucial importance is the late St. Gallen consensus meeting, 
which confirmed that neoadjuvant hormonal treatment should be continued until maximum treatment response.8 
Supplementary Table 1. Patient and tumor characteristics after final surgery in all patients
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C O N C L U S I O N
A sustained response to neoadjuvant treatment with the aromatase inhibitor, exemestane, was observed up 
to 6 months, exceeding the generally accepted neoadjuvant treatment period of  three months. Feasibility of  
BCS improved, consequently facilitating better cosmetic outcomes. Based on the results of  this study and in 
line with current consensus, it is advised that the duration of  NHT durations should be at least 6 months, in 
the absence of  progressive disease. The potential to predict efficacy of  adjuvant hormonal treatment based 
on initial response in the preoperative setting requires further exploration.
Supplementary Table 2. Adverse events reported by all patients in this study
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A B S T R A C T
Neoadjuvant chemotherapy (NCT) is an increasingly important component in the treatment of  both locally 
advanced and early-stage breast cancer. With this, a debate on the timing of  the sentinel lymph node 
biopsy (SLNB) has emerged. At the end of  the last century, the SLNB was introduced as an axillary staging 
modality, and this paper aims to further elucidate this issue in the context of  NCT. We compiled available 
data on the SLNB after NCT and provide clinical guidance for the timing of  the SLNB in this context. On 
the basis of  our findings, we recommend that the SLNB can be performed after NCT in all cases. In patients 
with a clinically node-negative (cN0) status prior to NCT, the SLNB should be performed after NCT, and 
in case of  a histologically confirmed negative SLNB, a completion axillary lymph node dissection (ALND) 
has no added value and can be omitted. In patients with clinically positive nodal involvement (cN+) prior to 
NCT, all axillary surgery can also  be performed after NCT. 
T I M I N G  O F  T H E  S E N T I N E L  L Y M P H  N O D E  B I O P S Y  I N  B R E A S T  C A N C E R  P A T I E N T S  R E C E I V I N G 
N E O A D J U V A N T  T H E R A P Y  –  R E C O M M E N D A T I O N S  F O R  C L I N I C A L  G U I D A N C E
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I N T R O D U C T I O N
Nodal status is one of  the most important determinants of  breast cancer prognosis.1, 2 Axillary staging is 
successfully achieved by sentinel lymph node biopsy (SLNB), 3, 4 followed by a completion axillary lymph 
node dissection (ALND) in patients with proven sentinel node metastases. Needless to say, the SLNB is a 
means of  staging and not a treatment modality. Earlier, some have questioned the need for completion 
ALND in patients with sentinel lymph node (SLN) involvement5, 6; about half  of  the patients with a positive 
SLN are known to have additional axillary nodal involvement7-9, and even in case of  omitting an ALND, 
the risk of  developing an axillary recurrence in the presence of  a positive SLN is less than one per cent.10
The American College of  Surgeons Oncology Group (ACOSOG) Z0011 trial was initiated to investigate 
whether there were differences in axillary recurrences and survival in patients who underwent a 
completion ALND versus a SLNB alone.11 In 2009 Bilimoria and colleagues investigated differences in 
axillary recurrences and survival in women with histologically confirmed node-positive breast cancer who 
underwent a SLNB with or without ALND.5 All had clinically node-negative (cN0) disease. After a median 
follow-up of  63 months, there were no differences in axillary recurrence and survival for SLNB alone versus 
ALND. Even when assessing micrometastases and macrometastases separately, no differences were found 
in axillary recurrence and overall survival.5 Despite evidence pointing towards equally good outcomes in 
terms of  recurrence and survival when the ALND is withheld, we still largely perform a completion ALND 
in patients with a positive SLNB. 
In the context of  neoadjuvant chemotherapy (NCT), a similar debate has emerged on the subject of  the 
appropriate use and optimal timing of  the SLNB. Multiple studies confirm downstaging of  the tumor and 
the axilla during NCT, increasing the likelihood of  less extensive surgery.12, 13 At present, one school of  
thought advocates performing a SLNB before commencing NCT, while the latter proclaim that the SLNB 
can be safely performed after completion of  the NCT regimen. With the increasing use of  NCT, clinicians 
are currently short of  sound clinical guidelines for the management of  the SLN in the context of  NCT. 
The objective of  this study was to aggregate available data on the SLNB after NCT and to provide clinical 
guidance for timing of  the SLNB in the context of  NCT.
M E T H O D S
Search strategy
The databases Pubmed and Medline were searched until May 1st 2012 using free text and MeSH (Medical 
Subject Headings) terms for “breast cancer”, “Neoadjuvant chemotherapy” and “sentinel lymph node 
biopsy”. Only papers written in English were eligible. Included, were original studies in which accuracy or 
feasibility of  the SLNB after NCT in invasive breast cancer was evaluated. There were no restrictions with 
regard to clinical nodal stage or tumor size. Completion of  an ALND after a SLNB was mandatory for 
inclusion. Additionally, references of  the included papers, and of  three meta-analyses14-16 and a systematic 
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review were checked.17 Abstracts and data solely presented at conferences were excluded. In case of  an 
update of  previously published data, the most recent publication was chosen to be included.
 
Data extraction
For all included studies we recorded year of  publication, number of  patients, inclusion period, inclusion 
criteria, clinical nodal status, type of  NCT, and conclusions made by the authors. For reason of  
comparison, accuracy parameters were calculated using a standard definition, and comprised 1) sentinel 
node identification rate (IR), 2) false negative rate (FNR), and 3) overall accuracy. IR was calculated as the 
number of  patients with a successful SLNB divided by the total number of  patients in whom a SLNB was 
attempted. True positive SLNB was defined as the number of  patients with a positive SLNB, with or without 
additional positive lymph nodes at ALND. True negative SLNB was defined as the number of  patients with 
a negative SLNB which was confirmed by a negative ALND. A false negative SLNB was defined as the 
number of  negative SLNBs with a positive ALND. FNR was calculated as false negative / (true positive 
+ false negative). Accuracy was calculated as (true positive + true negative) / number of  patients with a 
successful SLNB. Whenever possible, these numbers were also calculated for subgroups based on nodal 
status. Weighted means were calculated based on the number of  patients in each study.
R E S U L T S
A total of  40 original studies were retrieved for analyses, including 3328 patients. The studies were published 
between 2000 and 2011, and patients were included between 1994 and 2009. As some studies published 
data on various subgroups of  patients along with overall accuracy data, these studies were included more 
than once. Results are shown by clinical nodal status before and after NCT. 
Node-negative before NCT 
An overview of  the 17 studies including 1738 patients who were clinically node-negative (cN0) prior to 
NCT (pre-NCT) is shown in Table 1. The studies were published between 2001 and 2009, patients were 
included between 2001 and 2007. Mean sentinel lymph node IR was 95.0% (range 83.3%-100%); mean 
FNR was 11.4% (range 0%-28%); mean overall accuracy was 95.6% (range 80.6%-100%).  
In patients who were cN0 prior to NCT, performing a SLNB after NCT was determined to be accurate in 
14 out of  17 studies (Table 1). Three studies concluded otherwise.18-20 The study by Papa and colleagues 
prospectively investigated performing a SLNB before NCT versus after NCT and found a significantly lower 
IR (87% versus 100%, p<0.05) and higher FNR (15.8% versus 0%, p=0.04) in patients who underwent a 
SLNB after— versus before NCT.19 The other two studies found comparable higher FNRs.18,20
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Node-positive before NCT
Fifteen studies in which 839 patients who were clinically node-positive (cN+) prior to chemotherapy were 
included, is shown in Table 2. The studies were published between 2003 and 2011, patients were included 
between 1994 and 2009. Mean SLN IR was 86.5% (range 68.4%-100%); mean FNR was 10.3% (range 
5.1%-29.6%); mean overall accuracy was 92.8% (range 81.8%-96.7%).
Performing a SLNB after NCT was concluded to be accurate in 11 out of  15 studies (Table 2). Four studies 
concluded otherwise.18, 21-23 Various reasons exist for the studies with negative conclusions. Reasons were 
lower IR 18 and higher FNR 21, 22 than when performing a SLNB before NCT. Controversy still exists on this 
issue, as some negative studies reported lower IR but satisfactory FNR after NCT 18 while others reported 
that the latter was unsatisfactory with a similarly high IR.21, 22 Therefore, there is still no exact reason for the 
different negative studies. Another study did not state conclusions, because this was not the main research 
question of  the study.24
Table 1. Overview of  the results and conclusions of  the included studies, cN0 preNCT
C H A P T E R  1 5236
Node-negative and node-positive before NCT 
Some studies included both patients who were cN0 or cN+ prior to NCT, and only provided data for the 
whole study population. Results of  these 11 studies comprising 480 patients are shown in Table 3. The 
studies were published between 2000 and 2010, patients were included between 1994 and 2007. Mean 
sentinel lymph node IR was 83.6% (range 70.9%-100%); mean FNR was 9.5% (range 0%-20%); mean 
overall accuracy was 97.4% (range 87.5%-100%).
Performing a SLNB after NCT (post-NCT) was concluded to be accurate in 9 out of  11 studies. Two studies 
concluded otherwise.25, 26 Reasons were lower IR and high FNR (18.2%26 and 20%25 respectively).
Node-negative after NCT 
An overview of  the 8 studies including 348 patients who were cN0 after NCT, and whom, before NCT, were 
either cN0 or cN+ is shown in Table 4. The studies were published between 2000 and 2010, patients were 
included between 1996 and 2008. Mean SLN IR was 92.0% (range 85%-100%); mean FNR was 8.5% 
(range 0%-33.3%); mean overall accuracy was 94.6% (range 76.9%-100%).
Performing a SLNB after NCT was considered accurate in 7 out of  8 studies. One study concluded 
otherwise.27 Nason and colleagues investigated 82 patients with a clinically negative axilla and who 
underwent a SLNB followed by an ALND, of  which only 15 patients underwent NCT. This study found an 
IR of  80% and an increased FNR (33%); out of  9 patients with histologically confirmed positive axillary 
lymph nodes, three patients had a false-negative SLN.  
D I S C U S S I O N
We performed an in-depth investigation of  the different studies performed to date. Studies included either 
cN+ or cN0 patients only, or both (pre-NCT). We assessed a selection of  studies that combined cN0 and 
cN+ patients before NCT and, on the basis of  these results it was concluded that overall, performing 
a SLNB after NCT is accurate. In the majority of  the studies, it was concluded that the SLNB can be 
performed after NCT in patients with a clinically node-negative (cN0) disease before NCT. In case of  a 
histologically confirmed negative SLNB, a completion axillary lymph node dissection (ALND) has no added 
value. Similarly, in patients with clinically positive nodal involvement (cN+) before NCT, all axillary surgery 
can be performed after NCT. 
Staging procedure 
Historically, the SLNB was introduced in order to indicate disease stage and prognosis more accurately 
and to add value to treatment decisions based on prognostic indicators. The SLNB was not intended as 
a therapeutic procedure. Consequently, staging accuracy is not an endpoint in itself.28 Although a false-
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Table 2. Overview of  the results and conclusions of  the included studies, cN+ preNCT
Table 3. Overview of  the results and conclusions of  the included studies, cN0, cN+ preNCT
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negative result, i.e. a negative SLN in the presence of  positive axillary lymph nodes, may lead to incorrect 
nodal staging and thus to potential undertreatment with regard to adjuvant therapy, the clinical implications 
of  false-negative results in the neoadjuvant setting are not as critical. The decision to administer systemic 
therapy has already been made, and undertreatment is unlikely.22 We must bear in mind that current adjuvant 
treatment also incorporates breast and axillary irradiation to further reduce the probability of  axillary 
recurrences.29, 30 Surgical overtreatment, however, is conceivable, and the impact of  additional comorbidity 
following more extensive surgery where it could be prevented cannot be ignored.31 Furthermore, the risk of  
developing an axillary recurrence at 5 years when an ALND has been omitted in the presence of  a positive 
SLN remains low.10, 32 
Axillary Downstaging
One of  the major advantages of  axillary surgery after neoadjuvant therapy is the potential for less extensive 
surgery as well as reducing surgery to a single procedure. Overall, 20-44% of  node-positive patients achieves 
a complete pathological response in the axilla with NCT12, 13 and may thereby be spared an ALND, with its 
well-known comorbidities.31 Moreover, patients who are clinically node-negative before NCT may also be 
spared a second surgical procedure when the SLNB is performed after NCT.33 
Axillary response to NCT
One of  the arguments restraining the progression of  clinical guidelines is the potentially selective complete 
response following NCT in the SLN, but not in the axillary lymph nodes.34 Dixon and colleagues correctly 
state in an earlier editorial that the areas of  concern for surgeons as well as other physicians dealing with 
breast cancer patients include the alteration in lymphatic drainage leading to potentially lower IR and higher 
FNR.28 Excessive fibrosis of  the tumor involved lymphatics after neoadjuvant chemotherapy and the potential 
obstruction of  lymphatic channels with cellular debris or tumor emboli may lead to inaccurate lymphatic 
Table 4. Overview of  the results and conclusions of  the included studies, cN0 postNCT
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mapping35, although the latter has never been proven.28, 33 Alteration in lymphatic drainage is a heterogeneous 
process, and multiple studies have found that NCT does not influence mapping success.27, 36 Fringuelli evaluated 
the influence of  NCT on lymphatic drainage using lymphoscintigraphy before and after NCT in 129 patients; 
in 123 patients (95.3%), no change in drainage pattern between before and after NCT was observed.36 
Several studies observed a uniform axillary response to NCT.16 The SLN was shown to accurately predict 
axillary status, also after NCT.37-39 We must also acknowledge that only 40-60% of  patients with a positive 
SLN have additional axillary nodal involvement.7 Moreover, it is important to bear in mind that there 
will always be a risk of  axillary lymph node involvement, also in the absence of  a positive SLN, and that 
the introduction of  breast and axillary irradiation has further reduced axillary recurrences. Therefore, in 
patients with a histologically confirmed negative SLNB, an ALND has little added value.
Accuracy and Safety
In light of  the results of  previous practice-changing studies that lead to the introduction of  the standard 
staging procedure using the SLNB, accuracy rates in terms of  IR and FNR were similar to the current 
findings in the neoadjuvant setting. Some have commented that because these were early studies, rates are 
no longer acceptable in current clinical practice.18 However, several studies have also found that IR improves 
with augmenting experience.38-40 Furthermore, several direct comparisons of  the accuracy of  the SLNB 
with- versus without NCT have been conducted recently, and all have observed a similar accuracy for both 
strategies.39,41 Of  note, patients included in these studies were cN0 prior to NCT. 
Although results are comparable across studies, some consider it safe and accurate to perform a SLNB after 
NCT, whereas others do not recommend the procedure. The false-negative rate is a probability of  axillary 
nodal involvement when the SLN is negative. Currently, no FNR standard has been set, but an FNR of  5% 
has been deemed reasonable by several investigators.23,43,44 
The current SENTINA trial, a substudy of  the German Geparquinto neoadjuvant trial, is a four-arm trial 
in which the role of  the sentinel lymph node (cN0 and cN+) is being investigated in patients undergoing 
NCT.40,42 Recent results from the San Antonio Breast Cancer Symposium (SABCS) in 2012 showed that 
FNR is less favorable in patients who underwent SLNB after NCT than when the SLNB is performed before 
NCT.40 The other trial is the ACOSOG Z1071 trial, a phase II study in which a SLNB + ALND after NCT 
is performed in T0-4, N1-2, M0 patients.41 The primary objective is to determine FNR for sentinel lymph 
node surgery in women with node-positive breast cancer at initial diagnosis. To the author’s knowledge, the 
latter has currently been suspended, however, results presented at SABCS 2012 revealed that NCT results in 
conversion to node-negative disease in 40% of  node-positive cases, with a FNR of  12.8%.41 
Some argue that the FNR may not be the best endpoint to use in the neoadjuvant setting and that its value 
is slightly overrated. Instead, looking at the risk of  locoregional recurrences when an ALND is withheld may 
be a better approach to determining the future of  the management of  the axilla. Adjuvant locoregional 
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and systemic treatment has had a tremendous impact on improving locoregional control in recent years. In 
the 1980s, several studies reported on the effectiveness of  radiotherapy following breast conserving therapy 
in patients with a positive and/or negative SLN. The majority of  studies reported axillary recurrence 
rates below 4%, with the exception of  one study reporting a 16% axillary recurrence rate.42 A later study 
investigated the effect of  axillary radiotherapy on locoregional recurrences in patients with a positive SLN 
who did not undergo an ALND.43 Out of  73 patients, only one developed an axillary recurrence (median 
follow-up 32 months). All patients received adjuvant systemic treatment. In the context of  NCT, all patients 
will already have been systemically treated, therefore axillary radiotherapy may be a suitable alternative to 
axillary surgery in these patients. Furthermore, the majority of  hormone receptor-positive patients will also 
receive adjuvant endocrine therapy for a period of  five years or longer to further reduce recurrence rates. 
Based on comparable results, some consider it safe and accurate to perform a SLNB after NCT, whereas 
others do not recommend the procedure. The discrepant conclusions extend beyond individual studies. To 
date, three meta-analyses15-17, and one systematic review18 were completed. Although there is considerable 
overlap in the studies included, conclusions vary. Several contained studies with cN0 and cN+ patients 
prior to neoadjuvant therapy.15, 17, 18 and one restricted inclusion to studies consisting of  patients with cN0 
after NCT only.16 As different studies have investigated groups of  patients that are all at different risks of  
presenting with involved lymph nodes, there is a great variability in FNR. Unfortunately, small sample sizes 
may also obscure statistical analyses and outcomes. No evident publication bias was shown in previous 
reports.16, 17
SLN identification method
In the reviewed studies, we summarize the identification rates based on different detection methods.
(Supplementary Table 1) Several methods of  SLN identification were utilized, and a majority of  studies 
applied a combination of  blue dye and radioactive colloid (usually Technetium-99m (Tc99)). Studies also 
varied with respect to injection location. It is difficult to draw conclusions based on these results, as they vary 
across studies with respect to the different clinical presentations and procedures. Zhang et al. attempted to 
compare SLN identification techniques in different studies and found that a combined technique resulted in 
a higher IR than either dye or isotope alone.44
C O N C L U S I O N
In the context of  NCT, clinicians are still at a loss, given the discrepancies demonstrated in conflicting 
guideline recommendations. The ASCO guidelines dating from 200545 state that performing a SLNB 
after NCT is not recommended. Contrary, the more recent St. Gallen expert consensus meeting in 2009 
concluded that ‘results of  sentinel node biopsy after NCT are reliable, as described in a meta-analysis 
and supported by experience at a single institution’.46 As stated earlier, NCT is an essential element in the 
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treatment of  breast cancer in patients with large operable tumors with the potential of  being downstaged 
and undergoing breast conserving therapy. NCT is equally effective as adjuvant chemotherapy when 
adequate local treatment ensues.47 Similarly, adjuvant radiation therapy is of  critical significance in reducing 
axillary recurrences. In this multidisciplinary approach, surgical intervention is but one of  the components 
of  the entire treatment regimen. It is therefore unjustified not to adjust surgical treatment if  downstaging 
of  the tumor and axilla occurs through valid treatment. This would certainly undermine the true potential 
of  NCT, especially if  neglecting to do so brings additional comorbidity to patients already burdened by 
multiple demanding treatments. 
 
Supplementary Table 1. Identification rate by detection method*
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G E N E R A L  D I S C U S S I O N
Personalized medicine is the practice of  using established and novel techniques to optimize the management 
of  an individual patient’s disease based on unique patient and tumor characteristics whilst addressing 
personal needs and expectations in order to choose the most optimal treatment approach with the greatest 
possibility of  achieving the best medical outcomes. With regard to breast cancer, rapid advances in 
biotechnology have enabled us to look more profoundly at the biological and disease processes taking place 
in each patient and her tumor. Consequently, the terms ‘personalized’ or ‘tailored’ treatment have been 
coined to describe treatment that is fitted to the individual patient, combining conventional clinical and 
non-clinical characteristics with more recent molecular markers and involving patients in the decisions 
pertaining to their cancer.
In postmenopausal, endocrine-sensitive, early breast cancer patients, personalized endocrine treatment is 
still relatively unknown. Thus far, it has not yet been possible to choose the most optimal endocrine therapy 
regimen based on the combination of  tumor biological factors and personal characteristics including 
demographics, comorbidities, anticipated side effects, and quality of  life (QOL) and lifestyle issues. Being 
able to determine the best endocrine therapy regimen may be difficult when all the elements that define a 
patient and her disease are not completely taken into consideration. Furthermore, continuous monitoring 
and updating of  a patient’s prognosis based on subsequent events over time (such as disease events as well 
as other non-disease-related incidents) are needed as these may require re-evaluation of  the prescribed 
treatment regimen. Aiming at successful therapy, whilst preventing over- or under-treatment, it is crucial to 
take into account all aspects of  the individual patient and her disease. Above all, it is important to engage a 
patient in her own disease and treatment decision-making processes.
Predicting individual outcomes in breast cancer
Prognosis in medicine means estimating the probability or risk of  a future outcome in an individual based 
on his or her characteristics. In daily clinical practice, a doctor will, directly or indirectly, make use of  an 
array of  elements to estimate the risk or probability of  a certain outcome in an individual patient. In clinical 
trials, it is equally important to account for these characteristics using prognostic and predictive models in 
order to allow for more accurate estimations for individual patients. Using different cohorts of  endocrine-
sensitive, postmenopausal early breast cancer patients (Tamoxifen Exemestane Adjuvant Multinational 
(TEAM), Investigation on the Duration of  Extended Adjuvant Letrozole (IDEAL), and TEAM IIA trials), 
we studied several prognostic and predictive factors associated with outcomes of  endocrine treatment.1, 2 
Tumor- and patient-specific factors
Endocrine-sensitive breast tumors, characterized by the expression of  hormone receptors (estrogen receptor 
(ER) and/or progesterone receptor (PR)) on the cell surface, grow under the influence of  estrogen and/or 
progesterone. In postmenopausal breast cancer patients, anti-estrogens (tamoxifen and aromatase inhibitors 
(AIs)) are the mainstay of  endocrine treatment and, at present, are prescribed either as sequential treatment 
consisting of  tamoxifen followed by an AI, or as upfront treatment with an AI for a total of  5 years.2-6 
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Over the last few years, accumulating evidence is showing improvements in long-term survival when 
treatment with AIs is continued beyond the standard 5-year treatment period, although it is insufficiently 
clear for which patients extended adjuvant endocrine therapy is suitable, and the optimal duration thereof  
in terms of  offering maximal survival benefit with minimal toxicities.7, 8 Primarily, however, it is essential 
to emphasize the importance of  successfully completing the initial 5-year treatment period in the absence 
of  disease relapse and with the best possible prognosis, while taking into consideration individual QOL 
and treatment compliance issues. The studies included in this thesis largely focus on determining the best 
endocrine therapy regimen for each individual, based on different patient- and tumor-specific features.
Based on national and international treatment guidelines, adjuvant endocrine therapy is generally prescribed 
in patients whose tumors express a certain level of  hormone receptors, although currently no distinction is 
made between quantitative hormone receptor expression with respect to preference for either a sequential 
or upfront endocrine treatment regimen.9, 10 Analysis of  Dutch and Belgian patients included in the TEAM 
trial showed a preferential treatment benefit for exemestane upfront in patients whose tumors displayed 
a relatively high level of  ER expression (Allred score 7 and 8), while a sequential treatment regimen was 
more beneficial in tumors with lower levels of  ER expression (Allred score ≤6)(chapter 3).11 In considering 
the mechanism for these findings, greater estrogen dependency and the reduction in ER expression during 
tamoxifen treatment may play an important role.12 In breast tumors, ER expression is heterogeneous and it is 
possible that, through clonal selection, primary treatment with tamoxifen allows for the selective survival of  
tumor cells lacking ER expression.12 As tolerability and effectiveness of  tamoxifen treatment may diminish 
following ER down-regulation, the effect of  switching to an AI may instigate a new and enhanced response 
that counters estrogen-induced tumor growth in patients with lower levels of  ER expression. More detailed 
documentation and utilization of  quantitative ER expression in the clinical setting could therefore provide 
further tailored treatment recommendations and improve outcomes for individual patients.
After menopause, the main source of  estrogen is the body’s adipose tissue. A direct relationship has been 
established between body-mass index (BMI, kg/m2) and levels of  circulating estrogens.13 As obesity is 
associated with heightened estrogen synthesis, as well as hormone-dependent breast cancer growth,14-16 it is 
conceivable that adiposity could contribute to lower efficacy of  treatment with AIs. There have been several 
studies regarding the influence of  obesity on survival after breast cancer.15, 17, 18 Our study of  patients with 
available BMI data in the international TEAM trial did not show an association between BMI and survival.
(chapter 4) Furthermore, there was no evidence of  a preferential treatment benefit for sequential or upfront 
endocrine treatment in different BMI categories. Some of  the major trials comparing different endocrine 
therapy regimens have also touched upon the issue of  BMI in relation to preferential treatment benefit, 19-22 
but results vary tremendously. A direct comparison of  the results of  these studies is limited by the diversity 
of  BMI cut-off  points, and a meta-analysis of  the major studies would be justified. To add, a better insight 
into the role of  adjusting the prescribed doses of  endocrine treatment may also be relevant.
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With respect to other, potentially modifiable, lifestyle factors, physical activity (PA) can play an important 
role in improving breast cancer outcomes. PA contributes to benefiting daily physical, emotional and social 
functioning, with a subsequent positive effect on QOL as well as reducing the burden of  side-effects arising 
from endocrine treatment.23, 24 Particularly in the aging population, a decline in physical functioning is also 
associated with decreased social functioning, subsequent worsening of  QOL as well as increased mortality.25, 
26 Few studies, however, have addressed the role of  PA in affecting breast cancer survival. In our systematic 
review (chapter 5), we found that PA significantly improved overall survival as well as breast cancer-specific 
survival in elderly patients.27 In addition, our analysis regarding PA in the TEAM-Lifestyle side-study 
(chapter 6) showed that overall survival improved in patients who were physically active before and after 
breast cancer diagnosis. In older patients especially, pre-diagnosis PA revealed better overall survival. 
Quality of  life, treatment compliance and side effects
In considering the individual breast cancer patient with an indication for adjuvant endocrine treatment, 
maximal effectiveness can only be achieved if  the patient also maintains a good QOL while adhering to 
her prescribed treatment regimen. Side effects of  adjuvant endocrine treatment can seriously hamper daily 
functioning and QOL of  breast cancer patients, and are the greatest cause of  non-compliance to endocrine 
treatment. Approximately half  of  all patients prescribed adjuvant endocrine treatment discontinue before 
the pre-designated end-date.28 As observed in our study on compliance to extended adjuvant endocrine 
therapy (chapter 9), an additional 20% of  patients discontinue treatment in this setting.7 Considering that 
the goal of  (extended) adjuvant endocrine therapy is to further improve individual survival outcomes, it is 
important to address alternative ways of  reducing toxicities and improving compliance while maintaining 
maximal QOL and treatment benefit. 
Insight into the different side effects associated with endocrine therapy and understanding its impact on 
QOL and daily functioning is essential, given the growing acceptance of  extended adjuvant endocrine 
treatment durations (chapter 8). In clinical practice, it is important to carefully weigh potential treatment 
benefits against potential sacrifices in QOL and daily functioning. It is likely that a combination of  patient- 
and/or tumor-biological as well as lifestyle mechanisms contributes to the presence and severity of  AEs, 
and understanding the underlying mechanism for the manifestation of  AEs in some, but not all patients is 
of  much clinical interest.
When determining the optimal endocrine treatment strategy while maintaining QOL, a patient’s 
susceptibility to these specific AEs of  treatment is seldom taken into account. With respect to AIs, several 
specific side-effects, including vasomotor symptoms (hot flashes, night sweats) and musculoskeletal symptoms, 
may derive from the body’s response to a further reduction in circulating estrogen levels.29 Accordingly, we 
predicted that specific side effects of  endocrine treatment may be related to improved endocrine treatment 
outcomes, while taking into account confounders such as non-compliance. Longer survival was noted in 
patients who reported one or more specific AEs (vasomotor symptoms and/or musculoskeletal AEs) than 
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patients who did not report these symptoms (chapter 10 and chapter 11).30, 31 Some critics have suggested that 
reporting is selective, and patients who report their AEs may be inherently different from patients who do 
not report these specific AEs. For example, patients who report specific side effects are more likely to engage 
in other healthy lifestyles, which could contribute to better outcomes than in women who do not report 
these symptoms.32 It is plausible, however, that the majority of  reported side effects does not distinguish 
patients by their lifestyle habits. Bearing this in mind, we performed additional analyses which revealed 
that survival outcomes were still superior for patients with specific AEs when compared with patients who 
reported nonspecific AEs and patients who did not report any AE separately (data not shown).33
Not all patients undergoing endocrine therapy will develop specific AEs, implying that AEs may also be the 
result of  variable estrogen levels in AI-treated patients. Polymorphisms in the aromatase gene, CYP19A1, 
have been associated with differences in circulating estrogen concentrations previously34, and may be 
related to the diversity of  responses to AIs among breast cancer patients.35 CYP19A1 gene polymorphisms 
may thus play a causal role in the development of  specific AEs. This hypothesis was tested in chapter 
12, which revealed that specific AEs were more commonly reported by patients who expressed one of  
three CYP19A1 variants. Genetics-based treatment decisions have rapidly advanced in recent years and 
companies now market genetic tests (such as Oncotype DX and Mammaprint) capable of  predicting added 
benefit of  treatment based on a tumor’s genetic profile.36 With these tests, patients and doctors alike use this 
information to weigh potential treatment advantages with important lifestyle and QOL issues. For patients, 
it signifies more insight and fewer feelings of  uncertainty about the risk of  disease recurrence, and with this 
data, patients can better understand their disease process and actively engage themselves in the treatment 
decision-making process.
Dynamic prediction
The various studies described in this thesis demonstrated that several conventional and unconventional 
clinical factors are associated with predicting treatment success, QOL, and survival in postmenopausal, 
endocrine-sensitive early breast cancer patients. The majority of  determinants that influenced individualized 
treatment decisions were based on patient- and tumor-specific features that were measured at the time of  
diagnosis or at the start of  adjuvant endocrine treatment. In considering individualized treatment strategies, 
it is also important to re-evaluate a patient’s health and disease status during treatment and over time, using 
this knowledge to modify therapy where deemed necessary. As described in chapter 7, current statistical 
models still fall short of  taking into account changes in a patient’s health status or the occurrence of  specific 
events throughout the course of  treatment, which may alter previously predicted survival outcomes. The 
following example illustrates our need for better prediction models for all cancer patients. We consider our 
69-year-old postmenopausal breast cancer patient from chapter 7 who was diagnosed with a grade III, 
1.5cm, ER- and PR-positive tumor two years earlier. At the time, she underwent breast-conserving surgery, 
adjuvant radiotherapy and chemotherapy, and started adjuvant endocrine therapy. During her regular 
yearly visit she tells that she is suffering a number of  side effects and discusses the possibility of  discontinuing 
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her endocrine treatment. At the time of  diagnosis two years earlier, the woman and her physician solicited 
Adjuvant!37 to calculate her probability of  being alive 10 years later. Without additional chemotherapy or 
endocrine therapy, this probability was 38.9%, and with additional chemotherapy and endocrine therapy 
meant an additional 12.7% chance of  being alive 10 years later. What Adjuvant! could not take into account 
at that time was whether this patient’s survival probability would still be the same two years later. Does this 
woman still have a 38.9% chance of  being alive 10 years after her initial breast cancer diagnosis? Two years 
earlier it was not possible to know whether this woman would suffer a relapse, or that she might discontinue 
endocrine treatment because of  side effects that obstructed her QOL and daily functioning. 
Time has shown to play a vital role in predicting as well as modifying survival outcomes, and in our 
endeavour to tailor treatment to the individual patient, the occurrence of  events and the capacity for a 
patient’s health and disease status to change over time is frequently neglected. Furthermore, it is important 
to keep in mind that the individual’s QOL and daily functioning can be seriously affected by endocrine 
treatment, and dynamic prediction can help the patient and her doctor weigh the benefits and harms of  
discontinuing treatment against improvements in QOL. We have developed a clinically applicable dynamic 
prediction model which incorporates the key factor, time, into a survival model for breast cancer patients. 
Although external validation and fine-tuning of  this prediction model needs to be performed, our analysis 
reiterates the importance of  continuously re-evaluating the previously prescribed treatment regimens. It 
is our obligation as physicians to help patients weigh the benefits and detriments of  treatment against 
mortality risk and personal preferences during this long-term treatment relationship in order to attain the 
best possible treatment advice, tailored to suit the individual’s needs. 
Dynamic prediction can be considered a novel concept that provides more sophisticated estimates of  survival 
probabilities based on a more realistic reflection of  the course of  a patient’s health and disease status over 
time. At present, we are developing a more refined, user-friendly, web-based dynamic prediction tool that 
can be accessed during clinical follow-up visits so as to re-evaluate and, where necessary, modify individual 
treatment recommendations. Implementing and improving dynamic prediction in current clinical practice 
entails expanding existing multidisciplinary as well as national and international collaborations in order to 
develop better models based on more extensive datasets. Ultimately, these models will help guide patients 
and clinicians during the course of  treatment, not only with respect to breast cancer, but over the full scope 
of  clinical oncology, and likely, other ‘chronic’ conditions.
Pre-operative treatment
The final part of  this thesis is dedicated to pre-operative (neoadjuvant) systemic treatment for breast cancer 
patients and the role of  the sentinel lymph node biopsy (SLNB) in this context. Neoadjuvant treatment 
allows for downsizing and downstaging of  large (≥2cm) or locally advanced and/or inoperable primary 
tumors prior to surgical resection. In addition, neoadjuvant treatment provides the convenience of  efficiently 
gaining insight into the effects of  systemic treatment on various biochemical, molecular and histological 
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tumor features, on the basis of  which valuable biomarkers can be identified and clinical decisions can be 
made. 
In some patients, it can be challenging to determine the best neoadjuvant treatment regimen. Neoadjuvant 
chemotherapy may not be the most appropriate treatment option for elderly and/or frailer patients, as 
well as in patients whose tumors have high levels of  ER expression. Especially in these kinds of  patients, 
neoadjuvant endocrine treatment has been proposed as a valid alternative to neoadjuvant chemotherapy. 
In strongly endocrine-sensitive breast cancer patients, neoadjuvant endocrine therapy is gaining popularity, 
although there remains considerable uncertainty about issues such as the optimal treatment duration and 
the most suitable modality for response assessment. Neoadjuvant endocrine therapy trials have typically 
treated patients for 3 or 4 months prior to surgery, but emerging evidence suggests that longer treatment 
durations are feasible and that tumors continue to regress during longer treatment periods, without serious 
threats concerning safety and toxicity. In our phase II trial, we observed sustained tumor downsizing as 
well as more breast conservation (chapter 14). Similar results were described in our earlier review of  the 
literature on neoadjuvant endocrine therapy (chapter 13), with maximal responses when treatment was 
extended beyond 3-4 months.38 Our results strongly suggest that treatment periods of  at least 6 months 
should be sought after in clinical practice. 
The role and timing of  the sentinel lymph node biopsy (SLNB) as well as the axillary lymph node dissection 
(ALND) in the context of  neoadjuvant treatment still prompts much debate, and clinical guidelines are 
largely lacking or inconclusive.9, 39, 40 The SLNB was originally introduced to accompany surgical tumor 
excision as a means of  specifying disease stage and prognosis, as well as to guide further treatment decisions 
concerning systemic, locoregional and additional surgical intervention. As neoadjuvant treatment causes 
a shift in the timing of  surgery, it may seem logical to perform the SLNB at the moment of  primary 
surgery. Needless to say, some have argued that neoadjuvant chemotherapy can reduce staging accuracy 
of  the sentinel lymph node, although the clinical implications may be slightly overstated. Potential under-
treatment resulting from increased false-negative rates may not be as relevant, as the decision to administer 
systemic treatment has already been made and the risk of  developing an axillary recurrence after a 
positive SLN without an additional ALND is low.41 Yet the risk of  surgical over-treatment and the impact 
of  additional comorbidity following surgical intervention is significant. With the advent of  neoadjuvant 
systemic treatment as an important contributor to current breast cancer treatment, it is justified to adjust 
surgical treatment if  downstaging of  the tumor and axilla has occurred.
Tailored endocrine treatment - a pursuable goal?
“Individualization of  drug therapy is an evolution, not a revolution”, was the statement by Lesko and 
Schmidt 42, who describe that ‘personalized’ apothecary practice dates back to 2600 B.C. as evidenced by 
medical texts and prescriptions written on clay tablets.42 Although up until the late 19th and early 20th 
centuries the concoction of  formulations to treat the individual patient was common practice, the expansion 
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of  our medical knowledge and intensified production of  one-size-fits-all treatments made way for more 
efficient drug development and the evolution of  evidence-based medicine which now sets the standard for 
new treatments. With the advent of  evidence-based medicine, some critics convey that the use of  clinical 
trials does not truly allow for personalized medicine as the majority of  these trials maintain strict in- and 
exclusion criteria in which case only a certain subset of  patients can be included and results cannot be 
applied to the more general population.42, 43 
Personalized medicine requires more than an overall cohort benefit. In modern medicine, we have reached 
a tipping point, where treatment decisions based on large clinical trials and overall treatment benefits for 
large groups of  patients are replaced by more complex models targeting individual patients. In addition, the 
physician’s individual clinical expertise as well as the patient’s more active involvement with her condition in 
order to convey important issues driving individual preferences and maximizing the probability of  successful 
treatment have become an integral part of  a treatment plan.
In current clinical practice, there is a need for more accurate and easily accessible personalized prediction 
models that surpass the currently available selection of  genetic tests such as Mammaprint and OncotypeDX.36 
A major limitation of  genetic tests is that they lack the capacity to account for issues associated with daily 
functioning in individual patients, including QOL, compliance, and side effects. We demonstrated that 
patients vary in their responses to endocrine therapy. The studies that make up this thesis show that we are 
capable of  combining a wide range of  patient- and tumor-specific features into a single model that offers 
opportunities to adjust treatment advice over time, aimed at further personalized medicine. Moreover, the 
presented dynamic prediction model can help empower individual patients to convey personal preferences 
and partake in their own treatment decisions in order to put into perspective side effects and QOL aspects 
beside treatment benefit. For the scientific community, the need for solid prediction models underlines the 
importance of  further in-depth investigations and more large-scale collaboration to permit additional fine-
tuning of  our dynamic prediction model for an even broader target audience. Based on statistics, we can 
establish the best objective outcome for the disease, but based on an array of  unique characteristics, we can 
provide the best care for the individual patient.
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S U M M A R Y  O F  T H E  R E S E A R C H
This thesis describes several important aspects of  adjuvant endocrine therapy for postmenopausal women 
with endocrine-sensitive, early-stage breast cancer. In our ongoing efforts to tailor treatment so as to provide 
the best possible care for each of  our patients, we studied the influence of  various tumor- and patient-
related factors on outcomes of  adjuvant endocrine therapy. These factors include quantitative hormone 
receptor expression, body weight, age and physical activity, changes in prognosis over time, quality of  life, 
treatment compliance, treatment-specific side effects, and single nucleotide polymorphisms (SNPs) of  the 
aromatase gene (CYP19A1). The results of  these studies contribute to further individualization of  hormone 
receptor-positive early breast cancer and can improve survival outcomes while maintaining a good quality 
of  life. In addition, the effect of  preoperative (neoadjuvant) endocrine therapy in strong endocrine-sensitive, 
postmenopausal breast cancer patients is described. Finally, this thesis includes a chapter on the optimal 
timing of  the sentinel lymph node procedure in breast cancer patients treated with neoadjuvant systemic 
therapy in general.
Approximately 75% of  postmenopausal breast cancer patients have tumors that grow under the influence 
of  the hormone estrogen, and are thus classified as endocrine-sensitive. These tumors are characterized by 
the presence of  hormone receptors (estrogen receptors (ER) and/or progesterone receptors (PR)) lining the 
tumor cells. The decision to administer adjuvant endocrine therapy is largely dependent on the presence 
and level of  expression of  these hormone receptors, after earlier studies revealed that endocrine therapy 
is most effective in patients whose breast tumors express these receptors. Adjuvant endocrine therapy for 
postmenopausal, endocrine-sensitive early breast cancer patients is generally prescribed for a period of  
5 years or more. In the early years of  adjuvant endocrine therapy, the anti-estrogen, tamoxifen, initially 
prescribed for 2, and later 5 years, significantly improved breast cancer survival when compared with no 
treatment at all. Later, with the introduction of  aromatase inhibitors, also prescribed for five years or following 
2-3 years of  tamoxifen treatment (either regimen totaling 5 years of  treatment), further improvements 
in prognosis were established in these patients. More recently, studies have revealed that the addition of  
aromatase inhibitors for additional 2 to 5 years after 5 years of  tamoxifen provides an even greater survival 
benefit in high-risk patients.
Part I – Patient- and tumor-specific characteristics
Part I of  this thesis concerned the identification of  a variety of  factors that drive breast cancer outcomes 
in postmenopausal, endocrine-sensitive patients who participated in the Tamoxifen Exemestane Adjuvant 
Multinational (TEAM) trial. In the TEAM trial, patients who had undergone adequate local treatment 
were randomized to receive either sequential therapy (2-3 years of  tamoxifen followed by 3-2 years of  the 
aromatase inhibitor, exemestane) or five years of  exemestane. The TEAM trial was executed in nine different 
countries and included 9779 breast cancer patients, of  which 3168 were included in the Netherlands and 
Belgium. Central data management was carried out at the Datacenter of  the Department of  Surgery at 
Leiden University Medical Center in the Netherlands. In 2011, the main results of  the TEAM trial were 
published in the Lancet: there were no differences in disease-free survival (DFS) between the two study 
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groups. Central revision of  the available tumor material following publication of  the main manuscript has 
provided opportunities for further biomarker research.
In chapter 1, we provide a general introduction of  adjuvant endocrine therapy, its development over time 
and its application for treating postmenopausal, endocrine sensitive breast cancer patients. In chapter 2, we 
made use of  the centrally reviewed tumor material of  patients included in the Dutch and Belgian TEAM 
trial cohort to study the influence of  several tumor-specific biomarkers (ER, PR, and human epidermal 
growth factor receptor 2 (HER2)) on endocrine treatment efficacy. Treatment with upfront exemestane 
resulted in a better DFS than sequential treatment in women whose tumors expressed high levels of  the ER. 
In chapter 3, survival outcomes were studied in relation to histological subtype (ductal or lobular breast 
cancer) in Dutch and Belgian TEAM trial patients (n=3168). We compared the two treatment regimens in 
relation to histological subtype and quantitative ER expression (based on the Allred score). The Allred score 
evaluates the percentage and intensity of  tumor cells staining positively for hormone receptors (ER and PR). 
Lobular breast tumors frequently express higher levels of  ER when compared to ductal breast tumors and 
may thus show better survival outcomes. Although our results, did not reveal any differences in efficacy of  
the two endocrine treatment regimens between patients with ductal and lobular breast cancer, patients who 
were considered ER-rich, regardless of  histological subtype had better outcomes when treated with 5 years 
of  exemestane, while the sequential treatment regimen was superior for ER-poor patients. 
Obesity, defined as a body-mass index (BMI, kg/m2) of  ≥30, has been related to increased estrogen synthesis 
as well as to hormone-dependent breast cancer growth. After termination of  ovarian estrogen synthesis after 
menopause, estrogen production occurs in other tissues, including adipose tissue. It has been suggested that 
the increased estrogen synthesis in obese patients could reduce the efficacy of  adjuvant endocrine therapy, 
especially pertaining to aromatase inhibitors. Aromatase inhibitors function by lowering the conversion of  
androgens to estrogens. In chapter 4, BMI was studied in relation to breast cancer outcomes in postmenopausal, 
endocrine-sensitive, early breast cancer patients in the international TEAM cohort. BMI data were available 
for 4711 patients (median BMI 26.2 kg/m2 (SD 6.68)). 29.7% of  patients were normal-weight (BMI between 
18.5 and 25 kg/m2), 28.2% were overweight (BMI between 25 and <30 kg/m2), and 17.5% were obese (BMI 
between >30 and 45 kg/m2; 24.6% of  patients were missing BMI data). After a follow-up of  6.5 years, no 
differences in 5-year DFS or breast cancer-specific survival (BCSS) were observed between the treatment 
arms in relation to BMI, which is in contrast to what is generally reported in the currently available literature. 
The lack of  a statistically significant differences between the two treatment arms in relation to BMI may be 
due to the relatively short follow-up period. It is also possible that adiposity negatively influences effectiveness 
of  aromatase inhibitor treatment, which could explain the absence of  a preferential benefit for upfront 
exemestane therapy in overweight and obese patients in our cohort. 
In studying so-called ‘modifiable’ variables that can improve breast cancer outcomes as well as QOL, physical 
activity is an element where the individual patient can play an active role. In chapters 5 and 6, we investigated 
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the influence of  physical activity (PA) on breast cancer outcomes. First, we performed a systematic review 
of  the available evidence on the relation between physical activity and survival in postmenopausal breast 
cancer patients, which is described in chapter 5. Seventeen studies (n=497) investigated physical activity in 
relation to overall survival (OS), DFS and/or BCSS and met the inclusion criteria. In this review, we showed 
that, in older breast cancer patients, any form of  physical activity improved the aforementioned survival 
outcomes. In chapter 6, we studied physical activity in relation to breast cancer recurrence and survival in 
the TEAM-Lifestyle side-study (n=521) using the validated European Prospective Investigation into Cancer 
Physical Activity Questionnaire. Metabolic Equivalent Task (MET)-hours, a measure of  the intensity and 
duration of  a particular activity, were used to study physical activity in relation to OS and BCSS. 521 Dutch 
and Belgian TEAM trial patients completed questionnaires 1 and 2 years following breast cancer diagnosis, 
and the number of  hours spent on various activities (walking, cycling, gardening, household activities and 
sport, both before and after breast cancer diagnosis) were recorded. Our results showed that physical activity, 
both before and after breast cancer diagnosis, improved OS, especially in women over the age of  65 years.
Predictive models based on patient- and tumor-specific characteristics at the time of  breast cancer diagnosis 
are commonly used to help make decisions regarding adjuvant systemic therapy. When considering long-
term endocrine treatment, however, certain events that can have an effect on prognosis (such as early 
treatment discontinuation or disease recurrence) may occur during the course of  endocrine treatment. 
Furthermore, the impact of  certain patient- and tumor-specific characteristics (such as age, HER2 status 
and nodal status) on prognosis have shown to vary over time. Surprisingly, cancer prediction models to 
date have never before accounted for these prognosis-modifying events, therefore long-term outcome 
predictions are limited. Chapter 7 describes an innovative dynamic prediction model based on Dutch and 
Belgian TEAM trial patients and which consolidates conventional ‘static’ variables with time-changing and 
time-varying ‘dynamic’ variables. This dynamic prediction model shows us that as the time since diagnosis 
elapses, predictions concerning a patient’s prognosis, in fact, need to be updated. Patients and their doctors 
can utilize this model throughout endocrine treatment in order to adjust treatment strategies and/or lifestyle 
behaviors where reckoned necessary in order to improve prognosis and maintain quality of  life. Although 
external validation and further fine-tuning of  the dynamic prediction model is still awaited (and awaiting 
longer follow-up), this model is informative and it is conceivable that it will lead to the development of  more 
elaborate dynamic prediction models that can be consulted in clinical practice. 
Part II – Quality of  life, treatment compliance and side effects
Part II of  this thesis addressed a variety of  issues concerning adjuvant endocrine therapy that influence 
treatment outcomes for individual patients. Adjuvant endocrine therapy is associated with a variety of  
side effects that, in addition to the psychological impact of  the diagnosis breast cancer per se, can be of  
detriment to treatment compliance and significantly impair quality of  life (QOL) and daily functioning in 
breast cancer patients. Determining which elements of  QOL and daily functioning carry more weight than 
others is key when selecting the most appropriate treatment regimen, and chapter 8 describes differences in 
QOL of  543 Dutch TEAM trial patients who participated in the TEAM-Lifestyle side study (study setup 
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described above for chapter 6). No differences in overall QOL were found between the two randomized 
endocrine treatment regimens. However, emotional and sexual functioning, as well as symptoms of  fatigue, 
insomnia and shortness of  breath were statistically significantly worse in women treated with exemestane 
compared to women treated with tamoxifen. Only those differences pertaining to fatigue were considered 
clinically relevant. Importantly, our study also revealed that overall QOL as well as the majority of  
functioning and symptom scales improved between the 1st and 2nd measurements in the TEAM-Lifestyle 
side study. This implies that improvement and/or habituation occurs and can be of  use to those involved in 
the care of  women experiencing these symptoms.
QOL also plays an important role in early treatment discontinuation and non-compliance, particularly with 
regard to long-term treatment. Previous studies have shown that 40% to 60% of  patients undergoing adjuvant 
endocrine treatment discontinue within the first 5 years. Simultaneously, there is accumulating evidence that 
longer endocrine treatment durations are beneficial for breast cancer survival. The IDEAL (Investigation on 
the Duration of  Extended Adjuvant Letrozole) study investigates the efficacy of  extended adjuvant letrozole 
treatment (2.5 versus 5 years), after 5 years of  adjuvant endocrine therapy in postmenopausal early breast 
cancer patients. Because non-compliance can significantly influence treatment success in some patients, we 
investigated how many patients discontinued letrozole treatment and reasons therefore in chapter 9. Out of  
1215 studied patients, 18.4% were non-compliant within the first 2.5 years of  extended treatment. In more 
than 85% of  the cases, non-compliance was caused primarily by debilitating adverse events (AEs). Risk 
factors for early treatment discontinuation were: prior treatment with either tamoxifen or exemestane alone, 
a longer treatment-free interval between the first 5 years of  adjuvant treatment and the start of  letrozole, 
and low-risk nodal stage at diagnosis. Age was not a risk factor for non-compliance. 
Hot flashes and night sweats (collectively known as vasomotor symptoms) as well as musculoskeletal adverse 
events are frequently occurring side effects of  aromatase inhibitors and may be related to further lowering 
of  circulating estrogen levels in postmenopausal women. We investigated the intricate relationship between 
specific adverse events and treatment efficacy in patients who experience these specific side effects in 
chapters 10 and 11, first in the Dutch/Belgian cohort and subsequently in the international TEAM trial 
cohort. In both studies, we found that women who reported vasomotor symptoms and/or musculoskeletal 
adverse events had a better DFS than women who did not report these symptoms (respective hazard ratios 
(HR) 0.731 (95% confidence interval (CI) 0.616-0.866) and 0.826 (95%CI 0.694-0.982)). The strongest 
effect was found in patients who reported vasomotor symptoms. These data conclude that specific side 
effects of  adjuvant endocrine treatment are associated with better survival outcomes and can be used in 
clinical practice to predict endocrine treatment efficacy. 
It has yet to be discovered why some women undergoing adjuvant endocrine treatment develop specific 
adverse events while others do not. One hypothesis for the presence of  these specific adverse events in 
some patients, but not in others, is that genetic variants in the aromatase gene (CYP19A1) drive differences 
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in aromatase inhibitor metabolism and hence, treatment effectiveness. In chapter 12, we study genetic 
variations (‘single nucleotide polymorphisms’; SNPs) of  the aromatase gene (CYP19A1) in relation to 
the occurrence of  the abovementioned specific adverse events. Using a ‘tagging SNP’ approach, we were 
able to study approximately 80% of  the CYP19A1 gene for genetic variants. Based on the results of  737 
exemestane-treated Dutch TEAM trial patients, 3 SNPs (rs934635, rs16964189 and rs7176005) were found 
to be associated with reporting specific adverse events. These hypothesis-generating results require further 
investigation before implementation in clinical practice.
Part III – Pre-operative and operative treatment
In Part III of  this thesis, we focus on the role of  pre-operative, or neoadjuvant, systemic therapy as part of  
personalized breast cancer treatment. Neoadjuvant systemic therapy can be used to downsize and downstage 
large (or inoperable) tumors before surgical resection. In recent years, neoadjuvant treatment has facilitated 
in studying a tumor’s ‘in-vivo’ response to systemic treatment and in monitoring changes in biomarkers for 
the development of  novel targeted treatments. Neoadjuvant chemotherapy (NCT) is now well-integrated in 
current clinical practice, although studies have also shown that the effectiveness NCT decreases in stronger 
ER-positive tumors. Therefore, neoadjuvant endocrine therapy, also known as neoadjuvant hormonal therapy 
(NHT), with aromatase inhibitors has rapidly been gaining recognition for strongly endocrine-sensitive breast 
cancers as well as for patients who are considered unsuitable for neoadjuvant chemotherapy. The time it takes 
for a tumor to attain maximal response is, however, longer for NHT than for NCT, and no consensus has been 
reached as of  yet concerning the optimal duration of  neoadjuvant treatment with aromatase inhibitors. In 
previous clinical studies, patients have commonly been treated for 3-4 months, although our systematic review 
(chapter 13) presented ample evidence for the beneficial effect of  longer endocrine treatment durations on 
sustaining further reductions in tumor size. In the TEAM IIA study, we investigated the tumor downsizing 
and down-staging in 102 strongly endocrine sensitive (>50% ER positivity), postmenopausal breast cancer 
patients treated with neoadjuvant exemestane for more than 3 months (chapter 14). After a median treatment 
duration of  5.78 months, this study confirmed a continuing reduction in tumor size after 3 months of  NHT. It 
was concluded that in strongly ER-positive breast cancer patients who are eligible for NHT and whose tumor 
response to neoadjuvant therapy, the treatment should be continued beyond 3 months. 
In chapter 15, the timing of  the sentinel lymph node biopsy (SLNB) and the necessity of  performing a 
completion axillary lymph node dissection (ALND) in patients undergoing neoadjuvant systemic treatment 
was investigated, as there is no clear consensus on this topic. The SLNB replaced the conventional ALND 
at the end of  the last century and is now used for axillary staging. An additional advantage is that a 
number of  women now do not need to undergo an ALND, which has also lead to a significant decrease 
in the comorbidities associated with an ALND. Neoadjuvant systemic treatment is generally prescribed 
to achieve tumor downsizing as well as downstaging, with subsequent surgical resection. An advantage of  
performing the SLNB after completion of  neoadjuvant treatment is that all surgery can be performed in 
a single surgical procedure. Our systematic review revealed that the SLNB can be safely performed after 
neoadjuvant treatment in both clinically node-positive and node-negative patients.
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A variety of  different elements that contribute to the intricate web of  personalized breast cancer treatment 
are presented in this thesis. Chapter 16 discusses the findings presented in the different studies in the context 
of  personalized therapy. Aside from the known tumor-specific characteristics that determine whether or not 
to prescribe adjuvant endocrine therapy, we show how a variety of  patient-, treatment-, and tumor-specific 
specific characteristics are also important drivers of  adjuvant endocrine treatment success. In particular, our 
study of  dynamic prediction marks a pivotal point in oncology research, presenting a novel way of  continual 
evaluation of  endocrine treatment benefit in individual patients.
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N E D E R L A N D S E  S A M E N V A T T I N G
In dit proefschrift wordt ingegaan op verschillende aspecten van adjuvante hormonale therapie bij de 
postmenopauzale vrouw met een hormoongevoelig mammacarcinoom. De bestudeerde aspecten betreffen 
patiënt-gerelateerde en tumor-gerelateerde factoren, waarbij de mate van hormoonreceptorexpressie, het 
lichaamsgewicht, het effect van fysieke activiteit in relatie tot de leeftijd, de verandering van de prognose 
tijdens follow-up, kwaliteit van leven, therapietrouw, de relatie tussen het optreden van wel of  geen specifieke 
bijwerkingen en impact van kiembaanveranderingen in het aromatasegen (CYP19A1) tijdens de behandeling 
met hormonale therapie aan de orde komen. De resultaten beschreven in de verschillende studies van 
dit proefschrift dragen bij aan een verdere geïndividualiseerde behandeling van het hormoongevoelig 
mammacarcinoom bij de postmenopauzale vrouw, met als doel verhogen van de overlevingskansen met 
behoud van kwaliteit van leven. Daarnaast wordt ingegaan op het effect van preoperatieve (neoadjuvante) 
hormonale therapie bij de postmenopauzale vrouw met een hormoongevoelig mammacarcinoom en tot 
slot, het optimale tijdstip voor het uitvoeren van de schildwachtklierprocedure bij vrouwen die behandeld 
worden met neoadjuvante systemische therapie in het algemeen.
Bij ongeveer 75% van de postmenopauzale vrouwen met borstkanker is er sprake van een hormoongevoelig 
mammacarcinoom. De tumor groeit in deze gevallen onder invloed van het vrouwelijk hormoon oestrogeen 
en wordt gekenmerkt door de aanwezigheid van hormoonreceptoren ter hoogte van de tumorcellen. 
In de loop van de tijd is duidelijk geworden dat hormonale therapie met name effectief  is bij patiënten 
met een hormoongevoelige tumor (oestrogeen receptor (ER)-positief  en/of  progesteron receptor (PR)-
positief). De aanwezigheid van deze receptoren, en in het bijzonder de mate van ER positiviteit, vormt de 
basis voor verdere therapeutische beslissingen. Bij postmenopauzale vrouwen met een hormoongevoelig 
mammacarcinoom wordt veelal gekozen voor een adjuvante hormonale behandeling van 5 jaar of  langer. 
Behandeling met tamoxifen, een anti-oestrogeen, werd aanvankelijk gedurende 2, en later 5 jaar gegeven, 
en heeft de prognose bij deze patiënten aanzienlijk verbeterd ten opzichte van de prognose zonder adjuvante 
hormonale therapie. De introductie van aromataseremmers (non-steroidaal: anastrozol, letrozol; steroidaal: 
exemestaan), gegeven hetzij gedurende 5 jaar of  in een sequentie na tamoxifen (voor een totaalperiode van 5 
jaar) resulteerde in een verdere verbetering van met name de ziektevrije overleving. Ondertussen is gebleken 
dat verlengde hormonale therapie voor een verdere periode van 2-5 jaar voor hoog-risico patiënten ook 
meerwaarde heeft.
Deel I – Patiënt- en tumorspecifieke kenmerken
In Deel I van dit proefschrift, werd onderzoek gedaan naar verschillende factoren die mogelijk geassocieerd 
zijn met de effectiviteit van adjuvante hormonale therapie bij postmenopauzale, hormoongevoelige 
borstkankerpatiënten die deelnamen aan de Tamoxifen Exemestane Adjuvant Multinational (TEAM) 
studie. Respectievelijke borstkankerpatiënten die een adequate lokale behandeling kregen en in aanmerking 
kwamen voor adjuvante systemische hormonale therapie werden in de TEAM studie gerandomiseerd 
tussen een sequentiële behandelingsstrategie (2-3 jaar tamoxifen gevolgd door 3-2 jaar exemestaan) en 
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uitsluitend exemestaan gedurende 5 jaar. De TEAM studie was geactiveerd in 9 landen, en includeerde in 
totaal 9779 patiënten, waarvan 3168 in Nederland en België. Centraal datamanagement vond plaats via het 
datacenter Heelkunde van het Leids Universitair Medisch Centrum. In 2011 publiceerde de studiegroep 
het hoofdmanuscript in de Lancet. Na vijf  jaar follow-up werden géén verschillen in ziektevrije overleving 
gevonden tussen de twee behandelingsstrategieën. De centrale revisie van het tumorweefsel bood hierna 
mogelijkheden voor nader biomarker onderzoek.
Hoofdstuk 1 betreft een algemene inleiding over adjuvante hormonale therapie, de doorgemaakte 
ontwikkelingen van de laatste jaren en huidige toepassingen bij postmenopauzale vrouwen met borstkanker. 
In hoofdstuk 2 worden de resultaten beschreven van onderzoek in het Nederlands/Belgische TEAM cohort 
naar de impact van verschillende tumor-specifieke biomarkers (ER, PR, en human epidermal growth 
factor receptor-2 (HER2)) die mogelijk gerelateerd zijn aan de effectiviteit van de verschillende hormonale 
behandelingsstrategieën. Hierbij werd gebruik gemaakt van de resultaten verkregen na centrale revisie van 
het tumorweefsel. Bij vrouwen met borsttumoren met een hoge mate van ER expressie werd een betere 
5-jaars overleving gevonden indien zij behandeld waren met uitsluitend exemestaan in vergelijking met de 
sequentiële behandelingsstrategie. 
In hoofdstuk 3 werd de behandeling met exemestaan vergeleken met de sequentiële behandelingsstrategie 
in respectievelijk ductale en lobulaire tumoren in het Nederlands/Belgische cohort (n=3168), en werd de 
impact van de gekwantificeerde ER expressie (op basis van de Allred score) hierbij geëvalueerd. De Allred 
score voor hormoonreceptoren wordt gekwantificeerd op basis van het percentage positief  aankleurende 
tumorcelkernen en de intensiteit daarvan. Lobulaire borsttumoren zijn vaker sterk ER-positief  in vergelijking 
met ductale tumoren, hetgeen zou kunnen resulteren in een verschillende effectiviteit van de twee onderzochte 
behandelingsstrategieën. Er werden geen statistisch significante verschillen in effectiviteit gevonden tussen 
de twee behandelingen bij ductale en lobulaire tumoren. Een betere ziektevrije overleving werd echter 
wel geobserveerd bij vrouwen met sterk ER-positieve tumoren die behandeld waren met exemestaan ten 
opzichte van een sequentiële behandeling. Bij vrouwen met een minder sterk hormoongevoelige tumor 
resulteerde de sequentiële  behandelingsstrategie tot een betere ziektevrije overleving. 
Obesitas, gedefinieerd als een body-mass index (BMI, kg/m2) van ≥30, is geassocieerd met een 
verhoogde aanmaak van oestrogenen, en hierdoor met hormoon-afhankelijke borstkanker groei. Het 
termineren van de oestrogeenproductie door de ovaria na de menopauze zorgt ervoor dat oestrogeen 
elders wordt geproduceerd, onder anderen in vetweefsel. Bij vrouwen met obesitas kan de verhoogde 
oestrogeenproductie mogelijk leiden tot een verminderde effectiviteit van adjuvante hormonale therapie 
in het algemeen, en aromataseremmers in het bijzonder. Aromataseremmers blokkeren het aromatase 
enzym, hetgeen nodig is bij de omzetting van androgenen naar oestrogenen bij de postmenopauzale 
vrouw, en welke ook in vetweefsel aanwezig is. Hoofdstuk 4 beschrijft de relatie tussen BMI en 
borstkankeruitkomsten voor de twee behandelingsstrategieën in het internationale TEAM cohort. 
BMI data waren beschikbaar voor 4711 TEAM patiënten. De mediane BMI was 26.2 (SD 6.68) en 
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de verdeling in de verschillende BMI groepen was als volgt: 29.7% had een BMI tussen 18.5 en 25 
kg/m2, 28.2% een BMI tussen 25 en <30 kg/m2, en 17.5% tussen 30 en 45 kg/m2. Bij 24.6% van de 
patiënten was er geen BMI data beschikbaar. Na een follow-up van 6.5 jaar werden geen verschillen in 
de 5-jaars ziektevrije en borstkanker-specifieke overleving van de twee behandelingsstrategieën voor de 
verschillende BMI groepen aangetoond, in tegenstelling tot wat er in de recente literatuur is beschreven. 
De afwezigheid van een statistisch significant verschil tussen de twee behandelingsstrategieën is mogelijk 
te wijten aan een vooralsnog te korte follow-up periode en/of  de switch van tamoxifen naar exemestaan 
na ongeveer 2.5 jaar, waardoor eventuele verschillen zouden kunnen afnemen door toevoeging van een 
aromataseremmer. Verder onderzoek hiernaar is dus wenselijk.
Er zijn aanwijzingen dat de uitkomst van borstkanker beter is bij patiënten die fysiek actief  zijn, 
hetgeen suggereert dat de patiënt door beïnvloeding van leefstijlfactoren een actieve en leidende rol 
zou kunnen spelen als het gaat om borstkankeroverleving. In hoofdstukken 5 en 6 werd de invloed van 
fysieke activiteit op de overleving van postmenopauzale borstkankerpatiënten onderzocht. Hoofdstuk 5 
betreft een systematisch overzicht van de bestaande literatuur over de invloed van fysieke activiteit op de 
borstkankeroverleving bij postmenopauzale vrouwen. Op grond van de 17 studies (n=497 patiënten) die 
geïncludeerd werden in het overzicht werd geconcludeerd dat bij oudere vrouwen met borstkanker, enige 
vorm van fysieke activiteit een positieve invloed heeft op de overlevingsuitkomsten. In hoofdstuk 6 maken 
we gebruik van de gegevens verkregen in het kader van de TEAM-Lifestyle nevenstudie. Nederlandse 
patiënten vulden 1 jaar en 2 jaar na de start van de adjuvante hormonale therapie gevalideerde 
vragenlijsten over de kwaliteit van leven en leefgewoonten in. In dit hoofdstuk werd de invloed van 
fysieke activiteit op borstkankeroverleving en borstkanker-specifieke sterfte onderzocht bij 521 patiënten. 
Het aantal uren per week die besteed werden aan de volgende activiteiten: lopen, fietsen, tuinieren, 
huishouden en sport, zowel voor als na de diagnose borstkanker werden omgerekend naar Metabolic 
Equivalent Task (MET-uren), een mate van de duur en intensiteit van verschillende activiteiten. Wij 
toonden in dit hoofdstuk aan dat fysieke activiteit, zowel voor als na de diagnose borstkanker, de algehele 
overleving van postmenopauzale borstkankerpatiënten, in het bijzonder bij vrouwen boven de leeftijd 
van 65 jaar verbeterde. 
Predictieve modellen zijn een belangrijk onderdeel van de dagelijkse praktijk en kunnen faciliteren 
bij het bepalen van de beste behandelingsstrategieën voor individuele patiënten. In de huidige 
klinische praktijk wordt veelal gebruik gemaakt van prognostische modellen die gebaseerd zijn op o.a. 
tumor- en patiënt-specifieke kenmerken op het moment van de diagnose borstkanker. Gedurende de 
langdurige hormonale behandeling kunnen zich echter bepaalde gebeurtenissen (vroegtijdig staken 
van de hormonale therapie, ziekte-recidief  waarvoor eventuele nieuwe behandeling) voordoen die de 
prognose van een patiënte kunnen beïnvloeden. Ook is gebleken dat de impact van bepaalde patiënt- en 
tumorkenmerken (bijvoorbeeld leeftijd, HER2 status en lymfklierstatus) op de prognose niet stabiel is over 
de tijd. Een nadeel van bestaande predictiemodellen bij borstkanker is dat er vooralsnog geen rekening 
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wordt gehouden met deze prognose-modificerende gebeurtenissen en variabelen. In hoofdstuk 7 wordt 
een innovatief  dynamisch predictiemodel voor hormoongevoelige borstkankerpatiënten beschreven, 
ontwikkeld aan de hand van het Nederlands/Belgische TEAM cohort, waarbij conventionele ‘statische’ 
variabelen en nieuwe ‘dynamische’ variabelen worden meegenomen. Uit dit predictiemodel blijkt dat 
naarmate de tijdsperiode vanaf  de diagnose borstkanker vordert, er in feite een nieuwe situatie ontstaat, 
waarbij de prognose van een patiënte opnieuw geëvalueerd moet worden. Dit dynamische predictiemodel 
kan gedurende de hele behandelingsperiode overlevingsvoorspellingen doen en zowel arts als patiënte 
ondersteunen bij beslissingen omtrent de hormonale behandeling op dat moment. Hoewel externe 
validatie in andere patiëntencohorten nog moet plaatsvinden en het model verder uitgewerkt moet 
worden o.a. bij een langere follow-up periode, is het huidige dynamische predictiemodel erg informatief  
en is het niet ondenkbaar dat dit zal leiden tot de uitwerking van dynamische predictiemodellen die voor 
de klinische praktijk ingezet kunnen worden. 
Deel II – Kwaliteit van leven, therapietrouw en bijwerkingen
Deel II van dit proefschrift richtte zich op verschillende patiënt-specifieke en therapie-specifieke 
factoren die individuele uitkomsten kunnen beïnvloeden. De adjuvante hormonale behandeling van het 
hormoongevoelige mammacarcinoom kan immers gepaard gaan met hinderlijke bijwerkingen die de 
therapietrouw, de kwaliteit van leven en het dagelijks functioneren van een patiënte nadelig kunnen 
beïnvloeden. Bij het bepalen van de beste behandelingsstrategie is het nuttig om te weten op welke 
aspecten van de kwaliteit van leven en het dagelijks functioneren, en in welke mate dit een impact heeft 
bij vrouwen met borstkanker. In hoofdstuk 8 werd de kwaliteit van leven van 543 Nederlandse TEAM 
patiënten onderzocht in de TEAM-Lifestyle nevenstudie (studieopzet eerder beschreven bij hoofdstuk 6). 
Er werd geen verschil gevonden in de globale kwaliteit van leven tussen de twee behandelingsstrategieën. 
De resultaten toonden echter wel aan dat vrouwen die behandeld werden met exemestaan statistisch 
significant slechter scoorden met betrekking tot emotioneel en seksueel functioneren, en vaker te maken 
hadden met klachten van moeheid, slapeloosheid en kortademigheid dan vrouwen die tamoxifen 
gebruikten. Het verschil tussen de twee behandelgroepen werd echter alleen als klinisch significant 
beschouwd voor wat betreft slapeloosheid. Informatief, maar ook geruststellend is de observatie dat 
de kwaliteit van leven en de meerderheid van de verschillende functionele en symptoommetingen van 
vrouwen die deelnamen aan het kwaliteit van leven onderzoek tussen de 1e en 2e meting verbeterden, 
hetgeen aangeeft dat er in de loop van de tijd verbetering en/of  gewenning optreedt. Deze informatie is 
belangrijk voor hulpverleners van respectievelijke patiënten die bijwerkingen ervaren.
Meer en meer blijkt uit onderzoek dat adjuvante hormonale therapie binnen de eerste 5 jaar vroegtijdig 
gestopt wordt door 40% tot 60% van de vrouwen die dit geadviseerd krijgen, wat nadelig kan zijn voor de 
overleving en de kans op ziekterecidief. De IDEAL (Investigation on the Duration of  Extended Adjuvant 
Letrozole) studie onderzoekt de effectiviteit van verlengde behandeling met de aromataseremmer letrozol 
(2.5 of  5 jaar) nadat postmenopauzale borstkankerpatiënten al vijf  jaar met adjuvante hormonale therapie 
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zijn behandeld. Het thema therapietrouw is onderzocht in de patiëntenpopulatie (n=1215) van de IDEAL 
studie (hoofdstuk 9), waaruit blijkt dat 18.4% van de vrouwen tijdens de eerste 2.5 jaar van de verlengde 
hormonale therapie vroegtijdig stopten met letrozol. In meer dan 85% van de gevallen was dit vanwege 
bijwerkingen. Risicofactoren voor het vroegtijdig stoppen betroffen: eerdere monotherapie met hetzij 
tamoxifen of  een aromataseremmer, een langer therapievrij interval tussen de eerste 5 jaar van de adjuvante 
behandeling en de start van de verlengde hormonale therapie, en een gunstiger lymfklierstatus bij diagnose. 
Leeftijd was geen risicofactor voor vroegtijdig stoppen van letrozol. 
Opvliegers en nachtzweten (verzamelnaam vasomotorische symptomen) en spier- en gewrichtsklachten 
zijn veel voorkomende bijwerkingen van aromataseremmers en zijn mogelijk gerelateerd aan de verdere 
daling van al lage postmenopauzale oestrogeenspiegels. In hoofdstukken 10 en 11 wordt gerapporteerd 
over de bevindingen naar de relatie tussen deze ‘specifieke bijwerkingen’ en borstkankeroverleving, 
hetgeen werd onderzocht in het TEAM cohort. In zowel het Nederlands/Belgische cohort als in het 
internationale TEAM cohort werd gevonden dat vrouwen die vasomotorische symptomen en/of  spier- 
en gewrichtsklachten rapporteerden een betere ziektevrije overleving hadden dan vrouwen zonder deze 
klachten (respectievelijke hazard ratio’s (HR) 0.731 (95%CI 0.616-0.866) en 0.826 (95%CI 0.694-0.982)). 
Het sterkste effect werd geobserveerd bij vrouwen die vasomotorische symptomen rapporteerden. Deze 
data geven aan dat specifieke bijwerkingen geassocieerd zijn met betere overlevingsuitkomsten en in de 
toekomst mogelijk gebruikt kunnen worden in de klinische praktijk om de effectiviteit van de hormonale 
therapie te voorspellen.
Waarom sommige vrouwen met borstkanker specifieke bijwerkingen ontwikkelen en anderen niet is tot 
op heden niet bekend. In hoofdstuk 12 wordt ingegaan op de verschillende genetische variaties (‘single 
nucleotide polymorphisms’, SNPs) van het aromatasegen (CYP19A1) in relatie tot het optreden van deze 
specifieke bijwerkingen. Met behulp van een zogenaamde ‘tagging SNP’ approach werd ruim 80% van het 
CYP19A1 gen onderzocht voor genetische variaties. Op basis van de resultaten bij 737 met exemestaan 
behandelde Nederlandse TEAM patiënten werd geconcludeerd dat 3 SNPs (rs934635, rs16964189 en 
rs7176005) geassocieerd waren met het rapporteren van specifieke bijwerkingen. Verder onderzoek hiernaar 
is wenselijk, voordat het toepasbaar is in de klinische praktijk.
Deel III – Preoperatieve en operatieve behandelingsmogelijkheden
In Deel III van dit proefschrift werd de rol van preoperatieve (neoadjuvante) systemische therapie als onderdeel 
van de geïndividualiseerde borstkankerbehandeling verder onderzocht. Neoadjuvante systemische therapie 
wordt voorafgaande aan de chirurgische behandeling toegepast om grote of  niet-operabele tumoren in 
grootte of  stadium te doen afnemen, terwijl het ook de mogelijkheid biedt om ‘in vivo’ te beoordelen hoe de 
tumor reageert op de neoadjuvante behandeling. Eerdere studies hebben aangetoond dat de effectiviteit van 
neoadjuvante chemotherapie (NCT) afneemt naarmate tumoren sterker ER positief  zijn. In de laatste jaren 
is de populariteit van neoadjuvante hormonale therapie (NHT) bij sterk hormoongevoelige borstkanker en/
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of  bij patiënten die de behandeling met chemotherapie niet of  moeilijk kunnen verdragen sterk toegenomen. 
De tijd tot maximale tumorrespons is echter langer bij NHT dan bij NCT, en er bestaat op dit moment 
nog geen consensus over de optimale duur van de neoadjuvante behandeling met aromataseremmers. In 
de meerderheid van de studies betreffende NHT met aromataseremmers worden patiënten gedurende 3 tot 
4 maanden behandeld, hoewel er aanwijzingen zijn dat een behandelingsduur van langer dan 3 maanden 
voordelig is bij vrouwen bij wie de afname in tumorgrootte aanhoudt (hoofdstuk 13). In de TEAM IIA 
studie werd de afname in tumorgrootte onderzocht bij 102 sterk hormoongevoelige (>50% ER positiviteit), 
postmenopauzale borstkankerpatiënten die gedurende meer dan 3 maanden behandeld werden met 
neoadjuvant exemestaan (hoofdstuk 14). Na een mediane behandelingsduur van 5.78 maanden werd een 
voortgaande afname in tumorgrootte bij een behandelingsduur van langer dan 3 maanden bevestigd. In 
deze studie werd aangetoond dat vrouwen die langer dan 3 maanden behandeld werden met exemestaan, 
een aanhoudende afname in tumorgrootte plaatsvond, op basis waarvan geconcludeerd kan worden dat 
sterk hormoongevoelige borstkankerpatiënten die in aanmerking komen voor NHT en waarbij de tumor op 
de neoadjuvante behandeling reageert, een behandelingsduur van langer dan 3 maanden dient te worden 
aangehouden.
Hoofdstuk 15 behandelt de vraag wanneer de schildwachtklierprocedure en de eventuele aansluitende 
okselklier-dissectie te verrichten bij patiënten die behandeld worden met neoadjuvante systemische 
therapie, omdat hierover momenteel geen duidelijke consensus bestaat. De introductie van de 
schildwachtklierprocedure voor stadiëring en prognose bepaling heeft in het verleden geleid tot een 
significante daling in de comorbiditeiten die gepaard gaan met een volledige okselklier-dissectie (zowel 
op korte als lange termijn). De neoadjuvante behandeling met systemische therapie wordt veelal 
voorgeschreven om een afname in tumorgrootte of  tumorstadium te bereiken, waarna chirurgische resectie 
van de resterende tumor volgt. Een voordeel van het verrichten van de schildwachtklierprocedure na afloop 
van de neoadjuvante systemische behandeling betekent dat de operatieve verwijdering van de tumor en de 
schildwachtklier in een enkele chirurgische procedure kunnen plaatsvinden. Ons systematisch overzicht van 
de bestaande bewijsvoering toonde aan dat de schildwachtklierprocedure na afloop van de neoadjuvante 
behandeling veilig kan worden uitgevoerd, zowel bij de aanwezigheid (cN+) als afwezigheid van klinisch 
aangetoonde tumorpositieve lymfklieren (cN0). Tot slot worden de bevindingen van de verschillende studies 
verricht in het kader van dit proefschrift bediscussieerd en in perspectief  geplaatst (hoofdstuk 16). 
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